CA2172245C - Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein - Google Patents

Abstract

The present invention relates to methods and compositions for treating gram- negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasi ng antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.

Description

x 2112245 METHOD OF TREATING GRAM-NEGATIVE BAC'I7:aRIAL
INFEC,'TTON BY ADMINISTRATION OF
BACTERICIDAL/PERMEABILITY-INCREASING (BPn PROTEIN PRODUCT AND ANTIBIOTIC
BACKGROUND OF TIC ITTVENTION
The present invention relates generally to methods and compositions for treating gram-negative bacterial infections, and more specifically to the use of bactericidal!permeability-increasing- protein (BPn protein products for co-treatment of such infections with an antibiotic substance. Co-treatment with BPI protein products can improve the therapeutic effectiveness of antibiotics in gram-negative bacterial infections, increase the susceptibility of gram-negative organisms to antibiotics, and reverse resistance of gram-negative organisms to antibiotics.
BPI is a protein isolated from the granules of mammalian polymorphonuclear leukocytes (PMNs or neutrnphils), which are blood cells essential in the defense against invading microorganisms. Human BPI protein has been isolated from PMNs by acid extraction combined with either ion exchange chromatography [Elsbach, J. Biol. Chem., 254:11000 (1979)] or E. coli affinity chromatography jWeiss, et al., Blood, 69:652 (1987)]. BPI obtained in such a manner is referred to herein as natural BPI and has been shown to have potent bactericidal activity against a broad spectrum of gram-negative bacteria. The molecular weight of human BPI is approximately 55,000 daltons (55 kD). The amino acid sequence of the entire human BPI protein and the nucleic acid sequence of DNA
encoding the protein have been reported in Figure 1 of Gray et al., J. Biol.
Chem., 264:9505 (1989). The Gray et al. amino acid sequence is set out in SEQ ID NO: 69 hereto.
BPI is a strongly cationic protein. The N-terminal half of BPI accounts for the high net positive charge; the C-terminal half of the molecule has a net charge of -3. [Elsbach and Weiss (1981). supra.] A proteolytic N-terminal fragment of BPI

z ~ ~zz~5 having a molecular weight of about jd kD has an amphipathic character, containing alternating hydrophobic and hydrophilic regions. This N-terminal fragment of human BPI possesses the anti-bacterial efficacy of the naturally-derived 55 kD human BPI
holoprotein. [Ooi et al., J. Bro. Chem., 262: 14891-14894 (1987)]. In contrast to the N-terminal portion, the C-terminal region of the isolated human BPI
protein displays only slightly detectable anti-bacterial activity against gram-negative organisms. [Ooi et al. , J. Exp. Med. , 174: 649 ( 1991 ) . ] An N-terminal BPI fragment of approximately 23 kD, referred to as "rBPI~," has been produced by recombinant means and also retains anti-bacterial activity against gram-negative organisms.
Gazzano-Santoro et al., Infect. Immun. 60:4754-4761 (1992).
The bactericidal effect of BPI has been reported to be highly specific to gram-negative species, e.g., in Elsbach and Weiss, Injlamrnarion: Basic Principles and Clinical Correlates, eds. Gallin et al., Chapter 30, Raven Press, Ltd.
(1992).
BPI is commonly thought to be non-toxic for other microorganisms, including yeast, and for higher eukaryotic cells. Elsbach and Weiss (1992), supra, reported that BPI
exhibits anti-bacterial activity towards a broad range of gram-negative bacteria at concentrations as low as 10'8 to 10'' M, but that 100- to 1,000-fold higher concentrations of BPI were non-toxic to all of the gram-positive bacterial species, yeasts, and higher eukaryotic cells tested at that time. It was also reported that BPI
at a concentration of 10'~ M or 160 ~cg/ml had no toxic effect, when tested at a pH
of either 7.0 or 5.5, on the gram-positive organisms Staphylococcus aureus (four strains), Staphylococcus epidermidis, Streptococcus faecalis, Bacillus subtilis, Micrococcus lysodeiluicus, and Listeria monocytogenes. BPI at 10'~ M
reportedly had no toxic effect on the fungi Candida albicans and Candida parapsilosis at pH
7.0 or 5.5, and was non-toxic to higher eukaryotic cells such as human, rabbit and sheep red blood cells and several human tumor cell lines. See also Elsbach and Weiss, Advances in Inflammation Research, ed. G. Weissrr:ann, Vol. 2, pages 95-113 Raven Press (1981). This reported target cell specificity c~as believed to be the result of the strong attraction of BPI for lipopolysaccharide (LPS), which is unique to the outer membrane (or envelope) of gram-negative organisms.
The precise mechanism by which BPI kills gram-negative bacteria is not yet comnletelv elucidated. but it it hetieved rhar Rp1 miser first bind to the surface SUBSTITUTE SHEET (~iUL~ 26) of the bacteria through electrostatic and hydrophobic interactions between the cationic BPI protein and negatively charged sites on LPS. LPS has been referred to as "endotoxin" because of the potent inflammatory response that it stimulates, i.e., the release of mediators by host inflammatory cells which may ultimately result in irreversible endotoxic shock. BPI binds to lipid A, reported to be the most toxic and most biologically active component of LPS.
In susceptible gram-negative bacteria, BPI binding is thought to disnipt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and peptidoglycans, altering the permeability of the cell's outer membrane, and initiating events that ultimately lead to cell death. [Elsbach and Weiss (1992), supra].
BPI is thought to act in two stages. The first is a sublethal stage that is characterized by immediate growth arrest, permeabilization of the outer membrane and selective activation of bacterial enzymes that hydrolyze phospholipids and peptidoglycans.
Bacteria at this stage can be rescued by growth in serum albumin supplemented media [Mansion et al., J. Clip. Invest., 85;853-860 (1990)]. The second stage, defined by growth inhibition that cannot be reversed by serum albumin, occurs after prolonged exposure of the bacteria to BPI and is characterized by extensive physiologic and structural changes, including apparent damage to the inner cytoplasmic membrane.
Initial binding of BPI to LPS leads to organizational changes that probably result from binding to the anionic groups in the KDO region of LPS, which normally stabilize the outer membrane through binding of Mg++ and Ca++.
Attachment of BPI to the outer membrane of gram-negative bacteria produces rapid permeabilization of the outer membrane to hydrophobic agents such as actinomycin D. Binding of BPI and subsequent gram-negative bacterial killing depends, at least in part, upon the LPS polysaccharide chain length, with long O-chain bearing, "smooth°' organisms being more resistant to BPI bactericidal effects than short O-chain bearing, "rough" organisms [Weiss et al., J. Clin. Invest. 65: 619-628 (1980)].
This first stage of BPI action, permeabilization of the gram-negative outer envelope, is reversible upon dissociation of the BPI, a process requiring the presence of divalent cations and synthesis of new LPS [Weiss et al., J. Immunol. 132: 3109-3115 (1984)].
Loss of gram-negative bacterial viability, however, is not reversed by processes which restore the envelope integrity, suggesting that the bactericidal action is SUBSTITUTE St~~ET (RULE 26) ~' ~ 1~24y -4_ mediated by additional lesions induced in the target organism and which may be situated at the cytoplasmic membrane (Mannion et al., J. Clip. Invest. 86: 631-(1990)). Specific investigation of this possibility has shown that on a molar basis BPI
is at least as inhibitory of cytoplasmic membrane vesicle function as polymyxin B
(In't Veld et al., Infection and Irnmuniry 56: 1203-1208 (1988)) but the exact mechanism as well as the relevance of such vesicles to studies of intact organisms has not yet been elucidated.
BPI is also capable of neutralizing the endotoxic properties of LPS to which it binds. Because of its bactericidal properties for gram-negative organisms and its ability to neutralize LPS, BPI can be utilized for the treatment of mammals suffering from diseases caused by gram-negative bacteria, such as bacteremia or sepsis.
U.S. Patent No. 5,198,541 discloses recombinant genes encoding and methods for expression of BPI proteins, including BPI holoprotein and fragments of BPI. It also describes the use of N-terminal fragments of BPI protein for co-treatment with certain antibiotics, specifically penicillin, cephalosporins, rifampicin and actinomycin D.
Gram-negative bacteria include bacteria from the following species:
Acidaminococcus, Acinetobacter, Aeromorurs, Alcaligenes, Bacteroides, Bordetella, Branhamella, Brucella, Catymmatobacterium, Campylobacter, Cardiobacterium, Chromobacterium, Citrobacter, Edwardsiella, Enterobacter, Escherichia, Flavobacterium, Francisella, Fusobacterium, Haemophilus, Klebsiella, Legionella, Moraxella, Morganella, Neisseria, Pasturella, Plesio»aonas, Proteus, Providencia, Pseudomonas, Salmonella, Serratia, Shigella, Streptobacillus, Veillonella, Ytbrio, and Yersinia species.
Antibiotics are natural chemical substances of relatively low molecular weight produced by various species of microorganisms, such as bacteria (including Bacillus species), actinomycetes (including Streptomyces) and fungi, that inhibit growth of or destroy other microorganisms. Substances of similar structure and mode of action may be synthesized chemically, or natural compounds may be modified to produce semi-synthetic antibiotics. These biosynthetic and semi-synthetic derivatives are also effective as antibiotics. The major classes of antibiotics are ( 1 ) the (3-SUBSTITUTE SH~~ a (RILE 26) lactams, including the penicillins, cephalosporins and monobactams; (2) the aminoglycosides, e.g., gentamicin, tobramycin, netihnycin, and amikacin; (3) the tetracyclines; (4) the sulfonamides and trimethoprim; (5) the fluoroquinolones, e.g., ciprofloxacin, norfloxacin, and ofloxacin; (6) vancomycin; ('n the macrolides, which include for example, erythromycin, azithromycin, and clarithromycin; and (8) other antibiotics, e.g., the polymyxins, chloramphenicol and the lincosamides.
Antibiotics accomplish their anti-bacterial effect through several mechanisms of action ovhich can be generally grouped as follows: (1) agents acting on the bacterial cell wall such as bacitracin, the cephalosporins, cycloserine, fosfomycin, the penicillins, ristocetin, and vancomycin; (2) agents affecting the cell membrane or exerting a detergent effect, such as colistin, novobiocin and polymyxins;
(3) agents affecting cellular mechanisms of replication, information transfer, and protein synthesis by their effects on ribosomes, e.g., the aminoglycosides, the tetracyclines, chloramphenicol, clindamycin, cycloheximide, fucidin, lincomycin, puromycin, rifampicin, other streptomycins, and the macrolide antibiotics such as erythromycin and oleandomycin; (4) agents affecting nucleic acid metabolism, e.g., the fluoroquinolones, actinomycin, ethambutol, 5-fluorocytosine, griseofulvin, rifamycins; and (5) drugs affecting intermediary metabolism, such as the sulfonamides, trimethoprim, and the tuberculostatic agents isoniazid and para-aminosalicylic acid. Some agents may have more than one primary mechanism of action, especially at high concentrations. In addition, secondary changes in the structure or metabolism of the bacterial cell often occur after the primary effect of the antimicrobial drug.
The penicillins have a characteristic double-ring system composed of a S-lactam ring, which provides the antibacterial activity, and a thiazolidene ring.
The penicillins are differentiated by a single side chain that is unique for each penicillin. The compounds are bactericidal and act by inhibiting bacterial transpeptidase, an enzyme involved in synthesis of the bacterial cell wall.
Because of their mechanism of action, penicillins are generally active against growing, but not resting, cells. Penicillins, especially penicillin G, have largely gram-positive activity;
the relative insensitivity of gram-negative rods to penicillin G and several other penicillins is probably due to the permeability barrier of the outer membrane of gram-SUBSTITUTE Si~~~' (RULE ~6) WO 95/08344 PCTlLTS94/11225 2a?2245 negative bacteria. Ampicillin, carbenicillin, ticarciltin, and some other penicillins are active against gram-negative bacteria because they can pass through this outer membrane. Penicillins have relatively few adverse effects, the most important of which are the hypersensitivity (allergic) reactions. These compounds are widely distributed in the body, but do not enter cells and do not usually accumulate in CSF.
Bacterial resistance to the penicillins is by production of the enzyme S-lactamase, which catalyzes hydrolysis of the ~-lactam ring. The percentage of bacteria resistant to penicillin has risen to about 80 °rb . Several penicillins, including methicillin, oxacillin, cloxacillin, dicloxacillin and nafcillin, are not affected by the ~-lactamase of staphylococci. These antibiotics are useful against most S-lactamase-producing species of Staphylococcus. However, a small number of species are resistant even to these penicillins. Some penicillins, amoxicillin and ticarcillin, are marketed in combination with clavulanic acid, which is a ~-lactamase inhibitor that covalently binds to the enzyme and prevents it from hydrolyzing the antibiotics.
Another inhibitor, sulbactam, is marketed in combination with ampicillin.
The cephalosporins are characterized by a S-lactam ring, like the penicillins, but have an adjacent dihydrothiazine ring instead of a thiazolidene ring.
For convenience, these compounds are generally classified by generations. The first generation includes cephalothin, cephapirin, cefazolin, cephalexin, cephradine and cefadroxil. These drugs generally have excellent gram-positive activity except for enterococci and methicillin-resistant staphylococci, and have only modest gram-negative coverage. The second generation includes cefamandole, cefoxitin, ceforanide, cefuroxime, cefuroxime axetil, cefaclor, cefonicid and cefotetan.
This generation generally loses some gram-positive activity by weight and gains limited gram-negative coverage. The third generation includes cefotaxime, moxalactam, ceftizoxime, ceftriaxone, cefoperazone and ceftazidime. These compounds generally ~crifice further gram-positive activity by weight but gain substantial gram-negative coverage against Enterobacter and sometimes are active against Pseudomonas.
The cephalosporins bind to penicillin-binding proteins with varying affinity. Once binding occurs, protein synthesis is inhibited. Cephalosporins are usually well tolerated;
adverse effects include hypersensitivity reactions and gastrointestinal effects.
Cephalosporins may interact with nephrotoxic drugs, particularly aminoglycosides.
SU~~~I i E~ i ~ 5ti~~ ~Rt~~E 26~

to increase toxicity. Resistance to cephalosporins is mediated by several mechanisms, including production of ,B-lactamase, although some strains that do not produce (3-lactamase are nevertheless resistant.
Imipenem is a N-formimidoyl derivative of the mold product thienamycin. It contains a ~-lactam ring and somewhat resembles penicillin except for differences in the second ring. It has activity against both gram-positive and gram negative organisms and is resistant to most ~-lactamases, although not those from Pseudomonas. It is marketed in combination with cilastin, a compound that inhibits inactivation of imipenem in the kidney by renal dihydinpepddase I enryme.
Cilastin increases the concentration of imipenem in urine, although not in blood.
Aztreonam is the first of a new group of antibiotics referred to as the monobactams. These agents have a ,B-lactam ring but lack the second ring characteristic of the penicillins and cephalosporins. It acts by binding to penicillin-binding proteins, and produces long, filamentous bacterial shapes that eventually lyse.
Aztreonam is active only against aerobic gram-negative bacteria, is susceptible to inactivation by some ~-lactamases, and has few adverse effects.
The aminoglycosides contain amino sugars linked to an aminocyclitol ring by glycosidic bonds. They have similar mechanisms of action and properties, but differ somewhat in spectrum of action, toxicity, and susceptibility to bacterial resistance. The compounds are bactericidal, with activity against both gram-positive and gram-negative organisms, and act by binding to proteins on the 30S
ribosome of bacteria and inhibiting protein synthesis. The aminoglycosides also bind to isolated LPS and have a very weak outer membrane permeabilizing effect. [Taber et al ., Microbiological Reviews 53: 439-457 (1987)); Kadurugamuwa et al., Anrimicrobial Agents and Chemotherapy, 37: 715-721 (1993); Vaara, Microbiological Reviews 56:
395-411 (1992)]. This class of antibiotics includes amikacin, gentamicin, kanamycin, neomycin, netilinycin, paromomycin and tobramycin. The aminoglycosides are usually reserved for more serious infections because of severe adverse effects including ototoxicity and nephrotoxicity. There is a narrow therapeutic window between the concentration required to produce a therapeutic effect, e.g., 8 ~.glml for gentamicin, and the concentration that produces a toxic effect, e.g., 12 tcglml for SUBS'~'~~U ~ E ~EE~ ~U~E ~~~

?172245 _g-gentamicin. Neomycin in particular is highly toxic and is never administered parenterally.
Tetracyclines have a common four-ring structure and are closely congeneric derivatives of the polycyclic naphthacenecarboxamide. The compounds are bacteriostatic, and inhibit protein synthesis by binding to the 30S
subunit of microbial ribosomes and interfering with attachment of aminoacyl tRNA. The compounds have some activity against both gram-positive and gram-negative bacteria;
however, their use is limited because many species are now relatively resistant.
Adverse effects include gastrointestinal effects, hepatotoxicity with large doses, and nephrotoxicity in some patients. This antibiotic class includes tetracycline, chlortetracycline, demeclocycline, doxycycline, methacycline, minocycline and oxytetracycline.
The sulfonamides are derivatives of sulfanilamide, a compound similar in structure to para-aminobenzoic acid (PABA), which is an essential precursor for bacterial synthesis of folic acid. The compounds are generally bacteriostatic, and act by competitively inhibiting incorporation of PABA into tetrahydrofolic acid, which is a required cofactor in the synthesis of thymidines, purines and DNA.
Sulfonamides have a wide range of activity against gram-positive and gram-negative bacteria, but their usefulness has diminished with increasingly high prevalence of bacterial resistance. The sulfonamide class of antibiotics includes sulfacytine, sulfadiazine, sulfamethizole, sulfisoxazole, sulfamethoxazole, sulfabenzamide and sulfacetamide.
Adverse effects include hypersensitivity reactions and occasional hematological toxicity.
Trimethoprim is an inhibitor of the dihydrofolate reductase enzyme, which converts dihydrofolic to tetrahydrofolic acid, a required factor for DNA
synthesis. Adverse effects include gastrointestinal distress and rare hematological toxicity. ~ rimethoprim is also available in combination with sulfamethoxazole (also known as co-trimoxazole). The combination is usually bactericidal, although each agent singly is usually bacteriostatic. The combination is the drug of choice for Salmonella infections, some Shigelltx infections, E. coli traveler's diarrhea and Pneumocystis carinii pneumonia.
SUBSTITUTE S~E~ (~t~~ E 26) _y_ The fluoroquinolones and quinolones are derivatives of nalidixic acid, a naphthyridine derivative. These compounds are bactericidal, and impair DNA
replication, transcription and repair by binding to the DNA and interfering with DNA
gyr~se., an, enzyme which catalyzes negative supercoiling of DNA. The ' fluoroquinoiones, which include norfloxacin, ciprofloxacin, and ofloxacin, and the quinolones, which include cinoxacin, have a broad spectrum of antimicrobial activity against gram-negative and gram-positive organisms. These compounds distribute widely through extravascular tissue sites, have a long serum half life, and present few adverse effects. Because of their effect on DNA, the drugs are contraindicated in pregnant patients and in children whose skeletal growth is incomplete.
Vancomycin is a glycopeptide, with a molecular weight of about 1500;
produced by a fungus. It is primarily active against gram-positive bacteria.
The drug inhibits one of the final steps in synthesis of the bacterial cell wall, and is thus effective only against growing organisms. It is used to treat serious infections due to gram-positive cocci when penicillin G is not useful because of bacterial resistance or patient allergies. Vancomycin has two major adverse effects, ototoxicity and nephrotoxicity. These toxicities can be potentiated by concurrent administration of another drug with the same adverse effect, such as an aminoglycoside.
The macrolides are bacteriostatic and act by binding to the 50S subunit of 70S ribosomes, resulting in inhibition of protein synthesis. They have a broad spectrum of activity against gram-positive and gram-negative bacteria and may be bacteriostatic or bactericidal, depending on the concentration achieved at sites of infection. The compounds distribute widely in body fluids. Adverse effects include gastrointestinal distress and rare hypersensitivity reactions. The most common macrolide used is erythromycin, but the class includes other compounds such as clarithromycin and azithromycin.
The polymyxins are a group of closely related antibiotic substances produced by strains of Bacillus polymyxa. These drugs, which are cationic detergents, are relatively simple, basic peptides with molecular weights of about 1000. Their antimicrobial activity is restricted to gram-negative bacteria.
They interact strongly with phospholipids and act by penetrating into and disrupting the structure of cell membranes. Polymyxin B also binds to the lipid A portion of SUBST&~'tJT~ ~i~c'c"~ (R~I~E 26) ~ X2245 - to -endotoxin and neutralizes the toxic effects of this molecule. Polymyxin B has severe adverse effects, including nephrotoxicity and neurotoxicity, and should not be administered concurrently with other nephrotoxic or neurotoxic drugs. The drug thus has limited use as a therapeutic agent because of high systemic toxicity, but may be used for severe infections, such as Pseudomonas aeruginosa meningitis, that respond poorly to other antibiotics.
Chloramphenicol inhibits protein synthesis by binding to the SOS
ribosomal subunit and preventing binding of aminoacyl tRNA. It has a fairly wide spectrum of antimicrobial activity, but is only reserved for serious infections, such as meningitis, typhus, typhoid fever, and Rocky Mountain spotted fever, because of its severe and fatal adverse hematological effects. It is primarily bacteriostatic, although it may be bactericidal to certain species.
Lincomycin and clindamycin are lincosamide antimicrobials. They consist of an amino acid linked to an amino sugar. Both inhibit protein synthesis by binding to the SOS ribosomal subunit. They compete with erythromycin and chloramphenicol for the same binding site but in an overlapping fashion. They may be bacteriostatic or bactericidal, depending on relative concentration and suscer ~:bility. Gastrointestinal distress is the most common side effect.
Other adverse reactions include cutaneous hypersensitivity, transient hematological abnormalities, and minor elevations of hepatic enzymes. Clindamycin is often the drug of choice for infections caused by anaerobic bacteria or mixed aerobic/anaerobic infections, and can also be used for susceptible aerobic gram-positive cocci.
Some dnigs, e.g. aminoglycosides, have a small therapeutic window.
For example, 2 to 4 ~g/ml of gentamicin or tobtamycin may be required for inhibition of bacterial growth, but peak concentrations in plasma above 6 to 10 ~g/ml may result in ototoxicity or nephrotoxicity. These agents are more difficult to administer because the ratio of toxic to therapeutic concentrations is very low.
Antimicrobial agents that have toxic effects on the kidneys and that are also eliminated primarily by the kidneys, such as the aminoglycosides or vancomycin, require particular caution because reduced elimination can lead to increased plasma concentrations, which in turn may cause increased toxicity. Doses of antimicrobial agents that are eliminated by the kidneys must be reduced in patients with impaired SUSST~TUTE 5~~~~UL~ 26~

-lI-renal function. Similarly, dosages of drugs that are metabolized or excreted by the liver, such as erythromycin, chloramphenicol, or clindamycin, must be reduced in patients with decreased hepatic function.
Antibiotic resistance in bacteria is an increasingly troublesome problem. The accelerating development of antibiotic-resistant bacteria, intensified by the widespread use of antibiotics in farm animals and overprescription of antibiotics by physicians, has been accompanied by declining research into new antibiotics with different modes of action. [Science, 264: 360-374 (1994).] Antibiotic resistance, once acquired, can be rapidly spread to other bacteria, including bacteria of a different species. There are some species of bacteria that are resistant to all but one antibiotic; it may be only a matter of time before the appearance of bacterial strains that are resistant to all antibiotics.
Bacteria acquire resistance to antibiotics through several mechanisms:
(1) production of enzymes that destroy or inactivate the antibiotic [Davies, Science, 264:375-381 (1994)]; (2) synthesis of new or altered target sites on or within the cell that are not recognized by the antibiotic [Spratt, Science, 264:388-393 (1994)]; (3) low permeability to antibiotics, which can be reduced even further by altering cell wall proteins, thus restricting access of antibiotics to the bacterial cytoplasmic machinery; (4) reduced intracellular transport of the dmg; and (S) increased removal of antibiotics from the cell via membrane-associated pumps [Nikaido, Science, 264:382-387 (1994)].
The susceptibility of a bacterial species to an antibiotic is generally determined by two microbiological methods. A rapid but crude procedure uses commercially available filter paper disks that have been impregnated with a specific quantity of the antibiotic drug. These disks are placed on the surface of agar plates that have been streaked with a culture of the organism being tested, and the plates are observed for zones of growth inhibition. A more accurate technique, the broth dilution susceptibility test, involves preparing test tubes containing serial dilutions of the drug in liquid culture media, then inoculating the organism being tested into the tubes. The lowest concentration of drug that inhibits growth of the bacteria after a suitable period of incubation is reported as the minimum inhibitory concentration.

~~~2245 The resistance or susceptibility of an organism to an antibiotic is determined on the basis of clinical outcome, i. e. , whether administration of that antibiotic to a subject infected by that organism will successfully cure the subject.
While an organism may literally be susceptible to a high concentration of an antibiotic in vitro, the organism may in fact be resistant to that antibiotic at physiologically realistic concentrations. If the concentration of dnig required to inhibit growth of or kill the organism is greater than the concentration that can safely be achieved without toxicity to the subject, the microorganism is considered to be resistant to the antibiotic. To facilitate the identification of antibiotic resistance or susceptibility using in vitro test results, the National Committee for Clinical Laboratory Standards (NCCLS) has formulated standards for antibiotic susceptibility that correlate clinical outcome to in vitro determinations of the minimum inhibitory concentration of antibiotic.
Thus, there exists a desire in the art for agents that could act as adjuncts to conventional antibiotic therapy and that could act to improve the therapeutic effectiveness of antibiotics.
SUMMARY OF THE INVENTION
The present invention generally provides methods and compositions for prophylaxis or treatment of gram-negative bacterial infections, using BPI
protein products. The methods and compositions, in addition to being useful for treatment, are useful for prophylaxis of patients at high risk of gram-negative bacterial infection, e.g., patients who will undergo abdominal or genitourinary surgery, or trauma victims. Specifically, the present invention provides, in a method for treating a gram-negative bacterial infection with an antibiotic, the improvement comprising the step of concurrently administering BPI protein product in an amount effective to improve the therapeutic effectiveness of the antibiotic.
The present invention is based upon the fording that BPI protein product is useful as adjunct therapy with conventional antibiotics, and specifically the finding that concurrent administration, or co-treatment, of a BPI protein product and an antibiotic or combination of antibiotics can improve the therapeutic effectiveness of the antibiotic or combination of antibiotics. BPI protein product may impro~-. 'he ~UBSl'~T~4~E ~~~~T ~~U~.E 26~

2 ~ 7225 therapeutic effectiveness of antibiotics in a variety of ways, including by increasing susceptibility of gram-negative bacteria to a reduced dosage of antibiotics, by effectively reversing resistance of gram-negative bacteria to antibiotics, by providing synergistic or potentiating effects beyond the individual or additive effects of the BPI
protein product or antibiotic alone, or by neutralizing endotoxin released by bacteria killed by antibiotics. Concurrent administration of BPI protein product and antibiotic provides unexpectedly superior therapeutic effects in vivo than either agent provides when administered alone. Concurrent administration of BPI protein product according to this improved method of treatment is effective even when the gram negative bacteria involved are considered to be resistant to the bactericidal effects of BPI protein product alone and/or antibiotic alone.
The present invention provides a use of a BPI protein product for the manufacture of a medicament for the co-treatment with an antibiotic of a gram-negative bacterial infection in mammals. This aspect of the invention contemplates co-treatment with any antibiotic or combinations of antibiotics, including f3-lactam antibiotics with and without ~-lactamase inhibitors, aminoglycosides, tetracyclines, sulfonamides and trimethoprim, vancomycin, macrolides, fluoroquinolones and quinolones, polymyxins and other antibiotics.
This aspect of the invention also provides the use of a BPI protein product for the manufacture of a medicament for improving the therapeutic effectiveness of antibiotics in a gram-negative bacterial infection, use of a BPI protein product for the manufacture of a medicament for increasing the susceptibility to an antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, and use of a BPI protein product for the manufacture of a medicament for reversing resistance to an antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection.
The invention utilizes any of the large variety of BPI protein products known to the art including natural BPI protein, recombinant BPI protein, BPI
fragments, BPI analogs, BPI variants, and BPI peptides. Concurrent administration of BPI protein product with any antibiotic or combination of antibiotics is contemplated, including a-lactam antibiotics with or without /3-lactamase inhibitors, aminoglycosides, tetracyclines, sulfonamides and tri-methoprim, vancomycin, macrolides, fluoroquinolones and quinolones, polymyxins, and other antibiotics.
Either the BPI protein product or the antibiotic may be administered systemically or topically to a subject suffering from a suspected or confirmed gramnegative bacterial infection.
The BPI protein product and antibiotic may be administered by different routes and may be administered si~rnul.taneously or sequentially.
The invention also provides pharmaceutical compositions far treatment of gram-negative bacterial infections, comprising an antibiotic of the invention and a BPI protein product in an amount effective to improve the therapeutic effectiveness of the antibiotic. Such compositions optionally comprise pharmaceutically acceptable diluents, adjuvants or carriers.
The compositions may be formulated for systemic or topical administration to subjects. In addition, compositions comprising BPI protein product and an antibiotic can be used in a variety of in vitxo uses, such as use as a bactericide to decontaminate fluids and surfaces and to sterilize surgical and other medical equipment and implantable devices, including prosthetic joints.
Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of the invention which describes presently preferred embodiments thereof .
BRIEF DESCRIPTION OF ThE DRAWINGS
Figure 1 depicts survival data after treatment with rBPI21 and cefamandole, separately or in combination, in an E. coli 0111: B4 mouse peritonitis assay.
Figures 2-4 relate to results from an E. coli 0111: B4 mouse peritonitis assay with rBPI,l and cefamandole, separately or in combination. Figure 2 depicts survival data; Figure 3 shows bacterial counts from peritoneal lavage fluid; and Figure 4 shows bacterial counts in blood.
Figures SA and 5B display results from two trials of treatment with . . . . . . . . , _ , 1~~~45 -15-.
rBPI2, and cefamandole, separately or in combination, in an E. coli 07:K1 mouse peritonitis assay.
Figures 6-16 relate to results, including cardiovascular and metabolic > findings, from an E. coli 07:K1 rabbit bacteremia assay with rBPIZ, and cefamandole, separately or in combination. Figure 6 depicts survival data; Figure 7 shows bacterial count in blood, which Figure 8 displays as percentage of bacterial dose;
Figure 9 shows blood endotoxin levels; Figures 10 shows mean arterial blood pressure;
Figure 11, cardiac index; Figure 12, total peripheral resistance; Figure 13, arterial oxygen tension; Figure 14, alveolar-arterial oxygen gradient; Figure i5, respiration rate; and Figure 16, arterial blood pH.
Figure 17 depicts survival data after treatment with rBPIz, and gentamicin, separately or in combination, in an E, coli 07:K1 mouse peritonitis assay.
Figure 18 shows the bactericidal effect of rBPI2, and ceftriaxone, separately or in combination, on growth of ceftriaxone-resistant E. coli.
Figures 19-25 relate to the synergistic effect of rBPIz, on antibiotic killing curves for selected gram-negative organisms. Figure 19 shows the bactericidal effect of rBPIz, alone. Figure 20 shows the effect of rBPIzi in combination with trimethoprim/sulfamethoxazole; Figure 21, rBPIz, with ciprofloxacin; Figure 22, rBPI2, with piperacillin; Figure 23, rBPIz, with cefotaxime; Figure 24, rBPIz, with cefuroxime; and Figure 25, rBPIz, with amikacin.
DETAILED DESCItIpITON
The present invention relates to methods and compositions for treating a gram-negative bacterial infection, using a BPI protein product. The invention is based on the unexpected discovery that, when treating a gram-negative bacterial infection with an antibiotic, the concurrent administration of BPI protein product with the antibiotic improves the therapeutic effectiveness of the antibiotic, even at doses at which the BPI protein product alone or antibiotic alone may be inactive.
BPI
protein product by itself typically has an antibacterial potency less than that of conventional antibiotics. However, because its administration unexpectedly improves the therapeutic effectiveness of conventional antibiotic therapy, BPI protein product S~~$~~~~~ ~ ~ ~~$~

WO 95/08344 PCTlUS94111225 is useful as adjunct therapy with conventional antibiotic therapy for the treatment of gram-negative bacterial infections.
"Gram-negative bacterial infection," as used herein, encompasses conditions associated with or resulting from gram-negative bacterial infection (e.g., sequelae). These conditions include gram-negative sepsis, endotoxin-related hypotension and shock, and one or more of the conditions associated therewith, including fever, metabolic acidosis, disseminated intravascular coagulation anc ted clotting disorders, anemia, thrombocytopenia, leukopenia, adult respiratory .
ass syndrome and related pulmonary disorders, renal failure and related renal disorders, hepatobiliary disease and central nervous system disorders. These conditions also include translocation of bacteria from the intestines and concomitant release of endotoxin.
BPI protein product may improve the therapeutic effectiveness of the antibiotic in a variety of ways, including by increasing susceptibility of gram-negative bacteria to a reduced dosage of antibiotics, by effectively reversing resistance of gram-negative bacteria to antibiotics, by providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or antibiotic alone, or by neutralizing endotoxin released by bacteria killed by antibiotics.
Concurrent administration of BPI protein product and antibiotic is expected to provide more- effective treatment of gram-negative bacterial infection. Concurrent administration of the two agents may provide greater therapeutic effects in vivo than either agent provides when administered singly. It may permit a reduction in the dosage of one or both agents with achievement of a similar therapeutic effect.
Alternatively, the concurrent administration may produce a more rapid or complete bactericidallbacteriostatic effect than could be achieved with either agent alone.
Therapeutic effectiveness is based on a successful clinical outcome, and does not require that the antimicrobial agent or agents kill 100 ~ of the organisms involved in the infection. Success depends on achieving a level of antibacterial activity at the site of infection that is sufficient to inhibit the bacteria in a manner that tips the balance in favor of the host. When host defenses are maximally effective, the antibacterial effect required may be minimal. Reducing organism load by even one log (a factor of 10) may permit the host's own defenses to control the infection.
SU~~T~TU T E ~~~~ ~~~~,~. 2~~

In addition, augmenting an early bactericidal/bacteriostatic effect can be more important than long-term bactericidal/bacteriostatic effect. These early events are a significant and critical part° of therapeutic success, because they allow time for host defense mechanisms to activate. Increasing the bactericidal rate may be particularly important for infections such as meningitis, bone or joint infections.
[Stratton, Antibiotics in Laboratory Medicine, 3rd ed. (Lorian, V., Ed.) pp. 849-879, Williams and Wilkins, Baltimore MD (1991)].
The effect of BPI protein product to improve the therapeutic effectiveness of antibiotics in vivo may be demonstrated in in vivo animal models, or may be predicted on the basis of a variety of in vitro tests, including (1) determinations of the minimum inhibitory concentration (1VVIIC) of an antibiotic required to inhibit growth of a gram-negative organism for 24 hours, (2) determinations of the effect of an antibiotic on the kinetic growth curve of a gram-negative organism, and (3) checkerboard assays of the MIC of serial dilutions of antibiotic alone or in combination with serial dilutions of BPI protein product.
Exemplary models or tests are described in Eliopoulos and Moellering In Antibiotics in Laboratory Medicine, 3rd ed. (Lorian, V., Ed.) pp. 432-492, Williams and Wilkins, Baltimore MD (1991).
Using in vitro determinations of antibiotic MIC at 24 hours, a BPI
protein product may be shown to reduce the MIC of the antibiotic. With this result, it is expected that concurrent administration of the BPI protein product in vivo will increase susceptibility of the gram-negative organism to the antibiotic. A BPI
protein product may also be shown to reduce the MIC of an antibiotic from the range in which the organism is considered clinically resistant to a range in which the organism is considered clinically susceptible. With this result, it is expected that concurrent administration in vivo of the BPI protein product with the antibiotic will reverse resistance and effectively convert the antibiotic-resistant organism into an antibiotic-susceptible organism.
By measuring the effect of antibiotics on the in vitro growth curves of gram-negative organisms, in the presence or absence of a BPI protein product, the BPI protein product may be shown to enhance the early antibacterial effect of antibiotics at 0-24 hours. Enhancement of early bactericidal/growth inhibitory effects is important in determining therapeutic outcome.
The BPI protein product and antibiotic may also be shown to have synergistic or potentiating effects beyond the individual effects of each agent alone or the additive effects of the agents together. In a checkerboard assay, the combination of BPI protein product with antibiotics may be shown to result in a "synergistic" fractional inhibitory concentration index (FIC). The checkerboard method is based on additivity, which assumes that the result observed with multiple drugs is the sum of the separate effects of the drugs being tested; according to this system a FTC of less than 0.5 is scored as synergy, 1 is scored as additive, and greater than 1 but less than 2 is scored as indifferent. In contrast, kinetic assays are based on the idea that only one metabolic pathway at a time can be growth rate-limiting for an organism; according to this system, the combined effect of drugs that do not interact with one another (autonomous or indifferent) is simply the effect of the most active drug alone.
Concurrent administration of BPI protein products and antibiotics is shown herein to lower MICs of a variety of antibiotics for a variety of gram-negative organisms. It is also shown to reverse resistance of a variety of gram-negative organisms to antibiotics. In some cases where BPI protein product does not affect the MIC of antibiotic at 24 hours, BPI protein product is shown herein to enhance the early bactericidal effect of antibiotics on growth curves at 0-7 or 7-24 hours. The BPI protein products exert these effects even on gram-negative organisms that are not considered susceptible to the direct bactericidal or growth inhibitory effects of BPI
protein product alone. It is also shown herein that the concurrent administration of BPI protein products with antibiotics in vivo allows a reduction in the dosages of both agents to amounts that, if administered alone, would be insufficient to exert the same clinical effect.
Either the BPI protein product or the antibiotic, or both, may be administered at levels at which neither would alone be therapeutically effective against a gram-negative bacterial infection. Alternatively, according to a preferred method, the antibiotic and BPI protein product can be administered in amounts where each would alone be therapeutically effective against a gram-negative bacterial infection S~~~TiT~ s ~ ~~~~ T ~~~L~ 26) Z 1 ~2~45 ~I9-but wherein the combination of the two antibiotics provides even more potent effects.
The BPI protein product may be administered in an amount which increases susceptibility of gram-negative bacteria to reduced antibiotic dosage, or in an amount which reverses resistance of the gram-negative bacteria to an antibiotic.
S BPI protein product is thought to interact with a variety of host defense elements present in whole blood or semen, including complement, p15 and LBP, and other cells and components of the immune system. Such interactions may result in potentiation of the activities of BPI protein product. Because of these interactions, BPI protein products can be expected to exert even greater activity in vivo than in vitro. Thus, while in vitro tests are predictive of in vivo utility, absence of activity in vitro does not necessarily indicate absence of activity in vivo. For example, BPI
has been observed to display a greater bactericidal effect on gram-negative bacteria in whole blood or plasma assays than in assays using conventional media.
[Weiss et al., J. Clin. Invest. 90:1122-1130 (1992)]. This may be because conventional in vitro systems lack the blood elements that facilitate or potentiate BPI's function in vivo, or because conventional media contain higher than physiological concentrations of magnesium and calcium, which are typically inhibitors of the antibacterial activity of BPI protein products. Furthermore, in the host, BPI protein product is available to neutralize endotoxin released during antibiotic killing of bacteria, a further clinical benefit not seen in or predicted by in vitro tests.
It is also contemplated that the BPI protein product be administered with other products that potentiate the bactericidal activity of BPI protein products.
For example, semen complement potentiates the gram-negative bactericidal activity of BPI protein products; the combination of BPI protein product and serum complement provides synergistic bactericidallgrowth inhibitory effects. See, e.g., Ooi et al. J. Biol. Chem. , 265: 15956 (1990) and Levy et al. J. Biol. Chem. , 268:
6038-6083 (1993) which address naturally-occurring 15 kD proteins potentiating BPI
antibacterial activity. See also co-owned, co-pending PCT Application No.
US94/07834filedJuly 13, 1994, which corresponds to U.S. Patent No. 5,489,676.

These describe methods for potentiating gram-negative bactericidal activity of BPI protein products by administering lipopolysaccharide binding protein (LBP) and LBP protein products. LBP protein derivatives and derivative hybrids which lack CD-14 immunostimulatory properties are described in PCT
Application No. US94/06931 filed June 17, 1994, which corresponds to U.S. Patent No. 5,770,561.
An advantage provided by the present invention is the ability to provide more effective treatment of gram-negative bacterial infection by virtue of the improved therapeutic effectiveness of the antibiotic treatment. Another advantage is the ability to treat gram-negative organisms that are normally resistant to one or more antibiotics. Yet another advantage is the ability to accelerate the killing of gram-negative organisms by antibiotics. An additional advantage is the ability to neutralize endotoxin released during antibiotic killing of bacteria. A further advantage is the ability to use lower concentrations of toxic antibiotics such as gentamicin and polymyxin B, or expensive antibiotics such as vancomycin.
Because the use of some antibiotics is limited by their systemic toxicity or prohibitive cost, lowering the concentration of antibiotic required for therapeutic effectiveness reduces toxicity and/or cost of treatment, and thus allows wider use of the antibiotic. The present invention may also provide quality of life benefits due to, e.g., decreased duration of therapy, reduced stay in intensive care units or overall in the hospital, with the concomitant reduced risk of serious nosocomial (hospital-acquired) infections.
The invention further provides pharmaceutical compositions for treatment of gram-negative bacterial infections, comprising an antibiotic of the invention and a BPI protein product in an amount effective to improve the therapeutic effectiveness of the antibiotic. Such compositions optionally comprise pharmaceutically acceptable diluents, adjuvants or carriers.
The compositions may be formulated for systemic or topical administration to subjects. In addition, antiseptic compositions comprising BPI protein product and an antibiotic can be used in a variety of in vi tro uses such as use as a bactericide to decontaminate fluids and surfaces and to sterilize surgical . . . . . . . , , .

and other medical equipment and implantable devices, including prosthetic joints. The invention also provides improved methods of in vitro decontamination of fluids and surfaces comprising administering a BPI protein product in combination with an antibiotic of the invention.
Either the BPI protein product or the antibiotics may be administered systemically or topically. Systemic routes of administration include oral, intravenous, intramuscular or subcutaneous injection, intrathecal, intraperitoneal (e.g. by intraperitoneal lavage), transpulmonary using aerosolized or nebulized drug, or transdermal. Topical routes include administration in the form of salves, ophthalmic drops, ear drops, or irrigation fluids (for, e.g., irrigation of wounds).
"Concurrent administration," or co-treatment, as used herein includes administration of the agents together, or before or after each other. The BPI protein product and antibiotics may be administered by different routes. For example, the BPI protein product may be administered intravenously while the antibiotics are administered intramuscularly, intravenously, subcutaneously, orally or intraperitoneally. Alternatively, the BPI protein product may be administered intraperitoneally while the antibiotics are administered intraperitoneally or intravenously, or the BPI
protein product may be administered in an aerosolized or nebulized form while the antibiotics are administered, e.g., intravenously. The BPI protein product and antibiotics are preferably both administered intravenously. The BPI protein product and antibiotics may be given sequentially in the same intravenous line, after an intermediate flush, or may be given in different intravenous lines. The BPI protein product and antibiotics may be administered simultaneously or sequentially, as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations at the site of infection.
As used herein, "BPI protein product" includes naturally and recombinantly produced BPI protein; natural, synthetic, and recombinant biologically active polypeptide fragments of BPI
protein; biologically active polypeptide variants of BPI
protein or fragments thereof, including hybrid fusion proteins and dimers; and biologically active polypeptide analogs of BPI
protein or fragments or variants thereof, including cysteine-substituted analogs. The BPI protein products administered according to this invention may be generated and/or isolated by any means known in the art. U.S. Patent No. 5,198,541, the disclosure of which is incorporated herein by reference, discloses recombinant genes encoding and methods for expression of BPI proteins including recombinant BPI holoprotein, referred to as rBPIso and recombinant fragments of BPI. Co-owned, PCT
Application NO. 93/04752 filed May 19, 1993 discloses novel methods for the purification of recombinant BPI protein products expressed in and secreted from genetically transformed mammalian host cells in culture and discloses how one may produce large quantities of recombinant BPI products suitable for incorporation into stable, homogeneous pharmaceutical preparations.
Biologically active fragments of BPI (BPI fragments) include biologically active molecules that have the same or similar amino acid sequence as a natural human BPI holoprotein, except that the fragment molecule lacks amino-terminal amino acids, internal amino acids, and/or carboxy-terminal amino acids of the holoprotein. Nonlimiting examples of such fragments include a N-terminal fragment of natural human BPI
of approximately 25 kD, described in Ooi et al., J. Exp. Med., 174:649 (2991), and the recombinant expression product of DNA
encoding N-terminal amino acids from 1 to about 193 or 199 of natural human BPI, described in Gazzano-Santoro et al., Infect.
Immun. 60:4754-4761 (1992), and referred to as rBPI23. In that publication, an expression vector was used as a source of DNA
encoding a recombinant expression product (rBPI23) having the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in Figure 1 of Gray et al., supra, except that valine at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid ( specified by GAG) rather than lysine ( specified by AAG) .
Recombinant holoprotein (rBPI) has also been produced having the sequence (SEQ ID NOS: 145 and 146) set out in Figure 1 of Gray et al., supra, with the exceptions noted for rBPI23 and with the exception that residue 417 is alanine (specified by GCT) rather than valine (specified by GTT). Other examples include dimeric forms of BPI fragments, as described in co-owned U.S. Patent No. 5,447,913 and corresponding PCT
Application No. PCT/US95/03125 filed March 11, 1995. Preferred dimeric products include dimeric BPI protein products wherein the monomers are amino-terminal BPI fragments having the N-terminal residues from about 1 to 175 to about 1 to 199 of BPI
holoprotein. A particularly preferred dimeric product is the dimeric form of the BPI fragment having N-terminal residues 1 through 193, designated rBPI42 dimer.
Biologically active variants of BPI (BPI variants) include but are not limited to recombinant hybrid fusion proteins, comprising BPI holoprotein or biologically active fragment thereof and at least a portion of at least one other polypeptide, and dimeric forms of BPI variants. Examples of such hybrid fusion proteins and dimeric forms are described by Theofan et al. in co-owned U.S. patent No. 5,643,570 and PCT
Application No. US93/04754 filed May 19, 1993 and include hybrid fusion proteins comprising, at the amino-terminal end, a BPI protein or a biologically active fragment thereof and, at the carboxy-terminal end, at least one constant domain of an immunoglobulin heavy chain or allelic variant thereof.
Biologically active analogs of BPI (BPI analogs) include but are not limited to BPI protein products wherein one or more amino acid residues have been replaced by a different amino acid. For example, co-owned U.S. patent No. 5,420,019 and PCT
Application No. US94/01235 filed February 2, 1994 discloses polypeptide analogs of BPI and BPI fragments wherein a cysteine residue is replaced by a different amino acid. A preferred BPI
protein product described by this application is the expression product of DNA encoding from amino acid 1 to approximately 193 or 199 of the N-terminal amino acids of BPI holoprotein, but wherein the cysteine at residue number 132 is substituted with alanine and is designated rBPI210cys or rBPI2l. Other examples include dimeric forms of BPI analogs; e.g. co-owned U.S. patent No. 5,447,913 and PCT Application No. PCT/US95/03125 filed March 11, 1995.
Other BPI protein products useful according to the methods of the invention are peptides derived from or based on BPI
produced by recombinant or synthetic means (BPI-derived peptides), such as those described in co-owned and copending PCT Application No. US94/10427 filed September 15, 1994, which corresponds to U.S. Patent No. 5,652,332, PCT Application No.
US94/02465 filed March 11, 1994, which corresponds to U.S.
Patent No. 5,733,872 and PCT Application No. US94/02401 filed March 11, 1994.
Presently preferred BPI protein products include recombinantly-produced N-terminal fragments of BPI, especially those having a molecular weight of approximately between 21 to 25 kD such as rBPIz3 or rBPIzl, or dimeric forms of these N-terminal fragments (e. g., rBPI4z dimer). Additionally, preferred BPI protein products include rBPIso and BPI-derived peptides.
The administration of BPI protein products is preferably accomplished with a pharmaceutical composition comprising a BPI
protein product and a pharmaceutically acceptable diluent, adjuvant, or carrier. The BPI protein product may be administered without or in conjunction with known surfactants, other chemotherapeutic agents or additional known anti-microbial agents. A preferred pharmaceutical composition containing BPI protein products (e.g. , rBPIso, rBPIz3) comprises the BPI protein product at a concentration of 1 mg/ml in citrate buffered saline (5 or 20 mM citrate, 150 mM NaCl, pH
5.0) comprising 0.1% by weight of poloxamer 188 (Pluronic~ F-68, BASF Wyandotte, Parsippany, NJ) and 0.0020 by weight of polysorbate 80 (Tween~ 80, ICI Americas Inc., Wilmington; DE).
Another preferred pharmaceutical composition containing BPI
protein products (e. g. rBPIzl) comprises the BPI protein product at a concentration of 2 mg/ml in 5 mM citrate, 150 mM
NaCl, 0.20 poloxamer 188 and 0.0020 polysorbate 80. Such preferred combinations are described in co-owned, co-pending PCT Application No. US94/01239 filed February 2, 1994 which corresponds to U.S. Patent No. 5,488,034.
Suitable antibiotics, and therapeutically effective concentrations thereof when administered with BPI protein products, may be determined in in vivo models or according to in vitro tests, for example, the 3n vitro minimum inhibitory concentration (MIC) and in vivo mouse peritonitis or rabbit bacteremia assays taught herein. Suitable antibiotics are antibiotics that act on the bacterial cell wall, cell membrane, protein metabolism or nucleic acid metabolism. These would include antibiotics or combinations of antibiotics from the following classes: ~3-lactam antibiotics with or without lactamase inhibitors, aminoglycosides, tetracyclines, sulfonamides and trimethoprim, vancomycin, macrolides, fluoroquinolones and quinolones, polymyxins, and other antibiotics. Dosage and administration of suitable antibiotics are known in the art, and briefly summarized below.
PENICILLINS
When a BPI protein product is concurrently administered with a penicillin, for treatment of gram-negative bacterial infection, the BPI protein product is generally given parenterally in doses ranging from 1 ~.g/kg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mg/kg daily.
The penicillin is generally given in doses ranging from 1 ~.g/kg to 750 mg/kg daily, preferably not to exceed 24 grams daily for adults (or 600 mg/kg daily for children) , and is preferably administered as follows:
Penicillin G is preferably administered parenterally to adults in doses ranging from 600,000 to 1,000,000 units per day. In conventional administration, it is effective largely against gram-positive organisms. For treatment of pneumococcal meningitis, penicillin G is administered in doses of 20-24 million units daily, in divided doses every 2 or 3 hours. For children, the preferred parenteral dose of 21~~245 penicillin G is 300,000 to 1,000,000 units per day. One unit of penicillin G
contains 0.6 ~.g of pure sodium penicillin G (i.e., 1 mg is 1667 units).
Amoxicillin may be administered parenterally to adults in doses ranging from 750 mg to 1.5 grams per day, in 3 equally divided doses. For children, preferred parenteral doses of amoxicillin range from 20 to 40 mglkg per day in equally divided doses. Amoxicillin is also available in combination with clavulanic acid, a S-lactamase inhibitor. A 250 mg dose of the combination drug amoxicillin/clavulanate will contain 250 mg of amoxicillin and either 125 or 62.5 mg of clavulanic acid. The combination is preferably administered to adults orally in doses of 750 mg per day divided into 3 equal doses every 8 hours, with a preferred dose of 1.5 grams per day for severe infections, given in 3 equally divided doses.
In children, the preferned oral dose is 20 to 40 mglkg per day in 3 equally divided doses.
Ampicillin is preferably administered parenterally to adults in doses of 6 to 12 grams per day for severe infections, in 3 to 4 equally divided doses.
In children, the preferred parenteral dose of ampicillin is 50 to 200 mg/kg per day in 3 to 4 equally divided doses. Larger doses of up to 400 mglkg per day, for children, or 12 grams per day, for adults, may be administered parenterally for treatment of meningitis. Ampicillin is also available in combination with sulbactam, a ,B-lactamase inhibitor. Each 1.5 gram dose of ampicillin/sulbactam contains 1 gram of ampicillin and 0.5 grams of sulbactam. The combination is preferably administered parenterally to adults in doses of 6 to 12 grams per day divided into 4 equal doses every 6 hours, not to exceed a total of 12 grams per day.
Azlocillin is preferably administered parenterally to adults in doses of 8 to 18 grams per day, given in 4 to 6 equally divided doses.
Carbenicillin is preferably administered parenterally to adults in doses of 30 to 40 grams per day, given by continuous infusion or in 4 to 6 equally divided doses. Daily doses of up to 600 mglkg have been used to treat children with life-threatening infections. , Mezlocillin is preferably administered to adults parenterally in doses of 100 to 300 mglkg per day, given in 4 to 6 equally divided doses. The usual dose is 16 to 18 gams ver dav: for life rhrearPn;ng actions. 350 mg/kg per day may be ~U~ T ~T~T~ ~~~ ~ ~~t~L~ ~6~

217224 ~

administered, but in doses not to exceed 24 grams per day given in 6 equally divided doses every 4 hours. For children, the preferred parenteral dose of mezlocillin is 150 to 300 mg/kg per day.
Nafcillin is preferably administered intravenously to adults in doses of 3 grams per day, given in 6 equally divided doses every 4 hours, with doubled doses for very severe infections. In conventional administration, it is effective largely against gram-positive organisms. In children, the preferred par~enteral dose is 20 to 50 mg/kg per day, in 2 equally divided doses every 12 hours. The preferred oral dose for nafcillin ranges from 1 gram per day to 6 grams per day in 4 to 6 divided doses.
Oxacillin is preferably administered parenterally to adults in doses of 2 to 12 grams per day, in 4 to 6 equally divided doses. In conventional administration, it is effective largely against gram-positive organisms. In children, oxacillin is preferably administered in doses of 100 to 300 mg/kg per day.
Piperacillin is preferably administered parenterally to adults in doses ranging from 100 mg/kg, or 6 grams per day, in 2 to 4 equally divided doses, up to a maximum of 24 grams per day, in 4 to 6 equally divided doses. Higher doses have been used without serious adverse effects.
Ticarcillin is preferably administered parenterally to adults in doses ranging from 4 grams per day to 18 grams per day administereri in 4 to 6 equally divided doses. The usual dose is 200 to 300 mg/kg per day. For children, the preferred parenteral dose of dcarcillin ranges fmm 50 mg/kg per day to 300 mglkg per day, given in 3, 4 or 6 equally divided doses. The combination ticarcillin/clavulanate is preferably administered parenterally to adults in doses of 200 to 300 mg/kg per day (based on ticarcillin content), in 4 to 6 equally divided doses.
For adults, the usual dose is 3.1 grams (which contains 3 grams of ticarcillin and 100 mg of clavulanic acid) every 4 to b hours. The combination is also available in a dose of 3.2 grams, which contains 3 grams of ticarcillin and 200 mg of clavulanic acid.
In general, it is desirable to limit each intr3muscular injection of a penicillin or cephalosporin to 2 grams; larger doses should be administered by multiple injections in different large muscle masses.
SUBSTITUTE 5~~'~ ~~~~.~ 2B~

CEPHALOSPORINS
When a BPI protein product is concurrently administered with a cephalosporin, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~cgJkg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mg/kg daily. The cephalosporin is generally given in doses ranging from 1 ~.glkg to 500 mg/kg daily, preferably not to exceed 16 grams daily, and is preferably administered as follows:
Cefamandole is preferably administered parenterally to adults in doses ranging from 1.5 grams per day, given in 3 equally divided doses every 8 hours, to 12 grams per day for life-threatening infections, given in 6 equally divided doses every 4 hours. In children, cefamandole is preferably administered in doses ranging fmm 50 to 150 mg/kg per day, in 3 to 6 equally divided doses, not to exceed a total of 12 grams per day.
Cefazolin is preferably administered parenterally to adults in doses of 750 mg per day, given in 3 equally divided doses every 8 hours. In severe, life-threatening infections, it may be administered at doses of b grams per day divided iato 4 equal doses every 6 hours; in rare instances, up to 12 grams per day have been used. In children, the preferred parenteral dose of cefazolin is 20 to 50 mg/kg per day, divided into 3 or 4 equal doses, with 100 mglkg per day administered for severe infections.
Cefonicid is preferably administered parenterally to adults in doses ranging from 500 mg once daily, to 2 grams once daily for life-threatening infections.
For intramuscular administration, a 2 gram dose should be divided into two 1-gram injections.
Cefoperazone is preferably administered parenterally to adults in doses ranging from 2 grams per day, given in 2 equally divided doses every 12 hours, to 12 grams per day for severe infections, given in 2, 3 or 4 equally divided doses.
Doses up to 16 grams per day have been administered without complications.
Cefotetan is preferably administered parenterally to adults in doses of 1 to 4 grams per day, in 2 equally divided doses every 12 hours. Cefotetan may be administered in higher doses for life-threatening infections, not to exceed a total dose of 6 grams per day.
SUBSTIl'~TE ~~E~' ~~JL~ 26;

WO 95/08344 PCTlUS94111225 Cefotaxime is preferably administered parenterally to adults in doses - ranging from 1 to 12 grams per day, not to exceed 12 grams per day (2 grams every 4 hours) for life-threatening infections. In children, the parenteral dose of cefotaxime is preferably 50 to 180 mg/kg, divided into 4 to 6 equal doses.
Cefoxitin is preferably administered parenterally to adults in doses ranging from 3 to 12 grams per day, given in 3, 4, or 6 equally divided doses.
In children, cefoxitin is preferably administered parenterally in doses of 80 to 160 mg/kg per day, given in 4 or 6 equally divided doses, not to exceed a total dose of 12 grams per day.
Ceftazidime is preferably administered parenterally to adults in doses ranging from 500 mg per day, given in 2 to 3 equally divided doses (every 8 or hours), up to a maximum of 6 grams per day. In children, ceftazidime is preferably administered intravenously in doses of 30 to 50 mg/kg, to a maximum of 6 grams per day.
Ceftizoxime is preferably administered parenterally to adults in doses ranging from 1 gram per day, given in 2 equally divided doses every 12 hours, to 12 grams per day for life-threatening infections, given in 3 equally divided doses every 8 hours. The usual adult dose is 1 to 2 grams every 8 or 12 hours. For children, the preferred parenteral dose is 50 mg/kg every 6 or 8 hours, for a total daily dose of 200 mglkg.
Ceftriaxone is preferably administered parenterally to adults in doses ranging from 1 to 2 grams per day, given in 2 equally divided doses every 12 hours.
It may be given in. higher doses, not to exceed a total of 4 grams per day. In children, the preferred parenteral dose of ceftriaxone is 50 to 75 mg/kg per day, not to exceed 2 grams per day. In meningitis, ceftriaxone may be administered in doses of 100 mg/kg per day, not to exceed 4 grams per day.
Cefuroxime is preferably administered parenterally to adults in doses ranging from 2.25 to 4.5 grams per day, in 3 equally divided doses every 8 hours.
For life-threatening infections, 6 grams per day may be administered in 4 equally divided doses every 6 hours, and for meningitis, 9 grams per day may be administered in 3 equally divided doses every 8 hours. For children. the preferred ~ ~ ~Z24~

parenteral dose of cefuroxime is 50 to 150 mg/kg per day in 3 to 4 equally divided doses, or 240 mg/kg per day for meningitis.
Cephalexin is formulated for oral administration, and is preferably administered orally to adults in doses ranging from 1 to 4 grams per day in 2 to 4 equally divided doses. For children, the preferred dose is 20 to 50 mg/kg per day in divided doses, with doses being doubled for severe infections.
Cephalothin is usually administered parenterally to adults in doses of 8 to 12 grams per day.
OTI~R BETA-LACTAMS
When a BPI protein product is concurrently administered with an imipenem antibiotic, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~cg/kg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mglkg daily.
The imipenem is generally given in doses ranging from 1 ~,g/kg to 100 mg/kg daily, and is preferably administered as follows:
Imipenem is available in combination with cilastatin, an inhibitor of the renal dipeptidase enzyme that rapidly inactivates imipenem. The combination is preferably administered intramuscularly to adults in doses of 1 to 1.5 grams per day, given in 2 equally divided doses every 12 hours. Intramuscular doses exceeding 1.5 grams per day are not recommended. The combination is preferably administered intravenously in doses ranging from 1 to 4 grams per day, in 4 equally divided doses every 6 hours; doses exceeding 50 mg/kg per day, or 4 grams per day, are not recommended.
When a BPI protein product is concurrently administered with a monobactam antibiotic, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~g/kg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mglkg daily.
The monobactam is generally given in doses ranging from 1 ~.g/kg to 200 mglkg daily, and is preferably administered as follows:
Aztreonam is preferably administered parenterally to adults in doses ranging from 1 gram per day, given in 2 equally divided doses every 12 hours, up to a maximum recommended dose of 8 grams per day in cases of life-threatening infection, given in 3 or 4 equally divided doses.
A~OGLYC OSIDES
When a BPI protein product is concurrently administered with an aminoglycoside, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~,g/kg to 100 mglkg daily, and preferably at doses ranging from 1 mg/kg to 20 mglkg daily. The aminoglycoside is generally given in doses ranging from 1 ~g/kg to 20 mglkg daily, preferably not to exceed 15 mg/kg daily, and is preferably administered as follows:
When administering aminoglycosides, it is desirable to measure serum peak and trough concentrations to ensure the adequacy and safety of the dosage.
Dosages should generally be adjusted to avoid toxic peak and trough concentrations.
Amikacin is preferably administered parenterally to adults and children in doses of mg/ kg per day, divided into two or three equal doses every 8 or 12 hours, and not 15 to exceed a total dose of 1.5 grams per day. For uncomplicated infections, a dose of 500 mg amikacin per day, in 2 equally divided doses, may be administered.
Dosages should be adjusted to avoid prolonged serum peak concentrations of amikacin above 35 ~cg/ml and prolonged trough concentrations greater than 10 ~cglml.
Gentamicin is preferably administered parenterally to adults in doses of 3- mglkg per day, in three equally divided doses every 8 hours. For life-threatening infections, up to 5 mg/kg per day in 3 to 4 equally divided doses may be administered, but this dosage should be reduced to 3 mglkg per day as soon as clinically indicated. For children, gentamicin is preferably administered parenterally in doses of 6 to 7.5 mglkg per day. Dosages should be adjusted to avoid prolonged serum peak concentrations of gentamicin above 12 ~cg/ml and prolonged trough concentrations greater than 2 ~cglml.
Netilmicin may be administered parenterally to adults in doses ranging from 3 mg/kg per day, in 2 equally divided doses every 12 hours, to 6.5 mg/kg per day for serious systemic infection, in 2 or 3 equally divided doses. In children, the preferred parenteral dose is 5.5 to 8 mg/kg per day, in 2 or 3 equally divided doses.
Dosages should be adjusted to avoid prolonged serum peak concentrations of netilmicin above 16 ~eg/ml and prolonged serum trough concentrations above 4 ~g/ml.
~~~~~~~~ ~ ~ ~~ f ~~~ ~~~

Tobramycin is preferably administered parenterally to adults in doses of 3 mglkg per day, given in three equally divided doses every 8 hours. For life-threatening infections, tobramycin may be administered in doses up to 5 mg/kg per day, in 3 or 4 equally divided doses, but this dosage should be reduced to 3 mg/kg per day as soon as clinically indicated. In children, tobramycin is preferably administered parenterally in doses of 6 to 7.5 mg/kg per day. Prolonged senrm concentrations of tobramycin above 12 ~,g!ml should be avoided, and rising trough levels above 2 ~cglml may indicate tissue accumulation, which may contribute to toxicity.
Concurrent administration of BPI protein product with the aminoglycosides, including amikacin, gentamicin, netilmicin and tobramycin, may permit a lowering of the dose of these toxic antibiotics necessary to achieve a therapeutic effect.
TETRACYCLINES
When a BPI protein product is concurrently administered with a tetracycline, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~cg/kg to 100 mglkg daily, and preferably at doses ranging from 1 mg/kg to 20 mg/kg daily. The tetracycline is generally given in doses ranging from 1 ~,g/kg to 50 mg/kg daily, and is preferably administered as follows:
The tetracycline antibiotics are generally administered to adults in doses of 1 to 2 grams per day. An exception is doxycycline, which is preferably administered intravenously to adults in doses of 100 to 200 mg per day, and to children in doses of 2 mg/lb per day. Tetracycline may be administered parenterally to adults in doses of 0.5 to 2 grams per day, in 2 equally divided doses, and to children in doses of 10 to 20 mg/kg per day.
SULFONANimES
When a BPI protein product is concurrently administered with a sulfonamide or trimethoprim, for treatment of a gram-negative bacterial infection, the BPI protein product is generally given parenterally in doses ranging from 1 ~g/kg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mglkg daily.
The sulfonamide or trimethoprim is generally given in doses ranging from 1 ~.g!kg SUBSTiTU i ~ ~I~~~ ~R~L' 26) to 150 mg/kg daily, preferably not to exceed a combination dose of 960 mg trimethoprim/4.8g sulfamethoxazole daily, and is preferably administered as follows:
The combination trimethoprim/sulfamethoxazole is available in a formulation containing a 1:5 ratio of trimethoprim and sulfamethoxazole (e. g.
, 16 mg trimethoprim and 80 mg sulfamethoxazole). The combination is preferably administered intravenously to adults or children in doses of 8 to 10 mg/kg (based on the weight of the trimethoprim component) per day, in 2 to 4 equally divided doses.
For Pneumocystis carinii infection, the combination can be administered in doses of 20 mg/kg (based on the weight of the trimethoprim component) per day, in 3-4 equally divided doses, to a maximum recommended dose of 960 mg trimethopriml4.

g sulfamethoxazole per day. Trimethoprirn alone is preferably administered orally to adults in doses of 200 mg per day. Sulfamethoxazole alone is preferably administered orally to adults in doses of 2 to 3 grams per day, and to children orally in doses of 50 to 60 mg/kg per day.
FLUOROQUINOLONES
When a BPI protein product is concurrently administered with a fluoroquinolone or quinolone, for treatment of a gram-negative bacterial infection, the BPI protein product is generally given parenterally in doses ranging from 1 ~.g/kg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mg/kg daily.
The fluoroquinolone or quinolone is generally given in doses ranging from 1 ~cg/kg to 50 mglkg daily, preferably not to exceed 1 gram daily, and is preferably administered as follows:
Norfloxacin is preferably administered orally to adults in doses from 400 to 800 mg daily, divided into two doses every 12 hours. Cinoxacin is preferably administered orally to adults in doses of 1 gram per day, given in 2 or 4 equally divided doses. Ciprofloxacin is preferably administered to adults intravenously in doses from 400 to 800 mg daily, or orally in doses from 500 to 1500 mg daily, divided into two doses every 12 hours. Ofloxacin is preferably administered to adults intravenously in doses from 400 to 800 mg daily, or orally in doses from 400 to 800 mg daily. divided into two doses every 12 hours.
VANCOMYCIN

WO 95108344 PCTlUS94/11225 ~1'~~45 When a BPI protein product is concurrently administered with vancomycin, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~cg/kg to 100 rng/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mg/kg daily. The vancomycin is generally given in doses ranging from 1 mg/kg to 50 mg/kg daily, and is preferably administered parenterally to adults in doses of 2 grams per day, divided into 2 or 4 doses every 6 or 12 hours. In children it is preferably administered in doses of 40 mg/kg, given in 4 equally divided doses every 6 hours. In conventional administration, vancomycin is effective largely against gram-positive organisms.

When a BPI protein product is concurrently administered with a macrolide, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~eg/kg to 100 mg/kg daily, and preferably at doses ranging from 1 mglkg to 20 mg/kg daily. The macrolide is generally given in doses ranging from 1 ~.g/kg to 100 mg/kg daily, and is preferably administered as follows:
Erythromycin is preferably administered intravenously to adults and children in doses of 15 to 20 mg/kg per day, given by continuous infusion or in 4 equally divided doses every 6 hours. Erythromycin can be administered at doses up to 4 grams per day in cases of very severe infection.
Clarithromycin is preferably administered orally to adults in doses of 500 mg to 1 gram daily, in equally divided doses every 12 hours.
Azithromycin is preferably administered orally to adults at a dose of 500 mg on the first day of treatment followed by 250 mg once daily for 4 days, for a total dose of 1.5 grams.
OTHERS
When a BPI protein product is concurrently administered with other antibiotics, for treatment of a gram-negative bacterial infection, the BPI
protein product is generally given parenterally in doses ranging from 1 ~.glkg to 100 mg/kg daily, and preferably at doses ranging from 1 mg/kg to 20 mg/kg daily.
Polymyxin B is generally given in doses ranging from 1 unit/kg to 45.000 units/kg daily, and is preferably administered intravenously to adults and lTl~~'~ 5~~~ ~~~~~~26~
~U~ST

2112~4~

children in doses of 15,000 to 25,000 units/kg per day, divided into 2 equal doses every 12 hours. It may be administered intramuscularly in doses of 25,000 to 30,000 units/kg per day, although these injections are very painful. Doses of polymyxin B
as high as 45,000 unitslkg per day have been used in limited clinical studies to treat neonates for Pseudomonas aeruginosa sepsis. Polymyxin B is the treatment of choice for P. aeruginosa meningitis, and is preferably administered intrathecally to adults and older children in doses of 50,000 units once daily for 3 to 4 days, followed by 50,000 units every other day; in children under two years old, it is administered intrathecally in doses of 20,000 daily for 3 to 4 days, followed by 25,000 units every other day.
Chloramphenicol is preferably administered intravenously to adults in doses of 50 mg/kg per day, in 4 equally divided doses; in exceptional cases, it can be administered in doses up to 100 mg/kg per day. In children, chloramphenicol is preferably administered intravenously in doses of 25 mg/kg per day, although up to 100 mg/kg per day can be administered in cases of severe infection.
Clindamyciri is preferably administered parenterally to adults in doses ranging from 600 mg to 4.8 grams per day, given in 2, 3 or 4 equally divided doses.
It is recommended that the dose in each intramuscular injection not exceed 600 mg.
For children, clindamycin is preferably administered parenterally in doses of mg/kg per day, given in 3 or 4 equally divided doses.
Dosages of all antimicrobial agents should be adjusted in patients with renal impairment or hepatic insufficiency, due to the reduced metabolism and/or excretion of the drugs in patients with these conditions. Doses in children should also be reduced, generally according to body weight. Those skilled in the art can readily optimize effective dosages and administration regimens for the BPI protein product and the antibiotics in concurrent administration.
Other aspects and advantages of the present invention will be understood upon consideration of the following illustrative examples. Example addresses the bactericidal effect of gentamicin and BPI when administered to two different strains of E. coli. Example 2 addresses the bactericidal effect of gentamicin and BPI for a number of other gram-negative strains. Example 3 addresses the bactericidal effect of polymyxin B and BPI when administered to two different strains SUBSTITUTE SHEET (RULE 26) of E. coli. Example 4 addresses the bactericidal effect of polymyxin B and BPI
for a number of other gram-negative strains. Example 5 addresses the effect of a BPI
protein product with a cephalosporin antibiotic in an in vivo mouse peritonitis E. coli 0111:B4 challenge model. Example 6 also relates to the effect of a BPI protein product with a cephalosporin antibiotic in an ' in vivo mouse peritonitis E.
coli 0111:B4 challenge model. Example 7 relates to the effect of a BPI protein product with a cephalosporin antibiotic in an in vivo mouse peritonitis E. coli 07:K1 challenge model. Example 8 addresses the effect of a BPI protein product with a cephalosporin antibiotic in an in vivo rabbit bacteremia E. coli 07:K1 challenge model. Example 9 addresses the effect of a BPI protein product with an aminoglycoside antibiotic in an in vivo mouse peritonitis E. coli 07:K1 challenge model. Example 10 relates to the effect of a BPI protein product in vitro on the antibiotic susceptibility of ceftriaxone-resistant gram-negative organisms.
Examples 11-19 address large-scale screening of the antibiotic susceptibility-increasing effect of a BPI protein product on a variety of gram-negative organisms: Pseudomonas aeruginosa and other Pseudomonas species (Example 11), E. coli (Example 12), Citrobacter (Example 13), Klebsiella (Example 14), Enterobacter (Example 1S), Serratia (Example 16), Proteus (Example 17), Providencia (Example 18), Morganella (Example 19), Acinetobacter (Example 20), and Salmonella and Shigella (Example 21). Example 22 examines the early in vitro bactericidal effect of BPI protein product and selected antibiotics on E. coli J5, E. coli 07:K1, Enterobacter cloacae and Klebsiella pneumoniae. Example 23 examines the effect of a variety of BPI
protein products on several representative organisms, Acinetobacter anitratus, Enterobacter cloacae, and two strains of E. coli. Example 24 relates to the screening of BPI peptides for antibacterial activity against E. coli. Example 25 addresses the effect on E. coli 0111:B4 of concurrent administration of BPI protein product with tetracycline or gentamicin.

Example 1 SYNERGISTIC BACTERICIDAL EFFECTS OF GENTAMICIN AND BPI:
ADNE1VISTRATION TO E. COLI AND E. COLI Ol l l :B4 GRAM-NEGATIVE ORGANISMS
In this example, a micro dilution plate minimum inhibitory concentration (NBC) assay was conducted to determine the sensitivity of E.
coli organisms to the bactericidal effects of BPI protein products concurrently administered with the antibiotic gentamicin. The assays were conducted against the BPI sensitive organism E. coli J5 (an Rc rough mutant of E. coli 0111:B4), and a BPI
resistant organism E. coli 0111:B4.
Specifically, organisms were grown overnight on blood agar plates of 37°C in air, single colonies were then sub-cultured in 100 mL of nutrient broth No.
2 (Oxoid CM67) and incubated with gentle agitation on an orbital shaker for 5 hours until in log phase. Fifty mL of the bacterial suspension was then spun down in a Denley BR401 bench centrifuge at 4000 rpm for 15 minutes and the pellet was resuspended and washed twice using sterile normal saline. Bacteria were then resuspended in saline such that a 1:10 dilution had an optical density of 0.9 (+/-0.01) at 325 nm (corresponding to approximately 4x109 cells per mL) and diluted to give a final concentration of 4x106 cells per mL in "BPI media" (described below).
All assays and dilutions of BPI protein products and gentamicin were performed using "BPI media" consisting of 50 ~ peptone water (Oxoid L37, Lot:
25851279) with 0.1 M MOPS (Sigma M-1254) buffered to pH 6.00 with sodium hydroxide. This provides a nutritive media with a low protein and divalent canon concentration adjusted to a pH which is not inhibitory to bacterial growth and allows for readily measurable (though not optimal) BPI activity.
rBPI23 and gentamicin (Sigma G-1264, Lot: 91H00325) were diluted in BPI media such that 100 ~,L of diluted BPI, 50 ~.L of diluted gentamicin and 50 ~cL of bacterial suspension in the final volume of 200 ~L per well, gave concentrations in serial dilutions from 1000 nM (25 ~cg per mL) BPI and 32 ~g per mL of gerytamicin with a fixed concentration of 106 cells/mL. Checkerboards were then constructed in round bottomed 96 well microtitre plates (Greiner No.
650180) and incubated with non-sealing lids at 37 C in air for 18 hours. Plates were then read SUBSIfTUT~ SH~e~ (RULE 26) 2172~4~

by eye and in an automatic plate reader (Titretek Multiscan plus) at 580 nm with visible growth corresponding to an optical density of approximately 0.1 (see Table 1 for E. coli J5, and Table 3 for E. coli 0111:84). Viable counts were made from the wells adjacent to the cutoff of visible growth for the two E. coli plates (see Table 2 for E. coli J5, and Table 4 for E. coli Ol l l :B4) by dilution of 10 ~cL in 990 ~,L of Nutrient Broth No. 2 and spmad plates were prepared with 25 ~cL on blood agar.
The inhibitory activity of BPI protein product with antibiotic was evaluated by the method of Eliopoulos and Moellering In Antibiotics in Laboratory Medicine, 3rd ed.
(Lotion, V., Ed.) pp. 432-492, Williams and Willdns, Baltimore MD (1991), wherein a fractional inhibitory concentration index (FiC) of less than 0.5 was scored as synergy, 1 was scored as additive and greater than 1 but less than 2 was scored as indifferent.
A positive synergistic interaction was demonstrated between rBPI~ and gentamicin using the BPI sensitive E. coli J5 with gentamicin at a concentration of 0.25 ~,g per mL, reducing the MIC of BPI by approximately eight-fold from 500 nM
(12.5 ~,g per mL) to 62.5 nM (1.56 ~cg per mL) with similar reductions of the minimum bactericidal concentration (IvvfBC).

_39_ ~

~D 6I~O M ~D O N N
O O O N N N O M M
N

N ~G ~' 00 N Ov h O

p O O ~ N N N N t7 00 ~ ~ W C .--,N

_ p O O O N ~ N N N

'~ \O V'7 ~ N ~C O N
N O ~ O O -~ N N N

O
..., 'r N O O O O O ~
O

"O

C

cd M ~ tn ~ N M p~ph O O O SOD O p O O

U
'~
w o 0 0 0 0 0 0 0 w ~' N O O O O O O O O

h v~ h M ~' ~ 00 h ~ O O O O O O O O

~_ O

pp O O O O O O O

h O ~ M M o0 01 M

O O O O O O O O

,..., -~ ~ ~O 00 N h h O

N o 0 0 0 0 0 0 0 M

O O ~ N N ~D
Ca -r V'~ N ~-W O M ~' O

WO 95/08344 ~ PCTIUS94111225 U U U U U U

0 0 o z z z z z z 0 0 ~ z z z z z o + z z z z c ~ o ~ o o + Z z Z

U

a ~_ ~n o 0 0 0 + oo + O
c . + ~ + $

y n U N ,'r o ~ o z o 0 0 .-. "., ~ ~' w ~ z z o o o o o 0 o o .~ -~

U U U
z z z o 0 0 0 0 O

U

z z z z z z z z ' z z z z z z z z z ~.

z z z z ~ z z z O

U

M z z .~-~z z z z z U

t.

U

"'~O O O ~n O nj .~Nr~ M ~D O O
U

M M M M M M M

00 ~O Cv -~ I'~00 'C?'N
O a N N N N N N M

\O N ~ ONO~ OMOO~0o~0 O M N N N N N N M

w ~n ~n ~n O~ N O .-~O

pOp ~ N N N N N N N N

A

0 --~C1 ~ 00 vD N 00 V'1 N Ov t~ ~G C~ I~ C~ V7 tn ~' ~ ~ O O O ~ O O O O
O
O ~

M 'D
b _ _ O O O O O O O O

~n O o0 C, M -~ N O
N O O O O O O O O

t~7~ U7 "Ch ~
~, O O O O O O O O

_~
O O O O O O O O

M r 00 ~ ~' 00 P, O O O O O O O O

N O O O O O O O O
M . . , g O ~ N N ~G
-. m N .-. ~D M - O

U U U U U U U U

O z z z z z z z z cn U U U U U U U U

z z z z z z z z;

~o U U U U U U U U

z z z z z z z z z z z z z z z z + + + + + + +

+ + + + + + + +
+ + + + + + + + V

O

O
O O O O O (~. ~O
O ~ C --~O O
N

O

y w0 ~U .~ O O O O O O O O (I
+

,~ +

U
N O O O O O O O O

O

U
z z z z z z z z C
II

U

z z z z z z z z z : z z z z z z z z O

U

M z z ~r z .~-iz z z ~

~_-g O O ~ N N - vC O U
tn N ~ ~O M ~' Example 2 SYNERGISTIC BACTERICIDAL EFFECTS OF GENTAMICIN AND BPI:
ADMINISTRATION TO ADDTTIONAL GRAM-NEGATIVE ORGANISMS
In this example, micro dilution plate MIC assays were conducted according to the method of Example 1 to determine the sensitivity of a variety of gram-negative organisms to the cytotoxic effects of BPI protein products concurrently administered with gentamicin antibiotic. The results of those assays are shown in Table 5 below. Positive synergistic bactericidal interactions were observed against E. coli J5, E. coli O1:K1, E. coli (52252), K. oxytoca, E. tarda, Salmonella typhimurium (52136) and Salmonella arizonae. Possible synergistic bactericidal interactions (indicated as "additive (+)") were observed against E. cloacae (10005), E. gergoviae (11434), P. aeruginosa (10332) and P: aeruginosa (10662). The concurrent administration of gentamicin and rBPI~ had only additive, indifferent or indeterminate effects against the other tested gram-negative bacteria.

o ~ >, .

~

c c ~ c c ~ c c c a~ a~ ~. >,a~ ~ ~ ~ ~ ~ ~, ~ a~ a~ ~ ~ a~ ~ a~

w ':"w w w ~ ''~~ ~ '~ '~:~ ~ ~~w w , ~c ~ ~ ~ '~ '~'~ -o '~
W ~

s ~ ~ ~ ~ c ~ c ~, ~ v b c a, s ~ ~ s ~

. ..". ~ .~ ~ ..., .b ~ .
U U

O O ."C tn O O tn O O
~

-N-~h N ~ N O

O O O ~ \ ; i i ~ w w w N N
~ i i i ~J O O

y ~ M ~ N O ~ '-' N
'" ~ ~ N n ~"~N .-i M

U n .-rn n . N N n ~

H

..., v~ ~ ~ ~ O O ~n O O ~ ~ ~ O tnO O O O N O W O
~

V O ~ ~..iN O .-w.-~i i y -; p .-rN '~ N p N O

H '~a O

s o ~ c ~ o g o ~ o ~ ~ g g ~ g g o 0 ' n n n n n n n n n n n n ~ n n n ~d b U ~ ~
"'" N

~ ~
..., ~ ~' ,-~,M CL

V z ~ N ~n d' O cr~, ~ O

E. N i/1 O .-, ~
., ~t ~ ~ ~ O ~ N ~ N ~

U ~'~ CA ~ N ~ N ~ ~ ~, '' ~ ~ CfC3 ' O <t l'~' ~rN ~" N N C/~
' ~p ~ N ~ 5 a O ~

y --~O ~ O wrx p ~ O ~ U O 4~ 0~O a QOCO

. . . . . . Q O ..,~ O ~p ~ ~p~ ~0 ~

O O O O O O ~

O W W W W W W W W ~C ~CW W ~ 4,4; a, 4,a;

21722~~

C ~ C7 ~ w w w ,.,w w ~, ~,w _ , ~ ~ ~
, b b ~ b T3 b ..p.,.~ .~ ~ .~.~ .~ v~,<n~ ~ 4j ~. .~

U U C
'~ O ~~ O
' ~ tn ..~ O
N N N m' ..r Uo~ o o ~ ~"~ o .
~ ~ E-~ ~ ;~ p g ~ g ~ ~ n ' w .-r U
~

N -~ ~ th N O
N ~ n ' 3 a ~w N ~ n n aa ~
~

y U

U

H ~ ...

..r O

.-' ~ ~ N ~n O O O O ~ N ~ O O

w ~ p .--~.-..i~ .~.~ O n ""'"' i U,.

U r ~

ri ~
a n H ~ a ~

.

x v ~ g ~ g ~ g o g O a~
~

n n n n n n n n n n n a ~

N N
O

~O ~ ~ ~

N ~ z i U g H ~ ~:'~'~ ~ ~ ~ ~ >

V o _ " , H

U o ' 0 0 ~ ~, ~,,~ o ~ ~ ~ _ >

. .

~

o ~ :~0 0 0 0 ~ o C3Ci Cs oa .. ~.~ ~ ~ ~ C3 ~

pp , , a O a40: aC ~ W aC~ ~ ~ ~ W C
V

.

Example 3 SYNERGISTIC BACTERICIDAL EFFECTS OF POL~'lvfYXIN B AND BPI:
ADMINISTRATION TO E. COLI JS AND
E. COLI 0111:B4 GRAM-NEGATIVE ORGANISMS
In this example, micro dilution plate MIC assays were conducted according to the method of Example 1 to determine the sensitivity of E. coli JS and E. coli 0111:B4 to the cytotoxic effects of BPI protein products concurrently administered with the antibiotic polymyxin B. Polymyxin B solution with an activity of 10240 units/mL was prepared by preparing a solution of 1.595 mg of polymyxin B sulfate stock powder per mL, and diluting it in sterile water for injection as 20 ~cg in 12.54 mL.
A positive synergistic interaction was demonstrated between rBPI~ and polymyxin B using E. coli 0111:B4 (see Tables 8 and 9) but the administration of polymyxin B with BPI did not have synergistic bactericidal effects with BPI
when applied to E. coli J5 as illustrated by the results shown in Tables 6 and 7.

'- 217224 t~ioo N O

O

tn N N M M et 00 tn ~ ~ N ~

.-. p O O ~ .- N
-r -~

~r O try ~ - N tn O .-~M O

_ _ O O ~ O O ~ ~ ~ N

O

C..~.~ S S O ~ ~ ..~rN

O

A

Q N M .-~N_ _et~?'M

"O M ~ ~ ~ O

a H

o _ _ _ _ ~c ~' g g N M N

w a~

c O ~ ~ ~ ~ N
O ~ .-, O .~

y (7 1D M N N .-r N N O O ~ ~ O O O
O O

.

a ~ O O O O O O O O

n O ~ N N .-, CaN ~ tn N .-.Lp M O

WO 95/08344 ~ ~ ~ 2 2 4 5 PCT~S94111225 'n U U U U
0 0 0 0 ~ z z z z ~ o ~ + U G U U
0 M o z < z z +

o4 +

+ U v U U
;, ~ o o N + z z z z + o o ~ o o + + z z z z V
+ +

U

.a ... +

U U U U

M ,~ + + z z z z o W c o a H +
o +

w ~ o ~ ~ + z z z z o N + z z z z 0 0 ~ '~ U

z ~n U U U ,~ p z z z ~ 0 0 0 0 o v U U U
z z z z o 0 0 0 :.:

v _ N O O ~ ~ ~ M O C
C~ .-,~ N

Z17~245 n N

~ o o ~ ~ o o O

M N N N N N N N

O

O ~ ~ ~ ~ Ov O M M N N N N N M

t~1 -r o0 et M 'O Y

e N
N

~ N N N N N N N

A

0 ~ ~ ~ ~ O~

M O N N N N N N N

d' O ~ ~ 00 ~O \ 00 -~ M V'7 ~ O

_ _ O

G O ~ ~ N N N N N

y a ue p N ~~ ~ d ' ~ O .-~.-~ .-~.-~ N N N

=" ~, o 0 a ~ g g o o N

_~

~ M ~D ~G ~ ~ N

_ O O O O ~ ~ O O

O

O O O O O O O O

i-~

O O ~ N N

Cl N .-.~n N - ~ M O

WO 95108344 ~ PCTIUS94/11225 o z z z z z z z z z z z z z z z z + z z z z z z z + o b + U
M .~ + z z z z z z w o ~ ~ o + z z z z z z g H o ~~, +
_ ~ N + + + + + U U +
o -f- + + +
+ + + + + z z b + + + o + + +
z ~ + ,~ + + z ..

~, ~ ~

U

U
z p p p ~.

N N vC M p U

ale 4 SYNERGISTIC BACTERICIDAL EFFECTS OF POLYMYXIN B AND BPI:
ADMINISTRATION TO ADDITIONAL GRAM-NEGATTVE ORGANISMS
In this example, micro dilution MIC assays were conducted according to the method of Example 1 to determine the sensitivity of a variety of gram-negative organisms to the cytotoxic effects of BPI protein products concurrently administered with polymyxin B antibiotic. The results of those assays are shown in Table 10 below.
These assay results show additive or synergistic effects with the use of polymyxin B at concentrations of 0.3 ,ug/mL, a level of which is 10-20 times lower than when that antibiotic is used conventionally.

~ .7225 o ~

.S

~ c C4~ ~ ~' a, ~' a~ ~' >, ~, ~, ~, >, ~

a'~ w w ~ w ~ ~, a~n on oo a~noho o ~ ~ :~ a~ ~ ~ '~ a~ a~ a~ a~ a~
,...
~
, "

o w 0 0 .~

~O ~ ~G M

N N N O ' ~ ' O ~ O
O ~
O

~r ~ ~ g N ~ ~ $ N
~

N N N N l<1~~ n ~ N ~"r.-~N
~
~

n t.
as ~

3 "

._ H ~
~

_ 0 0 O ~ ~ V~ O O m O O ~ N N N N O
'~

p ~" ~"

"" ~ ~ N ~ ~ O ~ n N ~ ~ ~ ~ n a ~, v ~
O

U Q
C
a x ri o ~ g ~ ~ ~ ~ ~ ~ g ~
r .. o ~

N N N N N N N N N
v ~ N ~' n n n n n n n n n n a x ~_. ..._ .-._ E"'~ .~ ~ CW

._.. M O

O M O ~ O

N g '_" N _ 0_O_ ~

V N ~ ~ ~ ~ ~
z -. y i . p O O O

~7 C ~" ~ > ~ '~ fi'i_"._~_~_ /~

' _ O ~ U ~ ~ ~ ~ ~ O

~ :" ~ O Q O~ y O O C ~, o pp U U ~ V 0 ~ C3 Ci C3 C3 C3 .
O W W W W W ~ 0.: 0.;0.;0Øa.

Example 5 SYNERGISTIC EFFECTS OF CEFAMANDOLE AND
BPI PROTEIN PRODUCT IN VIVO IN MICE CHALLENGED
I1V TRAPERTTONEALLY WITH LIVE E. COLd O1 I I :B4 BACTERIA:
EFFECT ON SURVIVAL
In this example, the protective effect of cefamandole nafate antibiotic (MANDOL~, Lilly) a semisynthetic broad-spectmm cephalosporin antibiotic with and without a BPI protein product was evaluated by means of challenging ICR mice with an LD~,~ dose level of live E. coli 0111:B4 bacteria, a strain that is not susceptible to the bactericidal/growth inhibitory effects of BPI
protein product. Specifically, four groups of 15 ICR mice were treated such that each ICR mouse received an injection of bacteria (1.8 x 109 CFUlmouse) intraperitoneally; an intraperitoneal injection of cefamandole nafate (MANDOL~, 100 mg/kg) or saline; and then an intraperitoneal injection of rBPI2, (500~,g/mouse) or BPI buffer. Survival of the mice was then evaluated over a period of 7 days with the results illustrated in Figure 1.
Concurrent administration of BPI protein product with cefamandole, or administration of cefamandole alone, showed significant protection in mice challenged with E. coli Ol l l :B4 when compared to the buffer control (p <_ 0.001 and p S 0.05 respectively). The protective effect of the BPI protein product when administered without cefamandole was not evident. When compared to treatment with cefamandole alone, concurrent administration of BPI protein product with cefamandole showed improved protection at p s 0.1. These results indicate that the concurrent administration of cefamandole and a BPI protein product has synergistic therapeutic effects against E. coli O1I1:B4.
Example 6 SYNERGISTIC EFFECTS OF CEFAMANDOLE AND
BPI PROTEIN PRODUCT IN VIVO IN MICE CHALLENGED
INT'RAPERITONFALLY WITH LIVE E. COL/ Ol I1:B4 BACTERIA:
EFFECT ON SURVIVAL AND ON BACTERIAL CLEARANCE
FROM BLOOD AND PERITONEAL LAVAGE FLUID
The protective effects of a cephalosporin antibiotic and a BPI
protein product were evaluated in mice challenged intraperitoneally with E.
coli SUB~TtTU~~ S~tE~- (RULE 26) WO 95/08344 ~ ~ .~ 2 2 4 ~ PCT/US94111225 0111:B4, a strain that is resistant to the bactericidal effects of BPI protein product.
The assay was conducted using the following procedure. Male ICR mice (Simonsen Laboratories, Gilroy California), 5-7 weeks old, were housed under controlled climate and dark/light cycles and were allowed free access to food and water. Mice received an intraperitoneal injection of 0.5 ml of bacteria in doses near an LDP (2 x 109 CFUlmouse). Immediately after bacterial challenge the animals received an intraperitoneal injection of (1) vehicle only, (2) 500 ~,glmouse rBPI2, and vehicle, (3) 100 mglkg cefamandole nafate (Mandoh in phosphate buffered saline; Eli Lilly, Indianapolis, III and vehicle, or (4) 500 ~g rBPIz, and 100 mg/kg cefamandole.
Survival of the four groups was monitored for 7 days. Survival .data was statistically analyzed using the Chi-square test. In a separate experiment using a bacterial challenge of 2.5 x 109 CFU E. coli 0111:B4, blood and peritoneal lavage fluid were collected for culture at different time points following bacterial challenge. Blood was obtained from the retro-orbital sinus. At least ml of peritoneal lavage fluid was obtained after intraperitoneal injection of 3 ml of phosphate buffered saline. Bacterial counts (expressed as CFUImI) were determined by inoculating trypticase soy agar plates with 10-fold dilutions of blood or peritoneal lavage samples, incubating the plates ovennight at 37°C, and counting the colonies. Statistical comparisons of this data were performed with the analysis of variance.
Figure 2 shows effects on survival of cefamandole (100 mg/kg), rBPI2, (500 ~.g) or the concurrent administration of the two agents. The BPI
protein product alone had no effect, while cefamandole treatment alone increased survival, although not significantly. In contrast, the concurrent administration of rBPI2, with cefamandole resulted in a significant increase in survival (p <
0.05) above that achieved by either treatment alone. Figures 3 and 4 show that rBPI2, alone failed to reduce counts in either peritoneal lavage fluid or blood after challenge with bacteria, while cefamandole treatment alone significantly reduced counts in both (p < 0.01 vs. vehicle): However, the concurrent administration of rBPIz, and cefamandole reduced bacterial counts in the peritoneal lavage fluid by more than two orders of magnitude below that achieved by cefamandole alone ~UBSTiTUTE SHEET (RULE 26~

(p < 0.01 of concurrent administration vs. cefamandole only) at the 2 and 6 hour time points, and entirely eliminated counts after 24 hours. Blood of mice that received concurrent administration of rBPI2, and cefamandole was completely free of bacteria at all time points.
Thus, the concurrent administration of a BPI protein product, rBPI2,, with a suboptimal dose of a cephalosporin antibiotic, cefamandole, resulted in a superior therapeutic effect. The data indicates that BPI protein products and cephalosporin antibiotics produce a synergistic therapeutic effect. Since cefamandole alone reduced counts by approximately two orders of magnitude compared to vehicle-treated animals, another experiment was conducted to determine if rBPI2, alone reduced bacterial counts when the inoculum was reduced to 10' CFU. Data from this experiment showed that rBPI2, (500 ~cg) did not significantly reduce bacterial counts in blood or peritoneal lavage fluid after a challenge of 10' CFU. This suggests that an antibiotic-mediated reduction in the magnitude of the bacterial count cannot, in itself, explain the protection associated with concurrent administration of BPI protein product and antibiotic.
Examvle 7 SYNERGISTIC EFFECTS OF CEFAdVIANDOLE AND
BPI PROTEIN PRODUCT IN VIVO IN MICE CHALLENGED
INTRAPERITONEALLY WITH LIVE E. COL/ 07:K1 BAC1~RIA:
EFFECT ON SURVIVAL
The protective effects of a cephalosporin antibiotic and a BPI
protein product were evaluated in mice challenged intraperitoneally with E.
coli 07:K1 (ATCC Accession No. 23503), a strain that is susceptible to the bactericidal effects of BPI protein product. The general procedure described above in Example 5 was followed. Four groups of 20 mice were challenged intraperitoneally with 2 x 10' E. coli 07:K1 bacteria and then treated with (1) vehicle, (2) 50 ~cg rBPIz, only, (3) 20 mglkg cefamandole only, or (4) both 50 ~cg rBPI2, and 20 mg/kg cefamandole. Survival of the mice was followed over a period of 7 days; results of two trials are displayed in Figures SA and 5B.
In one trial, rBPIz, alone protected 11 ~ of the survivors compared to vehicle controls, cefamandole protected 47 ~ of the survivors compared to SUBSTITUTE S~i~E;' (RULE 26) vehicle controls (p < 0.05 vs. vehicle), and the concurrent administration of rBPIz, and cefamandole protected 100 ~ of the survivors compared to vehicle controls (p < 0.001 vs. vehicle, p < 0.01 vs. cefamandole alone). In the second trial, rBPIz, alone protected 0 °.& of the survivors compared to vehicle, cefamandole protected 12 ~ compared to vehicle, and the concurrent administration of rBPI21 and cefamandole protected 59 °.& compared to vehicle (p < 0.01 vs. vehicle, p < 0.05 vs.
cefamandole alone). In both trials, the increase in survival associated with the concurrent administration of rBPI2, and cefamandole was greater than the sum of the increases in survival due to the individual therapies. Thus, there appears to be synergy (a greater than additive effect) between cefamandole and BPI protein product in this model.
Exam 1e SYNERGISTIC EFFECTS OF CEFAMANDOLE AND
BPI PROTEIN PRODUCT Ih,~ VIVO IN RABBITS CHALLENGED
INTRAVENOUSLY WITH LIVE E. COLI O7:K1 BACTERIA:
EFFECT ON BACTERIAL CLEARANCE AND ON
CARDIOVASCULAR, RESPIRATORY AND METABOLIC PARAMETERS
Adult male New Zealand White rabbits (Charles River Laboratories, St. Constant, Canada) weighing between 1.8 and 2.3 kilograms were fasted for hours before the experiment. Each rabbit was anesthetized with an intramuscular injection of 8014 mg/kg Ketamine/xylazine. The left femoral artery was catheterized for blood pressure determinations and blood sample collection. A
catheter was placed adaacent the right atrium via the right jugular vein and a thermistor-tipped catheter was placed in the aortic arch via the right carotid artery.
The rabbits were allowed to stabilize for 90-120 minutes following catheterization to normalize hemodynamic and blood gas parameters.
The rabbits were divided into four treatment groups with 4 animals per group: (1) vehicle alone, (2) cefamandole and vehicle, (3) rBPI2, and vehicle, and (4) cefamandole and rBPI2l. The rabbits were administered cefamandole (Mandol'; Eli Lilly, Indianapolis, IN) or vehicle intravenously 5 minutes before the start of the bacterial infusion (considered to be T=0). At T=0. 2 x 10'°
CFU/rabbit of E. coli 07:K1 was infused intravenously over 10 minutes into the SI~~S~fT4~ i E SHEET (F~U~E 26) ear vein. . Simultaneously (at T=0), 10 mg/kg rBPI=I or vehicle was infused over minutes via the right jugular catheter. After the ten minute infusion, rBPh, was slowly infused at 10 mg/kg/hr for 2 hours (resulting in a total dose of 30 mg/kg rBPIz,). . .
5 Arterial blood samples for determination of bacterial counts and endotoxin levels were collected at the end of the 10 minute bacterial infusion and at 30 minutes, 1, 2, 3 and 4 hours. The whole blood was 10-fold serially diluted in sterile PBS and aliquots were plated onto tryptic soy agar plates, incubated at 37°C overnight, and the plates were counted for colony forming units (CF'L>]. The 10 results were expressed as CFU/ml blood and percent bacteria dose per ml blood.
The remaining portion of the blood was centrifuged, the plasma removed and passed through a 0.2 micron Whatman syringe filter to remove the bacteria. The endotoxin levels were determined using a modified lirztulus amoebocyte lysate assay (Pyrnchmme LAL Assay, Associates of Cape Cod, Woods Hole, MA).
These results were expressed as ng LPS per ml plasma.
Cardiovascular, respiratory and metabolic parameters were measured every 30 minutes. Mean arterial blood pressure (MABP) and heart rate were monitored continuously throughout the experiments and displayed on a cardiac output computer (Columbus Instruments Cardioma~ In or on a chart recorder. Heart rate was derived from the arterial pressure wave. Cardiac output was determined in duplicate with the thermodilution technique: Changes in blood temperature resulting from injection of 900 ~cl of room temperature PBS were recorded with the thermistor-tipped catheter in the aortic arch. The cardiac output computer then generated thermodilution curves that were visualized on the chart recorder, and derived cardiac output from the temperature-time curves. Cardiac index (Cn was then calculated as cardiac output per kg body weight. In addition, total peripheral resistance ('TPR) was determined by dividing blood pressure by cardiac output.
Blood samples for blood gas determinations were drawn from the femoral artery catheter every 30 minutes throughout the study. Blood gases were measured with a Ciba-Corning Blood Gas System, Model 278 (Ciba-Corning Diagnostics Corp., Medfield, MA). The blood gas system directly measures blood pH, partial pressure of pC02, and partial pressure of p02. Other parameters including the alveolar-arterial oxygen gradient, arterial oxygen content, estimated oxygen saturation, standard bicarbonate, and in vivo base excess were calculated using the formulas provided by Ciba-Corning Diagnostic Cotp. Plasma levels of glucose and lactate were determined using a GlucoselL-lactate Analyzer (2300 STAT, YSI, Yellow Springs, OH).
Survival data is shown in Figure 6. Two of the four animals (50~) treated with vehicle alone died before the end of the experiment. None of the animals concurrently treated with rBPIz, and cefamandole died. Bacterial counts in blood, expressed as CFUImI or percent bacteria doselml, are shown in Figures 7 and 8, respectively. In Figure 7, the squares represent treatment with vehicle alone, the diamonds represent cefamandole alone, the circles represent rBPI2, alone, and the triangles represent the concurrent administration of rBPI21 and cefamandole. In Figure 8, the bar with horizontal hatching indicates treatment with cefamandole alone, the hollow bar indicates the concurrent administration of rBPIz, and cefamandole, the bar with vertical hatching indicates rBPI2, alone, and the solid bar indicates buffer alone. The group concurrently treated with rBPIz, and cefamandole demonstrated a higher clearance of bacteria compared to the groups treated with either rBPI21 alone or cefamandole alone. There appears to be a synergistic effect at 30 and 60 minutes; at 30 minutes, the concurrent administration of rBPI21 and cefamandole resulted in a higher percentage clearance of bacteria than the sum of the separate treatments.
Endotoxin levels are displayed in Figure 9. The open diamonds indicate treatment with vehicle alone, filled diamonds indicate rBPI2, alone, the filled squares indicate cefamandole alone, and the open squares indicate concurrent administration of rBPIz, and cefamandole. Animals administered cefamandole alone have a much higher LPS level than animals treated with vehicle alone, due to release of LPS as cefamandole kills bacteria. The concurrent administration of rBPI2, and cefamandole produced a dramatic decrease in LPS levels compared to cefamandole therapy alone.
Cardiovascular/pulmonary parameters (MABP, CI, TPR, arterial oxygen tension, alveolar-arterial O- gradient, respiration rate, and arterial blood pH) are shown in Figures 10-16, respectively. These figures only display results for the groups treated with cefamandole alone (indicated by open squares) and concurrent treatment with rBPI2, and cefamandole (indicated by filled squares).
Single stars indicate that the concurrent administration of both agents provided statistically significant (p < 0.05) improvement over antibiotic alone, while two stars indicate p < 0.01. Cefamandole alone or rBPI2, alone failed to protect the animals; cardiovascular and respiratory dysfunction began during the bacterial infusion and the animals were in circulatory shock by the end of the infusion.
Cardiovascular shock lasted for the rest of the experiment. Arterial blood pH
began to decrease at 60 minutes in the group treated with cefamandole alone, and was at its lowest level by the end of the experiment. In contrast, concurrent administration of rBPI21 and cefamandole preserved cardiopulmonary function and prevented septic shock. Thus, the concurrent administration of BPI protein product with antibiotic protected the animals against the lethal effect of bacteremia and preserved cardiopulmonary function when antibiotic alone failed to do so.
Exam 1e SYNERGISTIC EFFECTS OF GENTAMICIN AND
BPI PROTEIN PRODUCT IN VIVO IN MICE CHALLENGED
INTRAPERITONEALLY WITH LIVE E. COL/ 07:K1 BACTERIA:
EFFECT ON SURVIVAL
The synergistic effects of an aminoglycoside antibiotic and a BPI
protein product were evaluated in mice challenged intraperitoneally with E.
coli 07:K1 (ATCC Accession No. 23503), a smooth encapsulated strain that is susceptible to the bactericidal effects of BPI protein product. The general procedure described above in Example 4 was followed. Six groups of 20 mice were challenged intraperitoneally with 2 x 10' E. coli 07:K1 bacteria and treated immediately with (1) vehicle, (2) 0.03 mglkg gentamicin, (3) 0.1 mg/kg of gentamicin, (4) 50 ~,g of rBPI2,, (5) 0.03 mg/kg gentamicin followed by 50 ug of rBPI2,, or (6) 0.1 mg/kg of gentamicin followed by 50 ~cg of rBPIz,. Survival was followed over 7 days. Results are shown in Figure 17. Neither antibiotic alone nor rBPI2, alone had any effect on mortality other than to slightly retard the death rate. However, the concurrent administration of rBPh1 with low-dose gentamicin SUBSTI i tITE SHEET (RULE 26) -60_ significantly increased survival (p < 0.5 vs. vehicle). Concurrent administration of rBPIZ, with high-dose gentamicin dramatically increased survival (p < 0.001 vs.
vehicle, and p < 0.05 vs. 0.03 mglkg gentamicin with rBPI2,), protecting all but two of the mice from the lethal effects of bacterial challenge. The results clearly indicate synergism between gentamicin and BPI protein product. The greater synergistic effect of the concurrent administration of BPI protein product with gentamicin, compared to the effect of the concurrent administration of BPI
protein product with cefamandole, may be related to the fact that aminoglycosides, which inhibit protein synthesis, have a different mechanism of action than BPI
protein product.
Example 10 EFFECT OF BPI PROTEIN PRODUCT IN VITRO ON
ANTIBIOTIC SUSCEPTIBILITY OF
CEFTRIAXONE-RESISTANT GRAM-NEGATIVE ORGANISMS
The ability of BPI protein product, BPIz,; to reverse the resistance of a variety of gram-negative organisms to ceftriaxone (Ruche Laboratories) was evaluated in vitro.
The strain of gram-negative bacteria to be tested was grown overnight at 37' C on Trypticase soy agar (TSA) plates. Colonies from the plate were then inoculated into nutrient broth (or triethanolamine-buffered minimal salts medium), grown overnight to stationary growth phase, diluted 1:10 in fresh medium, and grown to mid-late logarithmic growth phase (3 to 4 hours at 37°C) to an approximate concentration of 6 to 10 x 10$ organisms/mL. Organism counts were performed by making serial dilutions, plating in triplicate on TSA
plates, incubating at 37°C overnight, and counting colonies by visual inspection.
Following development of a standard curve, counts were made by measuring OD~,o and confirming by plating. The bacteria were sedimented by centrifugation at 6,000g for 10 min. and resuspended in sterile saline to the desired concentration.
Ceftriaxone solutions were prepared from standard powder (Ruche Laboratories). Solutions of BPI protein product were prepared from rBPh,.
Hanks solution, vitamin-free casamino acid, and TRIS-HC1 buffer, pH 7Ø Broth hHC
S~BSTITi USE SHEEZ (RULE 26) 2~?2~~~

studies were performed as follows: U-bottom, disposable, microtiter array plates (Dynatech) containing 100 tcLl well of broth and serial dilutions of 1:1 proportion rBPI2, and ceftriaxone were prepared using a multichannel pipetting instrument, inoculated with organisms diluted to approximately 2.5 x 105 CFLT/ml, and S incubated overnight at 37°C. Media controls containing no organism and growth controls containing organisms but no ceftriaxone or rBPIZI were also prepared.
The MIC was determined as the lowest drug concentration (fcglmL) that inhibited bacterial growth. Agar MIC studies were performed as follows: The organism was grown in Mueller-Hinton broth (Difco Laboratories) overnight at 37°C, transferred and grown to logarithmic phase, counted by optical densitometry, diluted with buffer and rBPIz, and ceftriaxone, and incubated for 30 minutes at 37°C. After the 30 minutes of incubation, samples were serially diluted in sterile saline and plated onto TSA agar for bacterial counts after overnight incubation at 37°C.
A variety of different bacterial species were tested, including Pseudomonas, Eraerobacter, Citrobacter, RZebsiella, and Escherichia species. A
summary of the results is displayed in Table 11 below, which reports the minimum inhibitory concentration (1VBC) of BPI protein product alone, the MIC
of ceftriaxone alone, and the MIC of both agents together (in a fixed 1:l proportion of rBPI21 and ceftriaxone). The experiments were replicated, and each number given in the table represents the highest, or worst-case, MIC for the group.

_62_ ~~ ~~~4 Synergistic Effect of rBPIz, and Ceftriaxone on Ceftriaxone-Resistant Organisms MIC of MIC
of Organism MIC of BPI alone Ceftriaxone alone BPI
+ Ceftriaxone G,cg~mi-) ~g~ n'L) Og~mI-) PA 589 64 > 64 4 PA 631 > 64 > 64 4 PA 677 > 64 > 64 4 EA 658 > 64 > 64 4 CF 595 4 > 64 1 CF 596 4 > 64 1 CF 597 > 64 > 64 8 KP 601 64 > 64 8 EC 004 > 64 > 64 < 0.1 EC 600 > 64 32 8 EC 664 64 > 64 32 ECL 03 16 > 64 16 ECL OS 16 > 64 16 ECL 07 > 64 64 16 ECL 13 > 64 > 64 16 ECL 14 16 > 64 32 ECL 15 > 64 > 64 32 ECL 19 > 64 > 64 32 PA 001 > 64 > b4 8 PA 003 > 64 > 64 8 I
PA 004 > 64 64 16 PA 005 > 64 > 64 64 PA 012 > 64 > 64 16 PA 014 > 64 > 64 8 Synergistic Effect of rBPIZ, and Ceftriaxone on Ceftriaxone-Resistant Organisms MIC of MIC of Organism MIC of BPI BPI + Ceftriaxone alone Ceftriaxone alone G,cg~mI-) (~g~mI-) (N~g~mI-) PA 017 > 64 > 64 32 PA 023 > 64 > 64 32 PA 028 > 64 > 64 16 PA = Pseudomonas aeruginosa EA = Enterobacter aerogenes CF = Citrobacter freundii KP = Klebsiella pneurnoniae EC = Escherichia coli ECL = Enterobacter cloacae Checkerboard synergy studies on selected strains were performed as follows. Microplates were prepared using the following organization: Column 1, control organisms (growth control); Columns 2 through 9, serial dilutions of ceftriaxone; Column 10, ceftriaxone alone; Column 11, rBPI2, alone; Column 12, control media; Rows 1 through 8, serial dilutions of rBPIz,. Columns 2 through thus contained a serial array of various proportions of ceftriaxone and BPI
concentrations. All wells, except the media control, were inoculated with suspended organisms and incubated overnight at 37°C. Turbidity was recorded at 24 and 48 hours.
Results of a representative synergy study of the effects of the concurrent administration of rBPIz, and ceftriaxone on ceftriaxone-resistant E. coli are shown in the checketfioard in Table 12 below. In this checkerboard assay, rBPI21 and ceftriaxone were each serially diluted to concentrations ranging from 100 ~eglml to 0.8 ~,g/ml. These results show that the concurrent administration of both agents is synergistic. There was uniform growth in all growth control wells (containing bacteria, no rBPI21 and no antibiotic), while there was no growth in the media control wells (containing no bacteria). There was uniform growth in all ceftriaxone control wells (bacteria with ceftriaxone alone). In the BPI
control wells (bacteria with rBPIz, alone) there was growth in the wells with a concentration of 6.2 ~glml rBPI2, or less, and no growth at higher concentrations of BPI protein product.
Survival (or kill) curve studies were performed as follows. Tubes containing (1) media alone, (2) media plus ceftriaxone, (3) media plus rBPI2,, and (4) media plus ceftriaxone and rBPIz,, were prepared, inoculated with the desired organism, and incubated as described above. At 0, 1, 2, 4, 8 and 24 hours, diluted aliquots from each tube were plated, incubated and counted as described above. Growth curves over 24 hours (plots of loglo CFUImL versus time) were constructed to demonstrate the dynamics of antibiotic-BPI protein product interactions on bacterial growth and survival.
Results of a representative killing curve study of the effects of the concurrent administration of rBPI2, and ceftriaxone on ceftriaxone-resistant E. coli are shown in Figure 18. The filled square is the control (neither rBPI:, nor ~u~s~Ei~~~ ~~r~r t~mE2~?

2 ~ X224 ceftraxone), the open square is rBPI2, alone, the filled diamond is ceftriaxone alone, and the open diamond is the concurrent administration of ceftriaxone and rBPI2,. Ceftriaxone or rBPI2, alone have some early bactericidal effect at 4-8 hours, but organism growth for both almost reaches that of the control curve by 24 hours (about a 1 log difference from control). In contrast, the concurrent administration of rBPI2, and ceftriaxone produces a significantly greater bactericidal effect that is sustained at 24 hours (a more than 6 log difference from control) .

WO 95!0S344 217 2 2 ~ ~ PCT/US94111225 a O O O O O O O O

O
--~
U

a U

a. a ~ o N U

k m a U ao ~

0 0 o o 0 0 o o a ~

' ~ U
a v 0 0 o o 0 0 0 0 ~

N N
W ~o U
.a~

o ~ o E'"

o o o o O O o O

V

w c'~
w U

C

K

+ o O O O o O o >, ~~ U

~

.
a~

~, 6 x + + 0 0 0 0 0 0 U p U

x y O

w O

~' ~ +
Q

.~.

CD

00 ~ .-.N V'7 O cWD N N
I

2 ~ 124 Example 11 EFFECTS OF BPI PROTEIN PRODUCT
AND ANT~IOTICS IN VITRO ON
PSEUDOMONAS SPECIES
The effects of a BPI protein product, rBPI2,, on the antibiotic susceptibility of clinical isolates of Pseudomonas aeruginosa and other Pseudomonas species (from Baxter Microscan~ library, Sacramento, CA) was evaluated using Microscan~ panel plates (Baxter Diagnostics, Inc. , Deerfaeld, IL) that allow simultaneous determination of minimum inhibitory concentrations for a number of different antibiotics. Contml assays confirmed that the formulation buffer for rBPI2, had no effect on the antibiotic susceptibility of various organisms.
The antimicrobial susceptibility tests performed on the Microscan~ panel plates are miniaturizations of the broth dilution susceptibility test. Antimicrobial agents are serially diluted in Mueller-Hinton broth (supplemented with calcium and magnesium, or with sodium chloride for oxacillin, or with thymidine phosphorylase for trimethoprim, sulfamethoxazole and trimethoprim/ sulfamethoxazole) to concentrations bridging the range of clinical interest. One well on the 96-well Microscan~
plate is a growth control well that contains dehydrated broth only. The remaining wells contain dehydrated broth and antibiotic (or broth and biochemical reagent indicator), which is rehydrated to the desired concentration by inoculation of a standardized suspension of test organism.
The chromogenic biochemical agent indicators are used to identify and characterize the species of bacteria based on detection of pH changes and substrate utilization. After incubation overnight, the minimum inhibitory concentration (MIC) of an antibiotic for the test organism is determined by observing the well with the lowest concentration of the antibiotic that shows inhibition of growth. Gram-negative organisms were tested using Neg Combo Type 16, MIC Plus Type 2, or Neg Breakpoint Combo Type 9 panel plates (Microscan~, Baxter Diagnostics. Inc.. Deerfield. IL). The SI~BS~f~~J i ~ ~H'~ ~r~U~E 26) ~ T 1:245 concentrations of antibiotics tested in these panel plates are shown below in Tables 13, 14 and 15, respectively. The antibiotic susceptibility standards (interpretation of an NiIC as resistant, intermediate or susceptible according to Microscan~'s NCCIS-derived standards) applicable to the gram-negative organisms tested in each panel plate appear in Tables 13A, 14A and 15A, respectively.

ANTIBIOTIC CONCENTRATIONS
TESTED IN

PLATE

Antibiotic Two-Fold Serial Dilutions Tested ~,g/ml Amikacin 2-16 Ampicillin 2-16 Ampicillin/Sulbactam 8/4-16/8 Aztreonam 8-16 Cefazolin 2-16 Cefotaxime 4-32 Cefoxitin 2-16 Ceftazidime 2-16 Ceftriaxone 4-32 Cefuroxime 2-16 Ciprofloxacin 1-2 Gentamicin 1-4, 6 Imipenem 4-8 Ofloxacin 2-4 Piperacillin 8-64 Ticarcillin 8-~

Tobramycin 1-4, 6 ~ Trimethoprim/Sulfamethoxazole0.5/9.5, 2138 WO 95/08344 PCTIUS94t11225 21~~~45 _ ,o _ MICROSCAN NEG COMBO
PANEL lfi ANTIBIOTIC SUSCEPTTBILTTY
RANGES
FOR GRAM-NEGATIVE BACTERIA

MIC (pg/ml) Antibiotic Resistant IntermediateSusceptible Amikacin > 16 < 16 AmpicillinE > 16 16 < 8 Ampicillin/SulbactamE > 16/8 16/8 < 8/4 > 16 16 < 8 Cefazolin > 16 16 < 8 Cefotaxime > 32 16-32 < 8 Cefoxitin > 16 16 < 8 Ceftazidime > 16 16 < 8 Ceftriaxone > 32 16-32 < 8 Cefuroxime > 16 16 < 8 Ciprofloxacin > 2 2 < 1 Gentamicin > 6 6 < 4 Imipenem > 8 8 < 4 Ofloxacin > 4 4 < 2 ~Pe~c~E > 64 32-64 < 16 PiperacillinP > 64 < 64 TicarcillinE > 64 32-64 < 16 Ticarcillinp > 64 < 64 Tobramycin > 6 6 < 4 TrimethoprimlSulfamethoxazole> 2138 < 2138 E Eraerobacreriaceae only P Pseudomonas only SUBSTITU i E StiEE~ (RL..~ 2fi~

TaBLE a4 ANTTIBIOTIC CONCENTlltATIONS
TESTED IN

Two-Fold Serial Antibiotic Dilutions Tested (Ecg/ml) Amoxicillin/K Clavulanate 110.5-32/16 Ampicillin/Sulbactam 1 /0. 5-32/ 16 Azlocillin Carbenicillin 16-128 Cefamandole 4-32 Cefonicid 2-16 Cefoperazone 4-32 Cefotaxime 2-~

Cefotetan 4-32 Ceftazidime I-32 Ceftizoxime 2-32 Ceftriaxone 2-64 Chloramphenicol 2-16 Ciprofloxacin 0.25-4 Imipenem ~ 0.5-16 Mezlocillin 16-128 Netilmicin 2 -16 Ticarcillin 16-128 TicarcillinlK Clavulanate 16-128 ~1~245 MICROSCAN MIC PLUS

SUSCEPTIBILITY RANGES
FOR GRAM-NEGATIVE
BACTERIA

MIC (~g/ml) Antibiotic Resistant IntermediateSusceptible Amoxicillin/K ClavulanateZ 32/ 16 16/8 S 8/4 Ampicillin/Sulbactam 232/16 16/8 S8/4 AzlocilIinp > 64 5 64 Aztreonam Z 32 16 S $

CarbenicillinE z 64 32 S 16 CarbenicillinP > 128 5128 Cefamandole Z 32 16 S 8 Cefonicid > 16 16 S 8 Cefoperazone > 32 32 S 16 Cefotaxime Z 64 16-32 S 8 Cefotetan > 32 32 <_ 16 Ceftazidime z 32 16 _< g Ceftizoxime > 32 16-32 <_ 8 Ceftriaxone ~ 64 16-32 < 8 Chloramphenicol > 16 16 < 8 Ciprofloxacin ~ 4 2 <_ 1 Imipenem Z 16 8 <_ 4 MezlocillinE Z 128 32-64 < 16 MezlocillinP >_ 128 <_ 64 Netilmicin > 16 16 < 8 TicarcillinE z 128 32-64 <_ 16 TicarcillinP >_ 128 <_ 64 Ticarcillin/K ClavulanateE~ 128 32-64 516 Ticarcillin/K ClavulanateP> 128 5 64 E Enterobacteriaceae only p Pseudomonas only ANTIBIOTIC CONCENTRATIONS
TESTED IN
NEG BREAKPOINT COMBO

Antibiotic Dilutions Tested (~cglm!) Nitrofurantoin 32 & 64 Cephalothin 8 & 16 Ampicillin 8 & 16 Ofloxacin 2 & 4 Ticarcillin 16 & 64 ~Pe~~ 16 & 64 Mezlocillin 16 & 64 Tetracycline 4 & 8 Ampicillin/Sulbactam 8/4 & 16/8 Amoxicillin/K Clavulanate8/4 & 16/8 Ticarcillin/K Clawlanate16 & 64 Gentamicin 4 & 8 Tobramycin 4 & 8 16 & 32 Ciprofloxacin 1 & 2 Imipenem 4 & 8 ~f~~ 8 & 16 Cefamandole 8 & 16 Cefuroxime 8 & 16 Cefotetan 16 & 32 Cefoxitin 8 & 16 ~~n~ 8 & 16 Ceftriaxone 8 & 32 Ceftazidime 8 & 16 Cefoperawne 16 & 32 Cefotaxime 8 & 32 Chloramphenicol 8 & 16 Trimethoprim/Sulfamethoxawle2/38 & 8/152 Norfloxacin 4 & 8 Cinoxacin 16 Trimethoprim g Sulfamethoxazole 256 WO 95!08344 PCTIUS94111225 ~ ~ ~~~4~

MICROSCAN NEG BREAKPOINT

ANTIBIOTIC SUSCEPTIBILITY
RANGES
FOR GRAM-NEGATIVE
BACTERIA

MIC (~glml) Antibiotic R~~tant IntermediateSusceptible Nitrofurantoin >64 64 532 Cephalothin > 16 16 S 8 AmpicillinE > 16 16 S 8 Ofloxacin > 4 4 5 2 TicarcillinE > 64 64 S 16 Ticarcillinp > 64 5 64 PiperacillinE > 64 64 516 Piperacillinp > 64 5 64 MezlocillinE > 64 64 16 Mezlocillinp > 64 5 64 Tetracycline > 8 8 S 4 Ampicillin/SulbactamE> 16/8 16/8 5 8/4 AmoxicilIin/K Clavulanate> 16/8 16/8 5 8/4 Ticarcillin/K ClavulanateE> 64 64 S 16 Ticarcillin/K ClavulanateP>64 564 Gentamicin > 8 8 _< 4 Tobramycin > 8 8 <_ 4 Amikacin > 32 32 ~ 16 Ciprofloxacin > 2 2 <_ 1 Imipenem > 8 8 <_ 4 Cefazolin > 16 16 5 8 Cefamandole > 16 16 <_ 8 Cefuroxime > 16 16 S 8 Cefotetan > 32 32 516 Cefoxitin > 16 16 _< 8 Aztreonam > 16 16 <_ 8 Ceftriaxone > 32 32 <_ 8 Ceftazidime > 16 16 <_ 8 Cefoperazone > 32 32 <_ 16 Cefotaxime > 32 32 S 8 Chloramphenicol > 16 16 <_ 8 Trimethoprim/Sulfamethoxaz>8/152 8/152 ~Z/38 ole Norfloxacin > 8 8 < 4 Cinoxacin > 16 <_ 16 Trimethoprim > 8 S 8 Sulfamethoxazole > 256 < 256 ntero acteriacaeae o y P Pseudomonas only For each experimental run, the following procedure was performed: The organism was streaked onto 5 ~ sheep blood agar plates (Remel, Lenexa, Kansas) and incubated for 18-24 hours overnight. Well-isolated colonies from the plates were emulsified in 3 mI of sterile Inoculum Water (catalog no. B1015-2, MicroScan~ system, Baxter Diagnostics, Inc., Deerfield, IL) to a final turbidity equivalent to 0.5 McFarland Barium Sulfate standard. This cell suspension was vortexed for 2 to 3 seconds and 100 ~cl was transferred to glass tubes containing 25 ml of Inoculum Water with Pluronic-D (catalog no. B1015-7, MicroScan~ system, Baxter Diagnostics, Inc., Dee~eld, IL) (hereinafter "Pluronic Inoculum Water"), or 25 ml of Pluronic Inoculum Water into which rBPI21 (in formulation buffer) had been diluted to the desired concentration between 0.5 to 64 ~cgfml rBPI=1.
The 25 ml of this inoculum containing rBPiZ, was mixed by inversion and poured into a tray. The inoculum was drawn up into a manual 96-well pipetting system (RENOK" rehydrator-inoculator system, Baxter Health Care Corporation, West Sacramento, CA) designed for use with the Microscan~ panel plates, and 110~d of the inoculum was delivered to each well of a Microscan~ Neg Combo Type 16 panel plate. When added to the wells, this inoculum achieves a final bacterial concentration of 4 x 105 to 7 x 105 CFUIml. The panel plates were then incubated at 35°C for 15-24 hours and head visually for cell growth.
No growth was defined as a slight whiteness in the well or a clear broth. Growth appeared as turbidity which could take the form of a white haze throughout the well, a white button in the center of the well, or a fine granule growth throughout the well. All wells were read against a black indirectly lighted background. Visual results of the biochemical reactions were head into a database for bacterial identification. The MICs for each antibiotic tested were determined by identifying the lowest concentration of antibiotic which inhibited visible growth.
The clinical isolates of Pseudomonas aeruginosa and other Pseudomonas species were tested using the Neg Combo Type 16 panel plate.
Tables 16. 17 and 18 below display a summary of the results of the antibiotic f x.
r..

217~~4~

screening panels, reported for each strain tested as the MIC of the tested antibiotics at the various concentrations of rBPI2~ indicated. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. Stars after the antibiotic name in the "antibiotic tested" column indicate whether rBPI2, reversed the resistance of that organism to the antibiotic tested (two stars) or converted an indifferent MIC into a susceptible MIC (one star). These data show that BPI
protein product reversed resistance to ticarcillin, cefazolin, cefoxitin, cefuroxime, ofloxacin, aztreonam, piperacillin, and amikacin for some strains of P. aeruginosa and increased the susceptibility of some P. aeruginosa strains to ticarcillin, aztreonam, imipenem, piperacillin, ofloxacin, ceftazidime, amikacin, ceftriaxone, cefotaxime, cefuroxime, tobramycin, ciprofloxacin, trimethoprim/sulfamethoxazole, gentamicin, and cefazolin. BPI
protein product reversed resistance of some P. cepacia strains to cefazolin, cefoxitin, cefuroxime, ceftriaxone, ticarcillin, and increased the susceptibility of some P. cepacia strains to ampicillin, ticarcillin, piperacillin, cefazolin, cefoxitin, cefuroxime, ceftriaxone, ampicillin/sulbactam, cefotaxime, gentamicin, tobramycin, and amikacin. BPI protein product reversed resistance of Xanthamonas maltophilia to trimethoprim/sulfamethoxazole, piperacillin and amikacin, and increased susceptibility to ciprofloxacin.
Tables 16, 17 and 18 also show the presence or absence of bacterial growth in the growth control wells, which contained varying concentrations of rBPI2, alone without antibiotic. "G" indicates growth, while "NG" indicates no growth. These results indicate that rBPI2, at a concentration of 32 ~,g/ml has direct bactericidal/growth inhibitory effects on some of the tested Pseudomonas isolates.

WO 95/0S344 ~ PCTlUS94/11225 Z~722 EFFECTS
OF rBPI2, t ANTTIBIOTICS
ON Pseudomonas aeruginosa Minimum Inhibitory Concentration of Antibiotic (Eag/mL) Microscan With With With Library Antibiotic 0 ~aglmI. 8 ~.g/mL 32 ~cg/mL
ID No. Tested rBPIz' rBPlz' rBPI2, BPI (; G G

Ticarcillin** > 64 64 64 Aztreonam * 16 a 8 < 8 19610 Piperacillin 32 16 < 8 Ofloxacin** > 4 4 < 2 Ceftazidime 8 8 4 Amikacin 16 g g BPI G G , NG

Aztreonam* 16 < 8 __ Ceftriaxone > 32 32 --18433 Cefotaxime > 32 32 --Cefuroxime* 16 4 --Tobramycin 2 < 1 --Amikacin 16 8 __ BPI G G G

Ciprofloxacin > 2 > 2 2 12892 Ofloxacin > 4 > 4 4 Ceftazidime 4 4 < 2 Cefotaxime > 32 > 32 32 Amikacin 16 16 8 WO 95108344 PCTIUS94/i1225 ~~~24~
_78_ EFFECTS
OF rBPI2, t ANTIBIOTICS
ON Pseu~omonas aeruginosa Minimum Inhibitory Concentration of Antibiotic ( fcg/mL) Microscan With With With Library Antibiotic 0 ~.glmL 8 ~,glmL 32 ug/mL
LD No. Tested rBPh' rBPIz' rBPIZI

BPI G G G

Trimethvpriml > 2 > 2 2 Sulfamethoxazole Ticarcillin 64 16 16 19054 Ceftriaxvne* 16 32 8 Gentamicin 4 4 2 Amikacin 16 8 4 Cefazolin > 16 > 16 16 Tobramycin > 6 > 6 6 BPI G G G

Aztreonam * > 16 < 8 < 8 *

Piperacillin** > 64 < 8 < 8 19551 Ceftriaxone 32 16 16 Gentamicin 4 < 1 < 1 Tobramycin 2 ~ < 1 < 1 Amikacin** > 16 < 2 < 2 ~11~~

EFFECT S OF rBPI2, t BIOTICS
ANTI ON Pseudomonas aeruginosa Minimum Inhibitory Concentration of Antibiotic (Ecg/mL) Microscan With With With Library Antibiotic 0 ~cg/mL 8 ~,g/mL 32 ~.g/mL
ID No. Tessted rBPI21 rBPIzi rBPI2, BPI G G NG

19660 Trimethoprim/ > 2 2 --Sulfamethoxazole Ceftriaxone* 16 8 -_ Cefotaxime 16 16 --BPI G G G

Ampicillina > 16 > 16 4 Trimethoprim/ > 2 > 2 2 Sulfamethoxazole Ticarcillin 16 16 < 8 OP~b Cefazolin** > 16 > 16 < 2 Cefoxitin** > 16 > 16 < 2 Cefumxime** > 16 > 16 < 2 Ceftriaxone* 16 8 < 4 Ampicillin/ > 16 a 16 < 8 Sulbactama Cefotaxime* 16 g < 4 The Microscan~ worksheet did not supply antibiotic susceptibility ranges, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).
b Strain 12.4.4, provided by S.M. Opal, Brown University, Providence, RI.

~~7245 EFFECTS OF rBPI21 ~ ANTIBIOTICS ON Pseudomonas aeruginosa Minimum Inhibitory Concentration of Antibiotic (fcg/mL) Microscan With With With Library Antibiotic p ~g~~, 4 ~gl~, 16 ~cglmL
ID No. Tested rgp~l rBPIzI rBPIz, BPI G G G
Ofloxacin* 4 4 < 2 N113-100 Gentamicin > 6 6 6 Tobramycin 2 2 < 1 BPI G G G
Aztreonam > 16 > 16 < 8 N113-101 Ofloxacin* 4 4 < 2 Gentamicin > 6 6 6 Tobramycin 4 2 < 1 BPI G G G
Piperacillin 64 < 8 < 8 Ceftriaxone* 32 16 8 Cefotaxime 32 16 16 Gentamicin 4 4 < 1 Amikacin 8 8 < 2 BPI G G G
N113-103 Ticarcillin 16 16 32 Amikacin 4 8 4 17~~:~

EFFECTS OF
rBPIzI
ANTIBIOTICS
ON Pseudomonas aeraginosa Minimum Inhibitory Concentration of Antibiotic (EcgImL) Mlcroscan With With With Library Antibioticp ~gl~ 4 ~cg/mL16 ~cg/mL
ID No. Tested rBPI2' rBPI2, rBPI2, BPI G G G

N113-104 Ceftazidime< 2 < 2 4 Ceftriaxone*16 8 8 BPI G G G

Ticarcillin64 32 32 Aztreonam 16 < 8 < 8 *

Ceftriaxone32 32 16 Cefotaxime32 32 16 Gentamicin2 2 < 1 BPI G G G

Ticarcillin16 16 < 8 Ceftriaxone*32 16 8 N113-106 Cefotaxime*16 16 8 Gentamicin4 2 2 Amikacin 8 4 4 BPI G G G

Ticarcillin> 64 > 64 64 Ciprofloxaci2 2 < 1 n*

N113-107 Ceftazidime8 4 4 Ceftriaxone32 32 > 32 Imipenem > 8 8 > 8 SU~~T~T~TL ~~#EET (RULE 26~

21 ~224~

EFFECTS OF
rBPI2, t ANTIBIOTICS
ON Pseudomonas SPECIES

Minimum Inhibitory Concentration of Antibiotic (~.g/mL) Microscan With With With Library Antibiotic 0 ~cg/mL 8 ~.g/mL 32 ~.g/mL
ID No. Tested rBPlzl rBPI2, rBPIZ, BPI G G NG

Ampicillin > 16 16 --Ticarcillin 32 < 8 --Piperacillin 32 < 8 --Cefazolin** > 16 8 --Cefoxitin** > 16 < 2 --31142 Cefuroxime** > 16 < 2 --(P. cepacia)Ceftriaxone** > 32 8 --Ampicillinl 16 < 8 --Sulbactam' Cefotaxime* 32 < 4 --Gentamicin* 6 < 1 --Tobramycin 2 < 1 --Amikacin 8 < 2 __ BPI G G G

Ticarcillin * > 64 64 32 *

12122 Fiperacillin 16 < 8 < 8 (P. cepacia)Cefuroxime 4 < 2 < 2 Amikacin 4 4 < 2 WO 95/08344 pCTIUS94I11225 EFFECTS OF
rBPI2, t ANTdBIOTICS
ON Pseudomonas SPECIES

Minimum Inhibitory Concentration of Antibiotic (~,cglmL) Microscan With With With Library Antibiotic 0 ~glmL 8 ~.glmL 32 ~cglmL
11? No. Tested rBPlz' rBPI2, rBPIz, BPI G G NG

17211 Trimethoprim/ > 2 2 --Sulfamethoxazole**

(XanthamonasPiperacillin** > 64 16 __ maltophilia)Amikacin** > 16 16 --Ciprofloxacin 2 2 --I

" The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).

WO 95108344 ~ ~ PCTIUS94/11225 Exam In a I2 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON STRAINS OF E. COLI
The effect of a BPI protein product, rBPI2l, on the antibiotic susceptibility of various strains of E. coli was evaluated in the Microscan~
antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI2, on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of E. coli (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (E,~.glml) of the antibiotic tested, is shown in Table 19 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product reversed the resistance of some strains to cefazolin and increased the susceptibility of other strains to ampicillin, cefuroxime, cefazolin, amikacin, and cefoxitin.

WO 95108344 Z 17 2 2 4 5 PCT~S94I11225 4 EFFECTS t ANTIBIOTICS
OF rBPI2, ON Escherichiu coli ~n Inhibitory Concentration of Antibiotic (fcglnzL) Microscan With With With Library Antibiotic 0 ~glmL 4 ~sglmL 16 ~.g/mL
ID No. Tested rBPIz' rBPI=, rBPh, 19536 Ampicillina 16 16 8 Cefuroxime 4 8 4 F101-309 Cefoxitin 4 < 2 4 Cefuroxime 8 4 4 Cefazolin** > 16 > 16 8 19612 Amikacin 16 8 8 Cefoxitin < 2 4 < 2 17164 Ampicillin 8 g 4 Cefoxitin 8 g 4 19522 Cefazolin 8 g 4 Cefoxitin > 16 > 16 16 The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).

WO 95!08344 PCT/US94/11225 Example 13 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON CITROBACTER SPECIES
The effect of a BPI protein product, rBPI2,, on the antibiotic susceptibility of various Citrobacter species was evaluated in the Microscan~ antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI2, on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Citrobacter species (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (~,cg/ml) of the antibiotic tested, is shown in Table 20 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product increased the susceptibility of the tested Citrobacter species to aztreonam, cefotaxime, tobramycin, amikacin, cefuroxime, ampicillin, ticarcillin, piperacillin, and cefuroxime.

EFFECTS
OF rBPIZI
t ANTTIBIOTICS
ON Citrnbader SPECIES

Minimum Inhibitory Concentration of Antibiotic (~eglmL) Microscan With With With Library Antibiotic 0 ~,g~ml, 4 ~gimL 16 ~.g~ml, ID No. Tested rBPhl rBPI2l rBPI21 Aztreonam > 16 > 16 16 18419 Cefotaxime > 32 32 32 (C. freundii)Tobramycin 4 2 < 1 Amikacin 4 < 2 4 18420 Cefuroxime > 16 > 16 1 16 (C. freundii)Amikacin > 2 > 2 > 2 Ampicillin > 16 > 16 16 F052-007 Ticarcillin > 64 > 64. 64 (C. diversusJPiperacillina32 16 < 8 Cefuroxime 8 4 4 The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).

_ 88 _ EXIIIIDIe 14 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON KLEBSIELLA SPECIES
The effect of a BPI protein product, rBPI2l, on the antibiotic susceptibility of various Klebsiella species was evaluated in the Microscan~
antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPIZI
on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Klebsiella species (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (Ea.g/ml) of the antibiotic tested, is shown in Table 21 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product reversed the resistance of one strain of K. pneumoniae to trimethoprimlsulfamethoxazole and increased the susceptibility of the tested species to cefoxitin, ampicillin/sulbactam, trimethoprim/sulfamethoxazole, cefazolin, and cefuroxime.

EFFECTS OF rBPI=1 t ANTIBIOTICS ON
Blebsiella SPECIES

Minimum Inhibitory Concentration of Antibiotic (fc.glmL) Microscan With With With S Library Antibiotic 0 ~uglmL 4 ~.g/mL16 ~eg/mL
ID No. Tested rBPI=' rBPIZI rBPI2~

19645 Cefoxitin 8 < 2 4 (K. pneumoniae)Ampicillin/ > 16 > 16 > 16 Sulbactarn 18427 Cefazolin < 2 4 < 2 (K. pneumoniae)Ampicillin/ 16 16 < 8 Sulbactam"

16135 Trimethopriml > 2 > 2 < 0.5 Sulfamethoxazole**

(K pneumoniae)Cefazolin* 16 16 8 30434 Cefazolin* 16 16 8 (K. oxytoca) Cefoxitin 4 < 2 4 Cefuroxime 8 4 8 Ampicillin/ < 8 16 < 8 Sulbactam The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).

Example 15 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON ENTEROBACTER SPECIES
The effect of a BPI protein product, rBPI2,, on the antibiotic susceptibility of various Enterobacter species was evaluated in the Microscan~ antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI21 on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Enterobacter species (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (~cg/ml) of the antibiotic tested, is shown in Table 22 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product reversed the resistance of one strain of E. cloacae to ticarcillin, cefuroxime, ceftazidime and cefotaxime. BPI protein product also increased the susceptibility of some Enterobacter species to ticarcillin, aztreonam, piperacillin, ciprofloxacin, cefotaxime, trimethoprimlsulfamethoxazole, cefuroxime, ceftazidime, ceftriaxone, and ampicillin/sulbactam.

EFFECTS OF
rBPI21 t ANTTIBIOTICS
ON Enterobacter SPECIES

Minimum Inhibitory Concentration of Antibiotic (tsg/mL) Microscan With With With Library Antibiotic 0 ~.g/mL 4 ~.gln~I,16 ~uglmL
ID No. Tested rBPhl rBPI2, rBPIZ, Ticarcillin 64 > 64 64 Aztreonam * 16 < 8 < 8 19565 Piperacillin > 64 > 64 64 (E. aerogenes)Ciprofloxacin* 2 < 1 < 1 Cefotaxime* 16 8 8 19626 Piperacillin > 64 64 64 (E. aerogenes)Ticarcillin > 64 > 64 > 64 19625 Trimethoprim/ 2 < 0.5 < 0.5 Sulfamethoxazole*

(E. aerogenes)Piperacillin > 64 > 64 > 64 _ Ticarcillin > 64 > 64 < 8 * *

Aztreonam > 16 16 < 8 Piperacillin* 64 32 < 8 19680 Cefuroxime** > 16 > 16 8 (E. cloacae) Ceftazidime** > 32 32 < 4 Ceftriaxone > 16 > 16 16 Ampicillin/ > 16 > 16 16 Sulbactam Cefotaxime** > 32 > 32 < 4 19686 Ceftriaxone 32 32 16 (E. cloacae) Piperacillin > 64 > 64. > 64 Example 16 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTTBIOTICS IN VITRO ON SERRATIA MARCESCENS
The effect of a BPI protein product, rBPI2l, on the antibiotic susceptibility of Serratia marcescens was evaluated in the Microscan~
antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI2, on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Serratia marcescens (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (~,cg/ml) of the antibiotic tested, is shown in Table 23 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCIrS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product reversed the resistance of some strains to ceftazidime and cefotaxime, and increased the susceptibility of other strains to piperacillin, cefoxitin, ceftazidime, ceftriaxone, cefotaxime, tobramycin, ampicillinlsulbactam, and ampicillin.

EFFECTS
OF rBPIZ, t ANTIBIOTICS
ON Serratia marcescens Minimum Inhibitory Concentration of Antibiotic (~g/mL) Microscan With With With Library Antibiotic 0 ~,g/mL 8 ~glmL 32 ~.glmL
ILl No. Tested rBPI21 rBPI21 rBPh, Piperacillin > 64 > 64 32 Cefoxitin 16 > 16 8 19646 Ceftazidime**> 16 > 16 8 Ceftriaxone* 32 16 8 Cefotaxime** > 32 32 < 4 Tobramycin 6 6 4 *

Piperacillina> 64 64 16 Cefoxitin 8 8 4 Ceftazidime* 16 16 4 19647 Ceftriaxone 8 < 4 < 4 Ampicillin/ > 16 > 16 16 Sulbactam Cefotaxime 8 < 4 < 4 Tobramycin 2 2 < 1 18443 Ampicilline 16 16 8 Ampicillin/ > 16 > 16 16 Sulbactam " The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).

Example 17 EFFECTS OF BPI PROTEIN PRODUCT
AND AN'TTIBIOTICS IN VITRO ON PROTEUS IVIIRABILIS
The effect of a BPI protein product, rBPI2l, on the antibiotic susceptibility of Proleus mirabilis was evaluated in the Microscan~
antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI2, on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Proteus mirabilis (from Baxter Microscan~
library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (fc.g/ml) of the antibiotic tested, is shown in Table 24 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an NiIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product increased the susceptibility of some strains to trimethoprim/sulfamethoxazole, cefazolin, cefoxitin, imipenem, tobramycin, and amikacin.

EFFECTS
OF rBPI2, t ANTIBIOTICS
ON Proteus mirabilis Minimum Inhibitory Concentration of Antibiotic (~cg/mL) Microscan With With With Library Antibiotic 0 teglmL 8 tcg/mL 32 tcglmL
ID No. Tested rBPIzt rBPI21 rBPI2~

Trimethoprim/ 2 < 0.5 < 0.5 Sulfamethoxazole*

Cefazolin 4 < 2 4 19593 Cefoxitin 8 < 2 < 2 Imipenem * 8 < 4 < 4 Tobramycin 2 2 < 1 Amikacin 8 4 4 Cefoxitin 4 < 2 . 4 F231-129 Imipenem* 8 < 4 < 4 Amikacin 4 < 2 < 2 WO 95/08344 PCTlUS94/11225 2 ~ 1224 Example 18 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON PROVIDENCIA SPECIES
The effect of a BPI protein product, rBPI2,, on the antibiotic susceptibility of various Providencia species was evaluated in the Microscan~ antibiotic susceptibility screening assay of Example l I using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI2, on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Providencia species (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (fcg/ml) of the antibiotic tested, is shown in Table 25 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product reversed the resistance of P. atuartii to cefazolin and cefuroxime, and increased its susceptibility to piperacillin, ceftazidime, ampicillin/sulbactam, imipenem, and amikacin. BPI protein product also increased susceptibility of P.
rettgeri to cefoxitin and cefuroxime.

EFFECTS OF TIBIOTICS
rBPIz, t ON Providencia AN SPECIES

Minimum Inhibitory Concentration of Antibiotic (~.g/mL) Microscan With With With Library Antibiotic 0 ~.glmI. 8 ~.g/mL 32 ~,glmL
ID No. Tested rBPh' rBPI2, rBPI2, 19614 Cefoxitin > 16 8 > 16 (P. rettgen~Cefuroxime* 16 8 < 2 Amikacin 16 16 16 Piperacilling> 64 32 16 Cefazolin** > 16 > 16 8 18435 Cefuroxime** > 16 > 16 8 (P. stt~artit~Ceftazidime 4 < 2 < 2 Ampicillin/ > 16 16 16 Sulbactam Imipenem * 8 < 4 < 4 Amikacin 16 16 8 " The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M7-A3, Table 2 (1993).

WO 95108344 ~ PCT/US94/11225 Example 19 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON MORGANF~.LA MORGANII
The effect of a BPI protein product, rBPIzI, on the antibiotic susceptibility of Morganella morganii was evaluated in the Microscan~
antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 panel plate. The direct growth inhibitory effect of rBPI2~
on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Morganella morganii (from Baxter Microscan~ library, Sacramento, CA).
A summary of the results of the antibiotic screening panels, reported as MICs (~,cg/ml) of the antibiotic tested, is shown in Table 26 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Table 13A. These results show that BPI protein product increased the susceptibility of the tested strains to ampicillinlsulbactam, amikacin and piperacillin.

WO 95/08344 ~ ~ 7 ~ ~ 4 5 PCT~S94111225 EFFECTS ANTTIBIOTICS
OF rBPI2, ON Morganella ~ morganu Minimum Inhibitory Concentration of - Antibiotic (~g/mL) Microscan With With With Library Antibiotic 0 ~.g/mL 8 ~,g/mL 32 ~.g/mL
ID No. Tested rBPIzI rBPIZ, rBPIZ, F19-004 Ampicillin/ > 16 16 16 Sulbactam Amikacin 4 < 2 4 F 19-005 Ampicillin/ > 16 < 8 < 8 Sulbactama Amikacin 4 < 2 < 2 F 19-006 Piperacillin > 64 64 64.

Amikacin < 2 < 2 4 " The Microscan~ worksheet did not supply antibiotic susceptibility ranges for this organism, but there was reversal of antibiotic indifference according to NCCLS standards, Publication M'7-A3, Table 2 (1993).

WO 95/08344 ~ PCT/US94I11225 Example 20 EFFECTS OF BPI PROTEIN PRODUCT
AND ANTIBIOTICS IN VITRO ON ACINETOBACTER SPECIES
The effect of a BPI protein product, rBPI2g, on the antibiotic susceptibility of various Acinetobacter species was evaluated in the Microscan~ antibiotic susceptibility screening assay of Example 11 using the Neg Combo Type 16 and MIC Plus Type 2 panel plate. The direct growth inhibitory effect of rBPIz, on these strains was also evaluated in the same assay. Assays were conducted on clinical isolates of Acinetobacter species (from Baxter Microscan~ library, Sacramento, CA). Different production lots of rBPIz, that had been formulated with surfactant or unformulated (without surfactant) were tested, but no difference was seen in results for formulated or unformulated rBPI2~.
A summary of the results of the antibiotic screening panels, reported as MICs (E.aglml) of the antibiotic tested, is shown in Tables 27 and 28 below. Results are reported for each strain tested, but susceptibility data is listed for only those antibiotics for which BPI protein product altered susceptibility. The antibiotic susceptibility standards (interpretation of an MIC as resistant, intermediate or susceptible according to Microscan~'s NCCLS-derived standards) applicable to the organism tested appear in Tables 13A and 14A. For interpretation purposes, when antibiotic susceptibility standards were given only for Enterobacter or Pseudomonas, the standards for Acinetobacter were considered to be the same as for Enterobacter.
These results show that BPI protein product reversed resistance of A. anitratus strains to amoxicillin/K clavulanate, ampicillinlsulbactam, aztreonam, carbenicillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, mezlocillin, netilmicin, ticarcillin, ticarcillinlK clavulanate, and trimethoprim/sulfamethoxazole, and increased susceptibility of some A.
anitrarus strains to amikacin. amoxicillin/K clavulanate. ampicillin, -lol-ampicillin/sulbactam, azlocillin, aztreonam, carbenicillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, chloramphenicol, ciprofloxacin, gentamicin, imipenem, mezlocillin, netilmicin, ofloxacin, piperacillin, ticarcillin, ticarcillin/K clavulanate, tobramycin and trimethoprim/sulfamethoxazole.
BPI protein product reversed resistance of A. lwo"gii strains to aztreonam, cefazolin, cefuroxime, ceftazidime, cefoxitin, trimethoprim/sulfamethoxazole and piperacillin, and increased susceptibility of A. lwo,~''ci strains to ampicillin, ampicillinlsulbactam, aztreonam, cefazolin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, piperacillin, ticarcillin and trimethoprim/sulfamethoxazole.
These results also show that rBPI2, at a concentration of 16 ~.g/ml has direct bactericidal/growth inhibitory effects on some of the tested Acinetobacter isolates.

WO 95/08344 ~ PCT/US94/11225 EFFECTS OF
rBPIl, ANTIBIOTICS
ON Acinetobacter SPECIES 'I

Minimum Microscan Inhibitory Library ntibiotic Concentration of Antibiotic (fcglmL) ID No. Tested with With With 0 ~.g/mL4 ~cglmL16 rBPIz' rBPIz, tcg~mL
rBPIz, BPI G G G

- Ampicillin > 16 16 16 (A. anitratus) Amikacin 4 < 2 < 2 BPI G G G

Ampicillin 4 < 2 4 Ticarcillin 16 < 8 < 8 NOl 1-003 Cefazolin** > 16 > 16 8 (A. anitratus)Cefoxitin** > 16 8 8 Cefuroxime 8 4 8 BPI G Reduced NG

Ampicillin 8 8 < 2 Trimeth/Sulfa**> 2 2 < 0.5 NO 11-070 Cefazolin * > 16 > 16 < 2 *

Cefoxitin* 16 16 < 2 A
i ( . an Cefuroxime* 16 8 < 2 tratus) Ceftazidime 4 < 2 < 2 EFFECTS OF BPIz, ANTTIBIOTICS
r ON Acinetobacter SPECIES

Minimum Microscan Inhibitory Library ntibiotic Concentration of Antibiotic (,ccgl mL) B~ No. Tested with With With 0 ~eg/mL4 ~.g/mL 16 rBPI2' rBPI2, ~,glmL
rBPI2, BPI G G Very reduced Ticarcillin* 32 < 8 < 8 Aztreonam > 16 16 16 Piperacillin* 32 16 < 8 Ciprofloxacin**> 2 2 < 1 Ofloxacin* 4 < 2 < 2 NOll-071 Ceftazidime 8 8 4 (A. anitratus)Ceftriaxone 32 16 16 Cefotaxime 32 16 16 Gentamicin** > 6 > 6 2 Tobramycin* 6 4 4 Amikacin * > 16 16 8 *

BPI G Reduced NG

Ampicillin* 16 16 < 2 TrimethlSulfa**> 2 > 2 < 0.5 Cefazolin** > 16 > 16 < 2 Cefoxitin* 16 16 < 2 - Cefuroxime 8 8 < 2 (A. anitratus)Gentamicin* 6 4 < 1 Tobramycin 2 < 1 < 1 Amikacin 8 4 < 2 ~ 17224 EFFECTS OF
rBPI=, ANTIBIOTICS
ON Acinetobacter SPECIES

Minimum Microscan Inhibitory Library ntibiotic Concentration of Antibiotic (~.c.g/mL) ID No. Tested with With With 0 ~.g/mL4 ~cg/mL 16 rBPI2' rBPI2, ~cglmL
rBPIz, BPI G G G

Aztreonam** > 16 > 16 < 8 Cefazolin** > 16 8 < 2 NO12-001 Cefuroxime** > 16 4 < 2 Ceftazidime** > 16 4 < 2 A
l i ( . Ampicill/Sulbact> 16 > 16 16 wo"~
t~

Cefotaxime 8 < 4 < 4 BPI G NG NG

Ampicillin 4 < 2 < 2 TrimethlSulfa**> 2 2 < 0.5 Aztreonam** > 16 < 8 < 8 N012-002 Cefazolin** > 16 < 2 < 2 (A. lwo"~ti) Cefoxitin** > 16 < 2 < 2 Cefuroxime 8 < 2 < 2 Ceftazidime 4 < 2 < 2 WO 95/08344 PCTlUS94l11225 EFFECTS OF BPI=~ ANTIBIOTICS
r ON Acinetobacter SPECIES

Minimum Microscan Inhibitory Library ntibiotic Concentration of Antibiotic (,ug/mL) ID No. Tested With With With 0 ~cg/mL4 ~cg/mL 16 rBPI2' rBPI2, ~cglmL
rBPIz, BPI G G NG

Ampicillin > 16 4 < 2 *

TrimethlSulfa*2 < 0.5 < 0.5 Ticarcillin* 64 < 8 < 8 Aztreonam * > 16 < 8 < 8 *

Piperacillin**> 64. < 8 < 8 N012-003 ~efazolin** > 16 > 16 < 2 (A. lwof~ii) Cefoxitin** > 16 8 < 2 Cefuroxime** > 16 < 2 < 2 Ceftazidime* 16 < 2 < 2 Ceftriaxone* 16 < 4 < 4 Cefotaxime 8 < 4 < 4 BPI G G G

Ampicillin 4 < 2 4 TrimethlSulfa*2 2 < 0.5 Cefazolin > 16 16 16 (A. lwo"~a) Cefoxitin* 16 < 2 4 Cefuroxime 4 < 2 < 2 WO 95/08344 ~ ~ PCT/US94/11225 EFFECTS OF
rBPI2, ANTIBIOTICS
ON Acinetobacter SPECIES

Minimum Inhibitory Microscan Concentration Library Antibiotic of Antibiotic (~,cglmL) B7 No. Tested With With With 0 ,ug/mL4 ~g/mL 16 rBPIz' rBPIz, ~,g/mL

rBPI2, BPI G G NG

Ampicillin 4 < 2 < 2 Trimeth/Sulfa*2 < 0.5 < 0.5 Cefazolin** > 16 > 16 4 (A.lwo"~i) Cefoxitin* 16 8 4 Cefuroxime 4 4 < 2 - log EFFECTS OF rBPIZ~ ANTIBIOTICS ON
Acinetobacter SPECIES

Minimum Inhibitory Concentration of Antibiotic (EcglmL) Microscan With With With Library Antibiotic 0 ~.g/mL 4 ~.g/mL 16 ~g/mL
ID No. Tested rBPIz' rBPI21 rBPI2, Ceftizoxime** > 32 < 2 < 2 Ceftazidime** > 32 32 < 1 Cefotaxime** > 64 8 < 2 Ceftriaxone** > 64 < 2 < 2 Cefoperazone** > 32 8 < 4 Cefonicid** > 16 16 < 2 Cefotetan** > 32 32 < 4 Netilmicin** > 16 < 2 < 2 12292 Cefamandole** > 32 < 4 < 4 Chloramphenicol**> 16 < 2 < 2 A
i ( . an Ticarcillin* 64 32 < 16 tratus) Azlocillin > 64 < 64 < 64 Imipenem 4 < 0.5 < 0.5 Amp/Sulbact** 32 4 < 1 Aztreonam * * 32 4 < 1 AmoxlK 16 < 1 < 1 Clavulanate*

Ciprofloxacin** > 4 1 < 25 Ticar/K 64 < 16 < 16 Clawlanate**

Mezlocillin** > 128 < 16 < 16 Carbenicillin** > 128 I < 16 [ < 16 ~

2~~22~~
- l08 -EFFECTS OF
rBPI2~ ANTIBIOTICS
ON Acinetobacter SPECIES

Minimum Inhibitory Concentration of Antibiotic (~g/mL) Microscan With With With Library Antibiotic 0 ~.g/mL 4 tcg/mL16 tcglmL
ID No. Tested rBPI2' rBPI2, rBPI2, Ceftizoxime** > 32 > 32 < 8 Ceftazidime 8 8 2 Cefotaxime** 64 64 < 2 Ceftriaxone* 32 32 < 2 Cefoperazone > 32 > 32 32 Cefonicid > 16 > 16 > 16 Cefotetan > 32 > 32 > 32 Netihnicin > 16 16 16 Cefamandole** > 32 > 32 < 4 (A. anitratus)Chloramphenicol**> 16 > 16 8 Ticarcillin < 16 < 16 < 16 Azlocillin > 64 < 64 < 64 Imipenem < 0.5 < 0.5 < 0. 5 Amp/Sulbact 2 2 < 1 Aztreonam 8 8 4 Amox/K 16 16 < 1 Clawlanate*

Ciprofloxacin** > 4 > 4 1 Ticar/K < 16 < 16 < 16 Clavulanate Mezlocillin** 128 128 < 16 Carbenicillin < 16 < 16 < i 6 WO 95/08344 217 2 2 4 5 pCT~S94/11225 EFFECTS OF rBPIl1 ANTIBIOTICS ON
' Acinetobacter SPECIES
I

Minimum Inhibitory Concentration of Antibiotic (~cg/mL) Micmscan With With With Library Antibiotic 0 ~,g/n~,4 ~eg/mL16 ~cg/mL
ID No. Tested rBPIzI rBPI21 rBPI2, Ceftizoxime** > 32 > 32 < 2 Ceftazidime** > 32 2 8 Cefotaxime** > 64 64 4 Ceftriaxone** > 64 > 64 < 2 Cefoperazone** > 32 > 32 < 4 Cefonicid > 16 > 16 > 16 Cefotetan > 32 > 32 32 12487 Netilmicin** > 16 < 2 < 2 (A. anitratus)Cefamandole** > 32 < 4 < 4 Chloramphenicol**> I6 8 < 2 Ticarcillin** 128 32 < 16 Azlocillin > 64 < 64 < 64 Imipenem 2 < 0.5 < 0. 5 Amp/Sulbact* 16 2 < I

Aztreonam** 32 16 < 1 AmoxIK 8 < 1 2 Clavulanate Ciprofloxacin* 2 1 < 0.25 Ticar/K 32 < 16 < 16 ' Clavulanate Mezlocillin** > 128 32 < 16 Carbenicillin**128 < 16 < I6 EFFECTS OF
rBPIz, ANTIBIOTICS
ON Acinetobacter SPECIES
I

Minimum Inhibitory Concentration of Antibiotic ( pcgl mL) Microscan With With With Library Antibiotic 0 ~g/~, 4 ~,g/~,16 ~cglmL
ID No. Tested rBp~1 rBPI2, rBPI2, Ceftizoxime > 32 > 32 > 32 Ceftazidime > 32 > 32 > 32 Cefotaxime > 64 > 64 > 64 Ceftriaxone > 64 > 64 > 64 Cefoperazone > 32 > 32 > 32 Cefonicid > 16 > 16 > 16 Cefotetan > 32 > 32 > 32 Netilmicin* 16 8 < 2 Cefamandole > 32 > 32 > 32 (A. anitratus)C~ordmphenicol**> 16 16 8 Ticarcillin > 128 < 16 128 Azlocillin > 64 > 64 > 64 Imipenem 4 2 < 0.5 Amp/Sulbact** 32 8 2 Aztreonam > 32 > 32 > 32 Amox/K 32 16 8 Clavulanate**

Ciprofloxacin** > 4 > 4 0.5 Ticar/K > 128 128 < 16 CIawIanate Mezlocillin >~128 64 32 Carbenicillin** > 128 64 < 16 -'111 -EFFECTS OF rBPI2, ANTTIBIOTICS
ON Acinetobacter SPECIES
I

Minimum Inhibitory Concentration of Antibiotic (~,g/mL) Microscan With With With Library Antibiotic 0 ~g/~, 4 ~.g/mL16 ~,g/mL
ID No. Tested rBPIzI rBPIzI rBPIa1 Ceftizoxime** > 32 > 32 4 Ceftazidime > 32 > 32 > 32 Cefotaxime > 64 64 32 Ceftriaxone > 64 64 16 Cefoperazone** > 32 > 32 8 Cefonicid** > 16 > 16 < 2 Cefotetan** > 32 > 32 < 4 Netilmicin > 16 > 16 > 16 Cefamandole > 32 > 32 16 Chloramphenicol> 16 > 16 < 2 * *

Ticarcillin** > 128 > 128 < 16 Azlocillin > 64 > 64 < 64 Imipenem 2 2 < 0.5 Amp/Sulbact** 32 32 2 Aztreonam** 32 16 < 1 Amox/K 16 8 4 Clawlanate*

Ciprofloxacin > 4 > 4 > 4 Ticar/K > 128 32 a 16 Clavulanate**

Mezlocillin** > 128 128 < 16 Carbenicillin**> 128 > 128 < 16 EFFECTS OF
rBPI2~ ANTIBIOTICS
ON Acinetobacter SPECIES

Minimum Inhibitory Concentration of Antibiotic (pcglmL) Microscan With With With Library Antibiotic p ~g/~ 4 ~.glmL 16 tcg/mL
ID No. Tested rBPIz' rBPI21 rBPIz, Ceftizoxime > 32 > 32 32 Ceftazidime* 16 16 8 Cefotaxime 64 64 64 Ceftriaxone 64 64 32 Cefoperazone > 32 > 32 > 32 Cefonicid** > 16 > 16 8 Cefotetan** > 32 > 32 8 Netilmicin** > 16 > 16 4 Cefamandole > 32 > 32 > 32 (A. anitratus)C~oramphenicol> 16 > 16 16 Ticarcillin > 128 > 128 32 Azlocillin > 64 > 64 > 64 Imipenem 1 1 < 0.5 Amp/Sulbact 32 32 16 Aztreonam 8 8 g Amox/K 32 8 4 Clavulanate**

Ciprofloxacin > 4 > 4 > 4 Ticar/K > 128 < 16 < 16 Clavulanate**

Mezlocillin > 128 > 128 64 Carbenicillin**> 128 > 128 < 16 2~7224~

Exam 1p a 21 EFFECTS OF BPI PROTEIN PRODUCT AND
ANTIBIOTICS IN VITRO ON S~9LMONF.LL~4 AND SHIGELLA SPECIES
Ten clinical isolates of Salmonella (F270-001 through -010) and 10 clinical isolates of Shigella (F321-010 and F325-002 through -010) (all isolates from Baxter Microscan~ library, Sacramento, CA), were evaluated in the Microscan~ antibiotic susceptibility screening assay of Example 11 using the Neg Breakpoint Combo Type 9 panel plate. Essentially no effect was seen at rBPI21 concentrations of 0, 4 and 16 ~cglmL.
Example 22 EFFFECCTS OF BPI PROTEIN PRODUCT ON
ANT~IOTIC KILLING CURVES FOR
E. COLI J5, E. C4LI 07:K1, ElV?EROBACTER GZ,OACAE, 5 AND KLEBSIF.LLA PNEUMON~9E
The effect of a BPI protein product, rBPIzI, on the killing curves of selected antibiotics was determined for selected organisms. Microscan~ panel plates were prepared for E. coli J5, E. coli 07:K1, Enrerobacter cloacae (Microscan library ID no. 19680) and Klebsiella pneumoniae (Microscan library ID no. 16135), according to Example 11. Cell suspensions were added to 25 ml Pluronic Inoculum Water containing 0 or 16 ,ug/ml rBPIa,. After inoculation, the panel plates were incubated at 35°C for 24 hours. At 0, 4, 7 and 24 hours after inoculation, 5 ~cl samples were removed from each growth control well (containing culture media without antibiotic) and from each well containing: 2/38 ~glml trimethoprim/sulfamethoxazole, 2 ~cg/ml ciprofloxacin, 64 ,ug/ml piperacillin, ~ug/ml cefotaxime, 6 ~g/ml cefuroxime, and 16 ~cg/ml amikacin. These 5 ~cl samples were diluted in sterile water and inoculated onto Trypticase Soy agar plates (Remel, Lenexa, Kansas). After 48 hours of incubation at 35'C, the plates were counted and the number of colony forming units of bacteria in the well was calculated.
The results are shown (below in Figures 19-25. In all of the figures the growth, in the presence of antibiotic but without rBPIz,, is indicated for: E.
coli J5 (a filled square}; E. coli 07:K1 (a filled diamond); E. cloacae (a filled SUBS3iT~ r ~ ~~iLco (RULE 26) 21722~~

triangle); and K. pneumoniae (an "X"). Also, in all figures, the growth in the presence of antibiotic with rBPI2, is indicated for E. coli JS (an open square); E.
coli 07:K1 (an open diamond); E. cloacae (an open triangle); and K. pneumoniae (a star).
Figure 19 shows the kinetic growth curve of organisms with rBPlz, (and without antibiotic) and without rBPI2, (and without antibiotic). In Figure 19, the growth curves for E. coli JS without rBPIz, (filled squares), E. coli 07:K1 with rBPI2, (open diamonds), E. coli 07:K1 without rBPIz, (filled diamonds), and K. pneumoniae without rBPI2, ("X" s) overlap substantially, while the growth curves for E. coli JS with rBPI2, (open squares) and E. cloacae with rBPI2, (open triangles) overlap at 0-7 hours but diverge by 24 hours. Figure 19 demonstrates that BPI protein product alone has a bactericidal effect at 0-7 hours on E.
coli J5 and K. pneumoniae, and a bactericidal effect on E. cloacae throughout the 24 hour period studied.
In Figure 20, the growth curves for E. coli JS with rBPI2, (open squares), E. cloacae with rBPI2, (open triangles) and I~ pneurnoniae with rBPIZ, (stars) overlap. Figure 20 shows that rBPI2, enhanced the bactericidal effect of trimethoprimlsulfamethoxazole on E. cloacae and K. pneumoniae at 0-24 hours, and slightly enhanced the antibiotics' effect on E. coli JS and E. coli O7:K1.
In Figure 21, the growth curves for E. coli JS with rBPI~, (open squares), E. coli JS without rBPI2, (filled squa.res), E. coli 07:K1 with rBPI2, (open diamonds), E. coli 07:K1 without rBPIz, (filled diamonds), E. cloacae with rBPI2, (open triangles), E. cloacae without rBPIz, (filled triangles), and K.
pneumoniae with rBPIz, (stars) overlap. Figure 21 shows that rBPIZ, reversed resistance of K. pneurnoniae to ciprofloxacin at 0-24 hours; the other organisms were already very susceptible to ciprofloxacin.
In Figure 22, the growth curves for E. coli 07:K1 without rBPI2, (filled diamonds) and E. cloacae without rBPI2, (filled triangles) overlap, while the growth curves for E. cwli JS with rBPI2, (open squares), E. coli JS without rBPIz, (filled squares), E. coli 07:K1 with rBPI2, (open diamonds), E. cloacae with rBPIz, (open triangles), K. pneumoniae without rBPI2, ("X"s) and K. pneumoniae with rBPh, (stars) overlap. Figure 22 shows that rBPI~, enhanced the bactericidal SUBS"fITUi~t S~i~~ (RULE, 26) effect of piperacillin on E. coli O?:K1 and E. cloacae; the other organisms were already susceptible to the drug.
In Figure 23, the growth curves for E. coli JS with rBPI2, (open squares), E. coli 07:K1 with rBPI21 (open diamonds), E. coli 07:K1 without rBPI2, (filled diamonds), K. pneumoniae without rBPI2, ("X"s) and K pneumoniae with rBPI2, (stars) overlap. Figure 23 shows that rBPI21 enhanced the bactericidal effect of cefotaxime on JS and E. cloacae; the other organisms were susceptible to the drug.
In Figure 24, all of the curves overlap. Figure 24 shows the effect of rBPI2, and cefuroxime; addition of rBPI21 had no effect on the killing curves because all of the tested species were very susceptible to the antibiotic.
In Figure 25, all of the curves overlap. Figure 25 shows the effect of rBPIz, and amikacin; again, all tested species were very susceptible to the antibiotic.
Example 23 EFFECTS OF A VARIETY OF BPI PROTEIN PRODUCTS
AND ANTIBIOTICS IN VITRO ON REPRESENTATIVE
GRAM-NEGATIVE ORGANISMS
The effects of a variety of BPI protein products, rBPI2,, rBPI23, rBPIso and rBPI42 dimer on the antibiotic susceptibility of various representative gram-negative organisms was evaluated in the Microscan~ antibiotic susceptibility screening assay of Example 11 using the MIC Plus Type 2 panel plate. Assays were conducted on clinical isolates of Acinetobacter anitratus and Enterobacter cloacae (from Baxter Microscan~ library, Sacramento, CA), and on E. coli JS-L
and 07:K1.
The results, reported as MICs (~c.g/ml) of the antibiotic tested at the various concentrations of BPI protein product indicated, are shown in Tables 29, 30, 31 and 32 below.

a E

~~r~ N ~ ~ N ~_ON V N
C

n M n n n n n _ n ~ ~ n n b N

N

N
rr a '"N'''<N'''c~.'c~e:~~ es N.

Ca .s vo c ao n n n n n n n n ~ :~ M n 0, n ~ N

U ,~

a M ~ ~ M ~ M ~

M
~ n n n n n n n n n ~ n N

O

a rr ~ ~ ~ d' ~ ~

N O
n M ~ M v n v v o ~ ~ et 00 v v v c~

z o a M M ~ M ~ M ~ M

o ~~.~ n n n n n n n n n n ~ n N

a U

y0 ~ ~n N N ~ ~ N ~O N ~O N
W"~ M M M M

...~M
d ~~ n n n n n n n n n ~ ~ n s, N

O ~ ~ M M ~ ~ M ~ N ~ M ~

c 00 ~ ~

o ~ ~ n n n n n n n n n n ~ n N

z a ~" M ~ M ~ N ~ ~

N O
~ ~~ n ~ n ~ n n M v v v n v o ~

x a W ~ M M ~ ~ ~ ~ ~

0 0 ~~ n n n n n n n n n n ~ n E-' U a~ c W E'~ 8 ~ ~ o O ,~ ~ ~ - ~ ~ L
D

O it _ it iG . ~ o ~ O ' C
W 'C V . C' E" O C_C C .r , cV G.
N ~ ~ ~ ~ c~ c~ O

i t~.~.4. t,:.cW.C ~ C) ~ ~ ~ U
U ~

U U U U V U z U o H ~..

U

SUSSTiI~U ~ ~ SAE i ~~U~.~ ~~~

2j~2245 a N

T3 00 M !t N M

N

N

z a N

_ A .~C~ ~ ~ M 00 f M
~

G e e~i a o E ~;

~ M

.y ~ C~ 00 f~ 00 d' a N ~C ~D
1~1 ~.1 ~r O ~ ~ V Wit''et N cN~7V V
~

O ~ a U ~ p N
~

c a~ a N O et L~ ~ M 00 d' M n O 'L7 U

O ~~"" . N
v~
w .+.r ,~ ~' ~ M M ~ et ~

~ ~ N

_ G~ 00 ~ ' ~ ~ M ~ ~ /~ N
1~7 0 ~ et z a a~

O ~ ~ et ~ N N V ~ V
i~i N

_ ~3 O ~ N N ~O
~

O M M
r V ~ ~ x ~ ~G c a~ a~

N ~

W S
O

w _ ~ W ~ v ~ ~ ~U
U ~ ~
~

~
~ C
'C

a~ a ~U U ~ ~ v E,:,U

, SUBSTITI~ i E SNE~f (RU! E 26) WO 95/08344 ~ ~ PCTlUS94111225 a 4.
H ~ ~ N
v0 iar ~~ ~C ~O ~ N V ~ V V
~-~ CWo 00 ~ ... V /~ /~ V
~O
O~
z ~o A .~ ~° ~ C4 V V V V V '~' N '~ N ~ ~ O
~o V V V V V V V
a °°
~D 00 Ar N '"" N N eh N et N ~ N ~ ~ O
pp V V V V V V V V V V V V V

C a _ w ~O ~C~D W N "" N N et N ~ N et N
c O -. spa V V V V V V V V V V V V V
O
...r a v y ~ ~.Y ~ \O N N
et ~ b tN ~ e:j M tN /~ /~ V /~ N ~ O
et .-.. /~ V
_o a o 04 W ~ M N M pp N ~ O
'+'I ~ ~ ~ OC1 ~ M M M ~ I~ A V I~ ~. N I~ V
H
~04~ ~ M N
~' ~ CG M ~ cN M ~ I~ I~ V M ~ 'a O
V V
z a et ~ pa M ~ M N ~ j N ~ eN ~ ~ /~ /~ V /~ ~ ~ /1 V
a ~r ~ 00 O ~ i~ M M ~ M M I\ M V /1 pp I~ /1 O O T7 O = ~ O
'it ~ ~ U .~. ~U 'C ~u ~ _~ U
p ~ ~ C ~ ~~ ~ ~ U
w 4. ~ L1 ~ 4. = ~ ~ ~~ p"
U U U U U U U z U o E., s U
SUBSTITU~'E S'rit~ (Mule 26) vN ~ N ~ ~D
N

W p ~ N ~C M ~" 00 ~ I~ v ~ v N
' .--~ M .r "
p0 ", C

~D

~r v ~ v v v v a b4 E h"r N ~G ~O ~D

~G 04 ""' ... .-..-, W v V v v V
q N pp O

C
a o ~ N
V ~ ~ ~ N 1~ ~O

w o : ~~ N v ~ v v v v z o U ..~~ N

~

o ~c~a ~ '~ ~ v ~': v ..N"

U

O

!f ~ M N~ M v N V N
~

. c H

~n N

pp v ~ v w z _.r N
N

X00 M .-~00 ~ ~ V ~

d' ~~ OC M v M N

o x.00 /~ ~ ~ v /~ v /~

C ~ G ~ ~ C
~ ~ ~

w ~ .~ .~
a ~ ~ '~ 'c ~a ~
. .

G ~ _ ..D v., Q~ a a~ v f~ U

SUBSTBTUT~ SHEET (R~~,L~ 26) 2~7~2~

a ~

N .-~N N ~ N ~ N et N .-. O

~ V V V V V V V V V V V V V

a ""~ N .--~N N et N et N t ~

e N
' ~'' a y ~ V V V V V V V V V V V V V
~p q a N .-.N N ~t N t ~ ~

e N ~ N O

~ v v v v v v v v v v v v v ar a "'" N - N N ~ N ~ ~ ~

N ~ N O
a"' o ~~p V V V V V V V V V V V V V
q a o a N G~
~

~ N .-~N N ~ N et N et N ~ D

o , v v v v v v v v v v v v v ~~~

U U

o n N .~-~N N d' N h ' W
~

~ e N ~ N .-~ O

pq V V V V V V V V V V V V V

C

z E ~ ~ ~ ~

~ N . N N et N et N e N O
' 2 ~ ~ V V V V V V V V V V V V V
pq as a ~ ~

~ N - N N ~ N ~ N ~ N O

~ v v v v v v v v v v v v v H

a w E
~ ~ ~

N ~ N N et N ~ N e! N O

o ~~ V V V V V V V V V V V V V

U a~
~ ~

E'~ ~ ~ ~ ~ O .aC . ~ C C E

G iG b i< ~G ~ ~ U "C ~ ~ '-C ~

c~ d U G7 ~ ~ G, ~: p ~ ~ y ~
.7 w ' U U U V V U U
~' E

I ~

U

SUBST6T~iT~ ~~iE~ ~~lILE 26) WO 95108344 21 ? 2 2 4 5 PCTIUS94/11225 E

' V V V V V
i :$

,. N N
p ", p ~O ~D v0 .C \O ~ ~' w.r . .., ....-, ~ V V N V V V V
~q a OD ~ H N

W O CO .r .r ..o, fY v v v v v v v ~ ~~

z ~

~D ~D ~O

.~,., ~r rr .~ . ..r .r .-, p 1..1 V V V V V V V
~~
a"

p p c _o ~O ~O ~D

M c ~ A4 N V N V V V V
~ 'o O

U

O ~ ~ N ~D W O

~.,w w~ w.r .r w.i a'' p N V .~ V V V V
~ ~
p c z ""' ~r ~ N V N V V V V
p0 C'~

a~

tp ~D ~O

dD ~ "" '~' . ..r ..r.w pp N V V V V V V

H

N
~D vC ~O

o ~ N V d. V V V V
C~

C

p ~ ~ '_ ,~ .~ ~ W
;~ c O c ~
.U U ~
U ~ ~Y

s , C
" O

O O ~
E-~ v~ ~ ~ ed Q U U H ~ U
U

SUBSTITUTE 5~~~ (~Ui~~ 26) - iz2 -a ' ~ N .-~N N ~ N et N '~ N

b V V V V V V V V V V V V V

o v~
~ ~

N --~N N e! N ~ N ~ N . O
-~

v v v v v v v v v v v v v V ~ ~ ~"'~ N .r N N ~ N ~' ' N ~ N
~ A'' rzj ~~p V V V V V V V V V V V V V
p U

z o a ~ ~

N ~ N N et N ~ N ~' N O

... V V V V V V V V V V V V V

a y ~ ~

N ~.~ N ~ N N d' N eI N ~' N
~ ~ V V V

M ~ pq V V V V V V V V V V
ij U

a U

O ~ H vp N .-.N N et N ~' ~

N ~ N ~ O

q V V V V V V V V V V V V V

a C

"

z N ~ N N d' N t ~ ~

e N et N O
O '~ V

~ ~ V V V V V V V V V V V V
pq 4 ~l 04 y n ~

N ~ N N ~' N ~ N ~ N O

q V V V V V V V V V V V V V

~ ~

N ~ N N ~ N ~ N et N O
~

o V V V V V V V V V V V V V

~ ~

E ~ ~ E ~ o ~ _ o ~

0 ~ ~ y .~ ~ _ C

H ~ ~ c~,~ ~ C :; ~ et!t3.~ ~"
4~ 4~ ~ ~

H~ '~ ~ ~ w v v y ~ c H _ -~ z U U U U ~

U U

U

SUBSTITUTE SHEET (RULE 26) WO 95/08344 217 2 2 4 5 p~~s94111225 a ~

_. ~ ~ Pr ~ ..r a . V V V V V V V
~.

~, pp .fl a ~ N ~D ~D ~D

-r .C ~D '00 ~ ~..m. .r pr Pr Ae V V V V V V V
pp n O

V Gp E o"~ N ~O vC ~C

"" -.r...~ . .., .-,.r tzj V V V V V V V

~

O

.O

U
a ~ ~
D

a"' W pr ..r N "
.r "~

O o ~~ V V V V V V V

~, a o a .y C X00 N ~O ~O ~O
'~
~

~ +~~ ~~' v v v v v v v ~

.
~

U

o ~

h N ~o vo vo 1 ~ a..1 ~ ml ~ v..y.l pp V V V ~/ V V V

H

E n _ _ _ N ~_O ~_O~_O

p~q V V V V V V V

_er N ~P ~O ~O
r '04 ~ .. ... . ..~ .~....~
o ~ v v v v v v v ~. ~~

a "' .o ~o ~o no a, -~ ~' ~' ~ ~ ~' o spa v v v v v v v c aG
,_, C :_~
c ~ ~V 'V
~

d,.~ ~
a~ ~ ~. "

a av u U E' U

SUBSTITLiTE Sti~ET (RULE 26) GRAM-NEGATIVE BACTERICIDAL ACTIVITY OF BPI PEPTIDES
BPI peptides were produced according to co-owned and copending PCT Application No. US94/10427 filed September 15, 1994, which corresponds to U.S. Patent No. 5,652,332, PCT
Application No. US94/02465 filed March 11, 1994, which corresponds to U.S. Patent No. 5,733,872 and PCT Application No. US94/02401 filed March 11, 1994.
The BPI peptides were screened for bactericidal effects on E. coli J5 and E. coli 0111: B4 bacteria in a radial diffusion assay. Specifically, an overnight culture of the bacteria was diluted 1:50 into fresh tryptic soy broth and incubated for 3 hours at 37°C to attain log phase growth of the culture. Bacteria were then pelleted at 3,000 rpm for 5 minutes in a Sorvall RT 6000B centrifuge (Sorvall Instruments, Newton, TC). 5 mL of 10 mM sodium phosphate buffer (pH 7.4) was added and the preparation was re-pelleted. The supernatant was decanted and 5 mL of fresh buffer was added, the bacteria were resuspended and their concentration.was determined by measurement of absorbance at 590 nm (an Absorbance value of 1.00 at this wavelength equals a concentration of about 1.25 x 109 CFU/mL in suspension). The bacteria were diluted to 4 x 106 CFU/mL in 10 mL of molten underlayer agarose (at approximately 45°C) and inverted repeatedly to mix in 15 mL
polypropylene tubes conventionally used for this purpose.
The entire contents of such tubes were then poured into a level square petri dish and distributed evenly by rocking the dish side-to-side. The agarose hardened in less than 30 seconds and had a uniform thickness of about 1 mm. A series of wells were then punched into the hardened agarose using a sterile 3 mm r, WO 95!08344 PCT/US94111225 punch attached to a vacuum apparatus. The punch was sterilized with 100 °b alcohol and allowed to air dry prior to use to avoid contaminating the bacterial culture.
or 10 ~,L of each of the BPI peptides were carefully pipetted into each well. As a negative control, dilution buffer (pH 8.3) was added to a separate 5 well, and rBPI~ at concentrations of S~.g/mL and l~.g/mL were also added as positive controls. Each plate was incubated at 37°C for 3 hours, and then 10 mL
of molten overlayer agarose (at approximately 45°C) was added into the level petri dish, allowed to harden and incubated overnight at 37°C. The next day, a clear zone was seen against the lawn of bacteria in those wells having bactericidal activity. In order to visually enhance this zone, a dilute Coomassie solution (consisting of 0.002 ~
Coomassie Brilliant Blue, 27 °~ methanol, 15 ~ formaldehyde (37 ~ stock solution) and water) was poured over the agar and allowed to stain for 24 hours. The bacterial zones were measured with a micrometer. The assay results for exemplary peptides (BPI.1 through BPI.169) are summarized in Table 33 for the Gram-negative bacteria E. coli JS (rough) and E. coli 0113 (smooth). The bactericidal activities are expressed as the amount of peptide (pmol/well and ~cg/well) required to generate a 30 mm2 bactericidal zone. Additional exemplary BPI peptides include BPI.221 through BPL281. BPI peptides which retain antibacterial activity are expected to improve the therapeutic effectiveness of antibiotics when concurrently administered therewith.
The peptides are screened for such activity in an in vivo model or according to in vitro tests, including models and tests described herein.

WO 95108344 ; PCT/US94111225 Table Bactericidal Activity"

BPI Sequence E. coli E. coli Peptide ID No. S 0111:B4 (pmol/well)(~cglwell)(pmol/well)(~,g/well) BPL l 4 b _ _ -BPL2 7 > 2733.5 > 5 -BPI.3 11 696 2.14 -BPL6 67 398 1.05 > 1904 > 5 BPI.7 54 175 0.46 > 1890.6 > 5 BPI.B 8 > 3797.1 > 5 - _ BPI.9 51 479 1.02 > 2345.9 > 5 BPI.10 102 0.41 697 2.76 BPL 11 13 638 1.06 - -BPL 12 14 525 1.78 - -BPI.13 15 441 0.75 > 2923.9 > 5 BPI.14 2 - - - -BPI.15 16 > 2797.8 > 5 - -BPI.16 17 > 2821.5 > 5 - -WO 95/08344 217 2 2 ~ ~ PCT/US94i11225 Table i Bactericidal Activity BPI Sequence E. coli E. coli Pe ide ID No. 5 0111:B4 (pmol/well)(E.cg/well)(pmol/well)(~,g/well) BPI.17 18 > 2807.2 > 5 - -BPI.18 19 > 2757.6 > 5 - -BPI.19 20 > 2712.8 > 5 - -BPL20 21 > 2821.5 > 5 - -BPI.21 22 > 2917 > 5 - -BPL22 23 > 2821.50 > 5 - -BPL23 24 1330 2.36 > 2821.15 > 5 BPL24 25 655 1.16 > 2821.50 > 5 BPL25 26 > 2866.8 > 5 - -BPL26 27 > 2852.1 > 5 - -BPL27 28 > 2797.8 > 5 -BPL28 29 > 2821.5 > 5 - -BPL29 56 442 1.5 > 1469.2 > 5 BPL30 52 76 0.23 608 1.84 BPL31 33 938 1.55 -BPI.32 34 614 1.04 - -Table Bactericidal Activity BPI Sequence E. coli E. coli Peptide ID No. 5 0111:B4 (pmollwell)(~,g/well)(pmol/well)(~cg/well) BPL33 35 575 0.95 - -BPL34 36 916 1.54 - -BPI.35 37 263 0.45 - -BPL36 38 1652 2.64 - -BPL37 39 1284 2.14 - -BPL38 40 1698 2.83 - -BPL39 41 316 0.52 - -BPI.40 42 1760 2.94 - -BPL41 43 2465 4.03 - -BPL42 44 265 0.44 > 3041.3 > 5 BPL43 45 729 1.21 > 3024.8 > 5 BPL44 46 481 0.8 2983 4.93 BPL45 31 1302 2.23 > 1696.7 > 5 BPL46 57 186 0.47 > 1811.2 > 5 BPL47 58 98 0.25 577 1.46 BPL48 59 42 0.1 254 0.61 Table Bactericidal Activitys BPI Sequence E. coli E. coli Peutide ID No. S 0111:B4 (pmol/well)(~,g/well) (pmol/well)(~cgl well) BPI.55 61 299 0.75 > 1592.2 > 5 BPL56 47 1387 2.54 - -BPL57 99 514 1.05 - -BPL58 9 1050 2.03 - -BPL59 30 > 2312.3 > 5 - -BPL60 32 > 2136.5 > 5 - -BPI.61 48 > 2093.5 > 5 - -BPI.63 53 87 0.31 512 1.8 BPI.65 10 895 1. 82 - -oxidized BPI.65 68 1362 2.77 - -reduced BPI.66 49 > 3496.7 > S - -BPL67 50 > 1901.8 > 5 - -BPL69 60 57 0.21 244 0.88 WO 95/08344 PCTlUS94/11225 Table Bactericidal Activity BPI Sequence E. coli E. coli Pe ide ID No. 5 0111:B4 (pmol/well)(,ug/well)(pmol/well)(~.cg/well) BPI.70 63 - - - -BPL71 64 2297 4.53 - -BPI.72 66 > 1911.2 > 5 - -BPL73 62 57 0.11 > 1810.9 > S

BPL74 70 732 2.21 > 2148.2 > 5 BPI.75 100 2030.8 4.96 - -BPI.76 71 > 3906.5 > 5 - -BPI.77 72 455 0.85 - -BPL79 73 > 2282.9 > 5 - -BPI.80 74 655 1.24 - -BPL81 75 284 0.52 > 2344.9 > 5 BPI.82 76 171 0.32 > 1197.8 > 5 BPI.83 77 155 0.27 > 2033.5 > 5 BPI.84 78 12 0.02 > 2016.9 > 5 BPL85 79 227 0.4 > 1881.2 > 5 BPL86 80 1520 2.58 - -Table Bactericidal Activity' BPI Sequence E. coli E. coli Peptide ID No. 5 0111:B4 (pmol/well)(~.g/well) (pmol/well)(~glwell) BPI.87 81 189 0.32 > 1535.8 > 5 BPI.88 82 70.32 0.13 540.15 1 BPI.89 84 229.09 0.43 > 1882.4 > 5 BPL90 85 83.11 0.16 1763 3.32 BPL91 86 > 3843.5 > 5 BPI.92 87 331.8 0.57 BPL93 88 212.87 0.76 > 980.3 > 5 BPI.94 89 922.54 1.59 > 922.5 > 5 BPL9S 90 330.88 0.6 > 1397.6 > 5 BPL96 101 378.33 0.65 > 2048.5 > 5 BPL97 92 296.58 0.53 -BPL98 83 > 1626.1 > 5 > 1626.1 > 5 BPI.99 93 722.9 2.99 > 1064.1 > 5 BPI.100 94 407.74 0.73 > 2655 > 5 BPI.101 9S 1329.3 4.79 > 1329.3 > 5 BPI.102 96 > 2635.6 > 5 > 2635.6 > 5 Table Bactericidal Activity BPI Sequence E< coli E. coli Peptide ID No. .15 0111:B4 (pmol/well)(~cg/well)(pmol/well)(~,g/well) BPL103 102 165.18 0.31 415.19 0.78 BPL104 103 385.85 0.64 1376.42 2.30 BPI.105 104 65.35 0.12 206.98 0.39 BPL106 105 427.12 0.72 > 3413.80 > 5 BPI.107 106 384.67 0.68 > 2795.70 > 5 BPI.108 107 661.05 1.17 > 3219.02 > 5 BPI.109 108 306.80 0.54 > 2822.90 > 5 BPI.110 109 812.33 1.44 > 2950.15 > 5 BPI.111 110 959.00 1.71 > 2808.69 > 5 BPI.112 111 1485.92 2.84 - -BPI.113 112 270.66 0.50 > 2950.15 > 5 BPI.114 113 2329.68 3.10 - -BPI.116 114 73.82 0.13 > 2788.19 > 5 BPI.119 115 106.70 0.20 536.44 1.02 BPI.121 117 154.35 0.3 1856.40 3.55 WO 95/08344 217 2 2 ~ ~ PCT/US94/11225 Table Bactericidal Activitya BPI Sequence E. coli E. coli Pe tide ID No. .TS 0111:B4 (pmol/well)(~,g/well) (pmol/well)(~,g/well) BPI.122 118 179.89 0.36 2123.57 4.2 BPI.123 119 247.20 0.43 > 2865.02 > 5 BPI.124 120 91.23 0.17 > 2580.12 > 5 BPI.125 121 428.85 0.75 > 3149.74 > 5 BPI.126 122 1979.97 3.39 - -BPI.127 123 406.01 0.68 -BPI.128 124 2271.14 3.80 - -BPI.129 125 1685.10 2.90 - -BPI.130 126 325.75 0.68 > 2903.34 > 5 BPL 131 127 1438.21 2.48 -BPL 132 128 > 2988.50 > 5 - -BPI.133 129 2316.59 3.91 -BPI.134 130 162.5 0.30 580.11 1.05 BPI.135 131 1052.02 1.74 3321.69 > 5 BPI.136 132 > 3030.74 > 5 - -BPI.137 133 N.T. N.T. N.T. N.T.

134- ~ ~ ~~2~~
Tabte Bactericidal Activity BPI Sequence E. coli E, coli Peptide ID No. JS 0111:B4 (pmol/well)(~,g/well) (pmol/well)(~cgl well) BPI.138 134 64.57 0.11 995.40 1.74 BPI.139 135 1261.37 2.13 3793.91 > 5 BPI.140 136 84.76 0.26 605.34 1.89 BPI.141 137 > 2809.51> 5 - -BPI.142 138 922.21 1.76 - -BPI.143 139 > 2838.99> 5 - -BPI.144 140 510.02 0.86 - -BPI.145 141 N.T. N.T. N.T. N.T.

BPI.147 143 > 2558.17> 5 - -BPL 148 144 > 2805.45> 5 - -BPL149 147 44.00 0.57 391.00 5.00 BPI.150 148 220.00 0.58 > 2380.67> 5 BPL151 N.T. N.T. N.T. N.T.

BPL152 N.T. N.T. N.T. N.T.

BPL153 149 N.T. N.T. N.T. N.T.

WO 95108344 ~ 217 2 2 4 ~ 1'CT/i1S94J11225 Table BactericidaD
Activity~

BPI Sequence E. coli E. coli Pe tide ID No. 5 0111:B4 (pmol/well)(~cg/well)(pmol/well)(~cg/well) BPI.154 150 197.00 0.55 2977.76 > 5 BPI.155 151 > 1795.66 > 5 > 1795.66 > 5 BPL156 152 N.T. N.T. N.T. N.T.

BPL157 153 N.T. N.T. N.T. N.T.

BPL158 154 N.T. N.T. N.T. N.T.

BPI.159 155 765.43 2.41 > 1589.88 > 5 BPI.160 156 288.78 0.81 > 1781.59 > 5 BPI.161 157 1201.79 2.00 - -BPL162 158 N.T. N.T. N.T. N.T.

BPL163 159 N.T. N.T. N.T. N.T.

BPL164 160 N.T. N.T. N.T. N.T.

BPL165 161 N.T. N.T. N.T. N.T.

BPI.166 162 514.00 0.83 > 3078.72 > 5 BPI.167 163 ~ > 4585.73 > 5 -BPI.168 164 1460.98 2.87 > 1948.48 > 5 WO 95108344 PCTlfJ594111225 Table Bactericidal Activitya BPI Sequence E. coli E. coli Peptide ID No. .15 0111:B4 (pmol/well)(~cg/well)(pmol/well)(~cglwell) BPL 169 165 4893.83 > 5 > 4974.43 > 5 BPI.170 227 3693.06 > 5 - -MAP.1 106 0.82 552.79 4.27 *

MAP.2** > 690.9 > 5 > 690.9 > 5 a Amount added to well to achieve a 30 mm2 hole as determined by PROBIT analysis as described in Examples 15 and 16.
b No detectable activity up to 5 ~cglwell.
c N.T. = not tested * MAP.1 - (3-Ala-Na,NE-[Na,NE(BPL2)Lys)Lys ** MAP.2 - a-Ala-Na,NE-(Na,NE (BPL 13)Lys]Lys R'O 95108344 PCTILTS94/11225 ~ ~ ~'~2 EFFECTS OF CONCURRENT ADMINISTRATION
OF BPI PROTEIN PRODUCT
AND TETRACYCLINE OR GENTAMICIN ON E. COLI 0111:B4 Additional MIC assays were performed to determine the sensitivity of E. coli 0111:84 (as described in Example 1) to the effects of BPI protein products concurrently administered with the antibiotic tetracycline or with the antibiotic gentamicin.
For these experiments, organisms were grown overnight at 37°C in 5 mL of Mueller-Hinton broth. This overnight culture was diluted 1:50 into 5 mL
of fresh broth and incubated for an additional 3 hours at 37°C to attain log-phase growth. Bacteria were pelleted for 5 minutes at 1500 x g and resuspended in fresh broth to give a final concentration of 2 x 106 cells per mL.
rBPI23 and antibiotic (either tetracycline or gentamicin) were diluted such that 100~c1 bacterial suspension, 50 ~cl antibiotic and 50 ~,1 diluted rBPI23, gave concentrations in serial dilutions from 10 ~,g/mL tetracycline or 2.5 ~cglmL
gentamicin and from 30 ~cgl mL rBPI23 with a fixed concentration of 106 cells/mL.
Incubation was carried out in flat bottom 96 well microtiter plates for 18 hours at 37°C, and the plates were read in an automatic plate reader (Titretek Multiscan) at 590 nm.
A 4-6 fold decrease in absorbance was observed with tetracycline or gentamicin with certain concentrations of BPI protein product. The MIC of tetracycline without rBPI23 of 10 ~,g/mL and was reduced by rBPI23 to 5 ~cg/mL.
The MIC of gentamicin without rBPI23 was 0.6 ~,g/mL and was reduced by rBPI23 to 0.3 ~cgl mL.

WO 95108344 ~ PCT/US94111225 A partial summary of the data described in the foregoing examples, grouped by general classes of antibiotics, appears below in Table 34 and is displayed as the effects of BPI protein products on the therapeutic effectiveness of antibiotics for various gram-negative organisms.

ANTIBIOTIC EFFECTS OF BPI PROTEIN PRODUCT WHEN

CLASS CONCURRENTLY ADMINISTERED WITH

ANTIBIOTICS WITHIN CLASS

/3-lactams: reversed resistance of Pseudomonas aeruginosa, other penicillins Pseudomonas, Xant>zamonas, E. coli, Citrobacter, and cephalosporinsKlebsiella, Enterobacter, Serratia, Providencia, Acinetobacter increased susceptibility of Pseudomonas aeruginosa, other Pseudomonas, E. coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Providencia, Morganella, Acinetobacter enhanced early bactericidal effect for E.
cola, Enterobacter in killing curves in vivo synergy shown for treatment of E.
coli infection in mouse and rabbit models ~i-lactams aztreonam:

other than reversed resistance of Pseudomonas aeruginosa, penicillins Acinetobacter and cephalosporins:increased susceptibility of Acinetobacter aztreonam increased susceptibility of Pseudomonas aeruginosa, and imipenem Citrobacter, Enterobacter imipenem:

increased susceptibility of Pseudomonas aeruginosa, Proteus, Providencia, Acinetobacter ANTIBIOTIC EFFECTS OF BPI PROTEIN PRODUCT WHEN

CLASS CONCURRENTLY ADMINISTERED WITH

ANTIBIOTICS WITHIN CLASS

aminoglycosidesreversed resistance of Pseudomonas aeruginosa, Xanthamonas, Acinetobacter increased susceptibility of Pseudomonas aeruginosa, other Pseudomonas, E. cola, Citrobacter, Serratia, Proteus, Providencia, Morganella, Acinetobacter checkerboard synergy (FIC < 0.5) for E. coli, Salmonella, Klebsiella, Edwardsiella; greater than additive interaction (FIC < I.0) for Pseudomonas aeruginosa, Enterobacter in vivo synergy shown for treatment of E.
coli infection in mouse model sulfonamides reversed resistance of Pseudomonas aeruginosa, and Xanthamonas, Klebsiella, Acinetobacter trimethoprim increased susceptibility of Enterobacter, Proteus, Acinetobacter enhanced early bactericidal effect for Klebsiella, Enterobacter in killing curves; slight early enhancement for E. coli fluoroquinolonesreversed resistance of Pseudomonas aeruginosa, and quinolonesAcinetobacter increased susceptibility of Pseudomonas aeruginosa, Xanthamonas, Enterobacter, Acinetobacter reversed resistance of Klebsiella in antibiotic killing curves polymyxins checkerboard synergy (FIC < 0.5) for Pseudomonas aeruginosa, E. coli, Providencfa; additive interaction (FIC

<_ 1.0) for Enterobacter chloramphenicolreversed resistance and increased susceptibility for Acinetobacter WO 95!08344 ~ ~ PCT/LTS94l11225 Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the foregoing description of the presently preferred embodiments thereof.
Consequently, the only limitations which should be placed upon the scope of the present invention are those which appear in the appended claims.

SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANTS: Cohen, Jonathan Kung, Ada H.C.
Lambent, Jr., Lewis H.
(ii} TITLE OF INVENTION: Method for Treating Gram-Negative Bacterial Infection by Administration of Bactericidal/Permeability-Increasing (BPI) Protein Product and Antibiotic (iii) NUMBER OF SEQUENCES: 227 {iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun (B) STREET: 6300 Sears Tower, 233 South Wacker Drive (C) CITY: Chicago (D) STATE: Illinois (E) COUNTRY: USA
(F) ZIP: 60606-6402 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/273,401 (B) FILING DATE: 11-JUL-1994 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/125,651 (B} FILING DATE: 22-SEP-1993 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Sharp, Jeffrey S.
(B) REGISTRATION NUMBER: 31,879 (C) REFERENCE/DOCKET NUMBER: 32251 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 312/474-6300 (B} TELEFAX: 312/474-0448 (C) TELEX: 25-3856 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "Domain I"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

21~22~~

Ala 5er Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His (2} INFORMATION FOR SEQ ZD N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear (ii} MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.14"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly His (2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 22 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.4°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu (2} INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D} OTHER INFORMATION: "BPI.1"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys (2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 15 amino acids ' (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.54"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: S:
Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro (2) INFORMATION FOR SEQ ID N0:6:
{i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

(A) NAME/KEY: misc feature {D) OTHER INFORMATION: "DomainII"

(xi) SEQUENCE DESCRIPTION: SEQ :6:

Ser Ser Gln Ile Ser Met Val ValGly Leu Lys Phe Ser Pro Asn Ile Ser Asn Ala Asn Ile Lys GlyLys Trp Lys Ala Gln Ile Ser Lys Arg Phe Leu Lys (2) INFORMATION
FOR SEQ ID
N0:7:

{i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

{A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.2' (xi) SEQUENCE DESCRIPTION: SEQ 7:
ID N0:

Ile Lys Ile Ser Gly Lys Trp GlnLys Arg Phe Leu Lys Lys Ala (2) INFORMATION
FOR SEQ ID
N0:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids {B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.B°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.58"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.65 oxidized"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Cys (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.3"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asn Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn I12 Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "Domain III°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu 5er Ala Leu Arg Asn Lys (2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.11"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Lys Ser Lys Val Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.12"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys WO 95!08344 (2) INFORMATION FOR SEQ ID N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.13"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2} INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.15"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
Ala Lys Zle Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D} OTHER INFORMATION: "BPI.16'°
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
Ile Ala Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.17"

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
Ile Lys Ala Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys {2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.18"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
Ile Lys Ile Ala Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: misc feature {D) OTHER INFORMATION: "BPI.19"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
Ile Lys Ile Ser Ala Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.20"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
Ile Lys Ile Ser Gly Ala Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear WO 95108344 ~ PCT/US94/11225 (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.21"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.22"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
Ile Lys Ile Ser Gly Lys Trp Ala Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.23"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:24:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.24"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:25:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.25"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:
Iie Lys Ile Ser G5y Lys Trp Lys Ala Gln Lys Ala Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (8) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.26°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:27:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Ala Leu Lys (2) INFORMATION FOR SEQ ID N0:28:
(i) SEQUENCE CHARACTERISTICS:
(Ay LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: °'BPI.27"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:28:
ile Lys Ile Ser 51y Lys Trp Lys Ala Gln Lys Arg Phe Ala Lys (2) INFORMATION FOR SEQ ID N0:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature WO 95/08344 ~ ; PCT/US94I11225 (D) OTHER INFORMATION: "BPI.28"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:29:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Ala (2) INFORMATION FOR SEQ ID N0:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.59"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:30:
Ile Lys Ile Ser Gly Ala Trp Ala Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.45"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:31:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.60"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:32:
Ile Ala Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Ala (2) INFORMATION FOR SEQ ID N0:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amine acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(Ay NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.31°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:33:
Ala Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: miec_feature (D) OTHER INFORMATION: "BPI.32"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:34:
Lys Ala Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.33"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:35:
Lys Ser Ala Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (Dy TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.34"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:36:
Lys Ser Lys Ala Gly Trp Leu Ile Gln Leu Phe His Lys Lys WO 95/08344 ~ PCTlUS94/11225 {2) INFORMATION FOR SEQ ID N0:37:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.35"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:37:
Lys Ser Lys Val Ala Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.36"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:38:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.37"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:39:
Lys Ser Lys Val Gly Trp Ala Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.38"

(xi) SEQUENCE DESCRIPTION: SEQ ZD N0:40:
Lys Ser Lys Val Gly Trp Leu Ala Gln Leu Phe His Lys Lys (2) INFORMATION
FOR
SEQ
ID
N0:41:

(i)SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (ix)FEATURE:

(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.39"

(xi)SEQUENCE DESCRIPTION: SEQ ID N0:41:

iysSer Lys Val 51y Trp Leu Ile Ala Leu Phe His Lys Lys (2) INFORMATION
FOR
SEQ
ID
N0:42:

(i)SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (ix)FEATURE:

(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.40"

(xi)SEQUENCE DESCRIPTION: SEQ ID N0:42:

LysSer Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Lys (2) INFORMATION
FOR
SEQ
ID
N0:43:

(i)SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (ix)FEATURE:

(A) NAME/KEY: misc feature _ (D) OTHER INFORMATION: "BPI.41"

(xi)SEQUENCE DESCRIPTION: SEQ ID N0:43:

LysSer Lys Val Gly Trp Leu Ile Gln Leu Ala His Lys Lys (2) INFORMATION FOR SEQ ID N0:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ~ ~~2~

(ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.42"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:44:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Lys (2)INFORMATION
FOR
SEQ
ID
N0:45:

(ij SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (ix)FEATURE:

(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.43"

(xi)SEQUENCE DESCRIPTION: SEQ ID N0:45:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Ala Lys (2)INFORMATION
FOR
SEQ
ID
N0:46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (ix)FEATURE:

(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.44"

(xi)SEQUENCE DESCRIPTION: SEQ ID N0:46:

Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Ala (2)INFORMATION
FOR
SEQ
ID
N0:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (ix)FEATURE:

(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.56"

(xi)SEQUENCE DESCRIPTION: SEQ ID N0:47:

Ile Lys Ile Ser Gly Lys Trp Lys Ala Lys Gln Arg Phe Leu Lys (2)INFORMATION
FOR
SEQ
ID
N0:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: °'BPI.61"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:48:
Ile Lys Ile Ser Gly Lys Phe Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids . (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (Dy OTHER INFORMATION: "BPI.66"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= D-Trp /note= "The amino acid at position 7 is D-tryptophan"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:49a ile Lys Ile Ser Sly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.67"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6..8 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is - beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:50:
ile Lys Ile Ser 51y Lys Ala Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:51:

WO 95/08344 PCTIUS94l11225 ~ ~ ~~2~5 lss (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.9"
{xi) SEQUENCE DESCRIPTION: SEQ ID N0:51:
Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.30"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:52:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:53:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.63"
(xi) SEQUENCE DESCRIPTION: SEQ ZD N0:53:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys 5er Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide WO 95/08344 PCTlUS94/11225 (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.7"
' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:54:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.10.1"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:55:
Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:56:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.29"
(xij SEQUENCE DESCRIPTION: SEQ ID N0:56:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.46"

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:57:
Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.47'°
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:58:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.48"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:59:
Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.69"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:60:

Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.55"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:61:
Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser (2) INFORMATION FOR SEQ ID N0:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.73"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:62:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.70"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8..10 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-3-pyridyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:63:

Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Leu Lys Arg Phe Lys (2) INFORMATION
FOR
SEQ
ID
N0:64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

feature (A) NAME/KEY: misc _ (D) OTHER INFORMATION: "BPZ.71"

(ix) FEATURE:

(A) NAME/KEY: Modified-site (B) LOCATION: 13..15 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 13 is beta-3-pyridyl-substituted"

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:64:

Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Leu Lys Arg Ala Lys (2) INFORMATION
FOR
SEQ
ID
N0:65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

(A) NAME/KEY: misc feature _ (D) OTHER INFORMATION: "BPI.10.2"

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:65:

Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Phe Gln Lys Arg Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION
FOR
SEQ
ID
N0:66:

(i) SEQUENCE CHARACTERISTICS:

{A) LENGTH: 17 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide {ix) FEATURE:

(A) NAME/KEY: misc feature _ (D) OTHER INFORMATION: "BPI.72"

(ix) FEATURE:

(A) NAME/KEY: Modified-site {B) LOCATION: 1..3 (D) OTHER INFORMATION: /label= D-alanine WO 95108344 PCTlUS94111225 /note= "The position 1 and position 2 alanine residues are both D-alanine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:66:
Ala Ala Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:67:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI. S"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:67:
Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu (2) INFORMATION FOR SEQ ID N0:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.65 reduced"
(ix) FEATURE:
(A) NAME/KEY: Disulfide-bond (8) LOCATION: 1..17 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:68:
Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Cys (2) INFORMATION FOR SEQ ID N0:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 487 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "rBPI"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:69:
Met Arg Glu Asn Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly His Tyr Ser Phe Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser Met Val Pro Aan Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser Ser Cys Ser Ser His Ile Asn Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val .' Ala Lys Lys Phe Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His Leu Ser Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro Ala Val Asp Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val Val Tyr Lys (2) INFORMATION FOR SEQ ID N0:70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.74"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:70:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.76"

WO 95/08344 ~ PCTIITS94111225 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10..12 (D) OTHER INFORMATION: /label= D-Phe /note= "The amino acid at position 11 is D-phenylalanine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:71:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.77"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:72:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.79"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:73:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Lys Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.80"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10..12 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 11 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:74:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:75:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: misc_feature {D) OTHER INFORMATION: "BPI.81"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:?5:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Phe Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:76:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.82"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:76:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.83"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10..12 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 6 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:77:

WO 95/08344 ~ , PCT/US94/11225 Lys Ser Lys Val Gly Ala Lys Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.84"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6..8 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:78:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.85"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:79:
Lys Ser Lys Val Leu Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.86"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:80:
Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:81:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.87"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:81:
iys Ser Lys Val 51y Trp Leu Ile Gln Leu Phe Leu Lys Lys (2) INFORMATION FOR SEQ ID N0:82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.88"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:82:
ile Lys Ile Ser 51y Lys Trp Lys Ala Phe Phe Arg Phe Leu Lys (2) INFORMATION FOR SEg ID N0:83:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (8) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.98"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Substituted-Trp /note= "The alanine at position 2 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:83:
Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys WO 95/08344 ~ ~ ~ ' PCT/L1S94111225 1b8 (2) INFORMATION FOR SEQ ID N0:84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.89"
(ix) FEATURE:
(A) NAME/KEY: Modified°site (B) LOCATION: 6..8 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:84:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Phe Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.90°' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6..8 (D) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:85:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Phe Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix} FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.91"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:86:

Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid ' (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.92"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:87:
Lys Ser Lys Val Gly Trp Leu Ile Lys Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.93"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6..8 (D) OTHER INFORMATION: /label= Substituted-Ala /note= °'The alanine at position 7 is beta-1-naphthyl-substituted"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:88:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:89:
(ij SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: °'BPI.94"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:89:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Phe Lys Lys WO 95/08344 ~ PCT/US94/11225 17~
{2) INFORMATION FOR SEQ ID N0:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.95"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:90:
Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.96"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:91:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Phe (2) INFORMATION FOR SEQ ID N0:92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.97"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:92:
Lys Ser Lys Val Lys Trp Leu Ile Gln Leu Phe His Lys Lys {2) INFORMATION FOR SEQ ID N0:93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.99"

WO 95/08344 217 2 2 4 5 pCT~S94111225 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:93:
Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:94:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.100"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:94:
Lys Ser Lys Val Lys Trp Leu Ile Lys Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:95:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.101"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:95:
Lys Ser Lys Val Lys Trp Leu Ile Lys Leu Phe Phe Lys Phe Lys Ser Lys Val Lys Trp Leu Zle Lys Leu Phe Phe Lys Phe (2j INFORMATION FOR SEQ ID N0:96:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.102"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:96:
Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lya Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:97:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1443 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: CDS

(B) LOCAT ION:1.. 1443 (ix) FEATURE:

(A) NAME/ KEY:mat peptide (B) LOCAT ION:76. .1443 ( ix) FEATURE:

(A) NAME/ KEY:misc ature fe (D) OTHER INFORMATION : LBP
r (xi) SEQUENCEESCRIPTION: SEQID :
D N0:97 GCC

MetGlyAla Leu ArgAla LeuProSerIle LeuLeuAlaLeu Leu Ala CCA

LeuThrSer Thr GluAla LeuGlyAlaAsn ProGlyLeuVal Ala Pro AAG

ArgIleThr Asp GlyLeu GlnTyrAlaAla GlnGluGlyLeu Leu Lys GAG

AlaLeuGln Ser LeuLeu ArgIleThrLeu ProAspPheThr Gly Glu CCC

AspLeuArg Ile HisVal GlyArgGlyArg TyrGluPheHis Ser Pro AGC

Leu Asn Ile His Ser Cys Glu Leu Leu His Ser Ala Leu Arg Pro Val CTG

ProGlyGln Gly SerLeu SerIleSerAsp SerSerIleArg Val Leu AAG

GlnGlyArg Trp ValArg LysSerPhePhe LysLeuGlnGly Ser Lys GTC

PheAspVal Ser LysGly IleSerIleSer ValAsnLeuLeu Leu Val TCC

GlySerGlu Ser GlyArg ProThrValThr AlaSerSerCys Ser Ser ATC GAC GAC
GCT ATG TTG
GAC GGG

Ser Asp ValGluVal Asp Ser Gly Trp Ile Met Asp Ala Leu Asp Gly TTC GAG AAA

Leu LeuAsnLeuPhe HisAsnGln IleGluSer LysPheGln Val Lys Leu GluSerArgIle CysGluMet I12GlnLys SerValSerSer Asp Leu GlnProTyrLeu GlnThrLeu ProValThr ThrGluIleAsp Ser Phe AlaAspIleAsp TyrSerLeu ValGluAla ProArgAlaThr Ala Gln MetLeuGluVal MetPheLys GlyGluIle PheHisArgAsn His Arg SerProValThr LeuLeuAla AlaValMet SerLeuProGlu Glu His AsnLysMetVal TyrPheAla IleSerAsp TyrValPheAsn Thr Ala SerLeuValTyr HisGluGlu GlyTyrLeu.AsnPheSerIle Thr Asp GluMetIlePro ProAspSer AsnIleArg LeuThrThrLys Ser Phe ArgProPheVal ProArgLeu AlaArgLeu TyrProAsnMet Asn Leu GluLeuGlnGly SerValPro SerAlaPro LeuLeu.AsnPhe Ser Pro GlyAsnLeuSer ValAspPro TyrMetGlu IleAspAlaPhe Val Leu LeuProSerSer SerLysGlu ProValPhe ArgLeuSerVal Ala ACC GGG

Thr AsnValSerAla ThrLeuThr PheAsnThr SerLysIleThr Gly AAG CTG GTT
GTA AAA
AAA

Phe LeuLysProGly Lys ValGlu GluSerLys Lys Leu Val Val Lys GlyLeuPheAsn AlaGluLeuLeu GluAlaLeu LeuAsnTyr TyrIle LeuAsnThrPhe TyrProLysPhe AsnAspLys LeuAlaGlu GlyPhe ProLeuProLeu LeuLysArgVal GlnLeuTyr AspLeuGly LeuGln IleHisLysAsp PheLeuPheLeu GlyAlaAsn ValGlnTyr MetArg Val (2) INFORMATION FOR SEQ ID N0:98:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 481 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "rLBP"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:98:
Met Gly Ala Leu Ala Arg Ala Leu Pro Ser Ile Leu Leu Ala Leu Leu Leu Thr Ser Thr Pro Glu Ala Leu Gly Ala Asn Pro Gly Leu Val Ala Arg Ile Thr Asp Lys Gly Leu Gln Tyr Ala Ala Gln Glu Gly Leu Leu Ala Leu Gln Ser Glu Leu Leu Arg Ile Thr Leu Pro Asp Phe Thr Gly Asp Leu Arg Ile Pro His Val Gly Arg Gly Arg Tyr Glu Phe His Ser Leu Asn Ile His Ser Cys Glu Leu Leu His Ser Ala Leu Arg Pro Val Pro Gly Gln Gly Leu Ser Leu Ser Ile Ser Asp Ser Ser Ile Arg Val Gln Gly Arg Trp Lys Val Arg Lys Ser Phe Phe Lys Leu Gln Gly Ser Phe Asp Val Ser Val Lys Gly Ile Ser Ile Ser Val Asn Leu Leu Leu Gly Ser Glu Ser Ser Gly Arg Pro Thr Val Thr Ala Ser Ser Cys Ser WO 95/08344 ~ 17 2 2 4 5 pCT~s94/11225 Ser Asp Ile Ala Asp Val Glu Val Asp Met Ser Gly Asp Leu Gly Trp Leu Leu Asn Leu Phe His Asn Gln Ile Glu Ser Lys Phe Gln Lys Val Leu Glu Ser Arg Ile Cys Glu Met Ile Gln Lys Ser Val Ser Ser Asp Leu Gln Pro Tyr Leu Gln Thr Leu Pro Val Thr Thr Glu Ile Asp Ser Phe Ala Asp Ile Asp Tyr Ser Leu Val Glu Ala Pro Arg Ala Thr Ala Gln Met Leu Glu Val Met Phe Lys Gly Glu Ile Phe His Arg Asn His Arg Ser Pro Val Thr Leu Leu Ala Ala Val Met Ser Leu Pro Glu Glu His Asn Lys Met Val Tyr Phe Ala Ile Ser Asp Tyr Val Phe Asn Thr Ala Ser Leu Val Tyr His Glu Glu Gly Tyr Leu Asn Phe Ser Ile Thr Asp Glu Met Ile Pro Pro Asp Ser Asn Ile Arg Leu Thr Thr Lys Ser Phe Arg Pro Phe Val Pro Arg Leu Ala Arg Leu Tyr Pro Asn Met Asn Leu Glu Leu Gln Gly Ser Val Pro Ser Ala Pro Leu Leu Asn Phe Ser Pro Gly Asn Leu Ser Val Asp Pro Tyr Met Glu Ile Asp Ala Phe Val Leu Leu Pro Ser Ser Ser Lys Glu Pro Val Phe Arg Leu Ser Val Ala Thr Asn Val Ser Ala Thr Leu Thr Phe Asn Thr Ser Lys Ile Thr Gly Phe Leu Lys Pro Gly Lys Val Lys Val Glu Leu Lys Glu Ser Lys Val Gly Leu Phe Asn Ala Glu Leu Leu Glu Ala Leu Leu Asn Tyr Tyr Ile Leu Asn Thr Phe Tyr Pro Lys Phe Asn Asp Lys Leu Ala Glu Gly Phe Pro Leu Pro Leu Leu Lys Arg Val Gln Leu Tyr Asp Leu G1y Leu Gln Ile His Lys Asp Phe Leu Phe Leu Gly Ala Asn Val Gln Tyr Met Arg Val (2) INFORMATION FOR SEQ ID N0:99:

2~~22~~

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.57"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:99:
Cys Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Pro Leu Cys (2) INFORMATION FOR SEQ ID NO:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids {B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide {ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.75"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:
Ile Lys Lys Arg Ala Ile Ser Phe Leu Gly Lys Lys Trp Gln Lys (2) INFORMATION FOR SEQ ID NO:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.282'°
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:
Lys Trp Lys Ala Phe Phe Arg Phe Leu Lys Lys Trp Lys Ala Phe Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:102:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide WO 95108344 217 2 2 4 5 pCT~S94111225 (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.103"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:102:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Trp Lys Arg Phe Leu Lys Lys (2) INFORMATION FOR SEQ ID N0:103:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.104"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:103:
Lys Ser Lys Val Gly Trp Leu Ile Ser Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:104:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.105"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 13 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:104:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Trp Lys Arg Ala Leu Lys Lys (2) INFORMATION FOR SEQ ID N0:105:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.106"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:105:
Lys Ser Lys Val Gly Trp Leu Ile Thr Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:106:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.107"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:106:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Trp Lys Lys (2) INFORMATION FOR SEQ ID N0:107:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.108"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:107:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Trp (2) INFORMATION FOR SEQ ID N0:108:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.109"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 11 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:108:

WO 95108344 217 2 2 4 5 pcT/US94/11225 Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Ala His Lys Lys (2) INFORMATION FOR SEQ ID N0:109:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.110"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:109:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Lys (2) INFORMATION FOR SEQ ID NO:110:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.111"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= '°The alanine at position 14 is beta-1-naphthyl-substituted.'°
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Ala (2) INFORMATION FOR SEQ ID NO:111:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.112"

2~7224j (ix) FEATURE:
(A) NAME/KEY: Modified-site (8) LOCATION: 7 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 11 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:112:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.113"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:112:
Lys Ser Lys Val Gly Trp Leu Ile Gln Phe Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:113:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.114"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:113:
Lys Trp Gln Leu Arg Ser Lys Gly Lys Ile Lys Ile Phe Lys Ala (2) INFORMATION FOR SEQ ZD N0:114:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.116"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 6 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:114:
Lys Ser Lys Val Lys Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:115:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D} OTHER INFORMATION: "BPI.119"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A} NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 10 is beta-1-naphthyl-substituted.~
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:115:
Ile Lys Ile Ser Gly Lys Ala Lys Ala Ala Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:116:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D} OTHER INFORMATION: "BPI.120°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:116:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Lys Leu Lys (2) INFORMATION FOR SEQ ID N0:117:

WO 95/08344 PCTlUS94111225 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.121"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 10 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 11 is beta-1-naphthyl-substituted.°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:117:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:118:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.122"
(ix) FEATURE:
(A~) NAME/KEY: Modified-site (B) LOCATION: 7 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 7 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 10 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 11 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:118:

WO 95!08344 PCT/US94J11225 ile Lys Ile Ser 51y Lys Ala Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:119:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid -' (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.123"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "The phenylalanine at position 9 is p-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:119:
Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:120:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.124"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:120:
Lys Ser Lys Val Lys Trp Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:121:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature ' (D) OTHER INFORMATION: "BPI.125"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:121:
Lys Ser Lys Val Gly Trp Leu Ile Tyr Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:122:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.126"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= D-Trp /note= "The amino acid at position 6 is D-tryptophan."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:122:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:123:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.127"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:123:
Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:124:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.128"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= D-Phe /note= "The amino acid at position 6 is D-phenylalanine."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:124:
Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Pro His Lys Lys WO 95/08344 21 ~ 2 2 4 5 , pCTlUS94/11225 (2) INFORMATION FOR SEQ ID N0:125:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.129"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= '°The alanine at position 6 is D-1-beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:125:
Lys Ser Lys Val Gly Ala Leu I12 Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:126:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.130"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= '°The alanine at position 6 is 2-beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:126:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:127:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.131"
(ix) FEATURE:

(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 6 is D-2-beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:127:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:128:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.132"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 6 is pyridyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:128:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:129:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.133"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "The phenylalanine at position 6 is para-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:129:
Lys Ser Lys Val Gly Phe Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:130:
(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.134"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "The phenylalanine at position 5 is para-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:130:
Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:131:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.135"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:131:
Lys Ser Lys Val Gly Lys Leu Ile Gln Leu Pro His Lys Lys (2) INFORMATION FOR SEQ ID N0:132:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.136"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:132:
Ile Lys Ile Ser Gly Lys Trp Lys A1a Gln Glu Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:133:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.137"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:133:
Cys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Cys (2) INFORMATION FOR SEQ ID N0:134:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.138"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:134:
Lys Ser Lys Val Lys Phe Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:135:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.139"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:135:
Lys Ser Lys Val Gly Tyr Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:136:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.140"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 WO 95108344 217 2 ~ ~ ~ PCTlUS94111225 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 1 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /label= Substituted-Ala - /note= "The alanine at position 2 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:136:
Ala Ala Arg Phe Leu Lys Phe (2) INFORMATION FOR SEQ ID N0:137:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature {D) OTHER INFORMATION: "BPI.141"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:137:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Trp Leu Lys (2) INFORMATION FOR SEQ ID N0:138:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.142"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:138:
Lys Ser Lys Val Gly Trp Leu Ile Gln Trp Phe His Lys Lys _' (2) INFORMATION FOR SEQ ID N0:139:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.143"

21 ~Z25~

(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:139:
Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:140:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.144"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 6 is cyclohexyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:140:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:141:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.145"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:141:
Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:142:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide WO 95/08344 217 2 2 4 5 ' pCTIUS941i1225 (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.146"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 12 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 14 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:142:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe Ala Lys Ala (2) INFORMATION FOR SEQ ID N0:143:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.147"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:143:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Glu Lys Lys Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:144:
(i) SEQUENGE CHARACTERISTICS:
(A) LENGTH: 14 amino acids ~~- (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.148"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:144:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe Ala Lys Lys (2) INFORMATION FOR SEQ ID N0:145:
(i)SEQUENCE CHARACTERISTICS:

(A) LENGTH:
1813 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS:
single (D) TOPOLOGY: linear (ii)MOLECULE TYPE:cDNA

(ix)FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 31..1491 (ix)FEATURE:

(A) NAME/KEY: peptide mat (B) LOCATION: _ 124. 1491 (ix)FEATURE:

(A) NAME/KEY: misc feature _ (D) OTHER INFORMATION:
"rBPI"

(xi)SEQUENCE DESCRIPTION: 5:
SEQ ID N0:14 GGTTTTGGCA
GCTCTGGAGG
ATG
AGA
GAG
AAC
ATG
GCC
AGG
GGC

Met Arg Glu Asn Met Ala Arg Gly AGA CTG

ProCysAsn Ala Pro Trp Val Ser MetVal LeuVal AlaIle Arg Leu GCG CCT

GlyThrAla Val Thr Ala Val Asn GlyVal ValVal ArgIle Ala Pro GAC CAG

SerGlnLys Gly Leu Tyr Ala Ser GlnGly ThrAla AlaLeu Asp Gln AGG CCT

GlnLysGlu Leu Lys Ile Lys Ile AspTyr SerAsp SerPhe Arg Pro GGG TAT

LysIleLys His Leu Lys Gly His SerPhe TyrSer MetAsp Gly Tyr CTT CAG

IleArgGlu Phe Gln Pro Ser Ser IleSer MetVal ProAsn Leu Gln TCC GCC

ValGlyLeu Lys Phe Ile Ser Asn AsnIle LysZle SerGly Ser Ala WO 95/08344 217 2 2 4 5 pCTIUS94/11225 LysTrpI.ysAlaGlnLys ArgPheLeu LysMetSer GlyAsnPhe Asp LeuSerIle GluGlyMet SerIleSer AlaAspLeu LysLeuGly Ser AsnProThr SerGlyLys ProThrIle ThrCysSer SerCysSer Ser HisIleAsn SerValHis ValHisIle SerLysSer LysValGly Trp LeuIleGln LeuPheHis LysLysIle GluSerAla LeuArgAsn Lys MetAsnSer GlnValCys GluLysVal ThrAsnSer ValSerSer Lys LeuGlnPro TyrPheGln ThrLeuPro ValMetThr LysIleAsp Ser ValAlaGly IleAsnTyr GlyLeuVal AlaProPro AlaThrThr Ala GluThrLeu AspValGln MetLysGly GluPheTyr SerGluAsn His HisAsnPro ProProPhe AlaProPro ValMetGlu PheProAla Ala HisAspArg MetValTyr LeuGlyLeu SerAspTyr PhePheAsn Thr AlaGlyLeu ValTyrGln GluAlaGly ValLeuLys MetThrLeu Arg AspAspMet IleProLys GluSerLys PheArgLeu ThrThrLys Phe PheGlyThr PheLeuPro GluValAla LysLysPhe ProAsnMet Lys IleGlnIle HisValSer AlaSerThr ProProHis LeuSerVal Gln ProThrGly LeuThrPhe TyrProAla ValAspVal GlnAlaPhe Ala 21 ~2~~~

AAC TCC

ValLeu Pro SerSer Leu Ala LeuPhe LeuIleGlyMet His Asn Ser TCC GCC

ThrThr Gly MetGlu Val Ser GluSer AsnArgLeuVal Gly Ser Ala CTG CTG

GluLeu Lys AspArg Leu Leu GluLeu LysHisSerAsn Ile Leu Leu CCG CAG

GlyPro Phe ValGlu Leu Leu AspIle MetAsnTyrIle Val Pro Gln GTG AAC

ProIle Leu LeuPro Arg Val GluLys LeuGlnLysGly Phe Val Asn ACG CAG

ProLeu Pro ProAla Arg Val LeuTyr AsnValValLeu Gln Thr Gln AAC GGT

ProHis Gln PheLeu Leu Phe AlaAsp ValValTyrLya Asn Gly AGGGGTGCCG GCTGTGGGGC
GGGGCTGTCA
GCC

ACCGGCTGCC ATCTTAA CCAAGAGCCC CTTGCAAACT

TTTCCCCAGG
GAATCCTCTC
CAG

AGATTCAGAA TGGAAAAGTG
ATGATCTAAA
CAC

ATTTTAGGGA AGAGA
TTATGAGCTT
CTT

TCGTGTTTCA
ATTGTAACCA
AG

TTTTT TG

(2)INFORMATIONFORSEQ ID N0:146:

(i) SEQUE NCECHARACTERISTICS:

(A) LENGTH:

amino acids (B) TYPE:
amino acid (D) TOPOLOGY:
linear (ii) MOLECULETYPE: protein (xi) SEQUENCE DESCRIPTION: ID N0:146:
SEQ

Met Arg Glu Asn Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly His Tyr Ser Phe Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser Ser Cys Ser Ser His Ile Asn Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys 150 155 ' 160 Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val Ala Lys Lys Phe Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His Leu Ser Val Gln Pro Thr GIy Leu Thr Phe Tyr Pro Ala Val Asp Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val Val Tyr Lys (2) INFORMATION FOR SEQ ID N0:147:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.149"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:147:
Lys Trp Lys Val Phe Lys Lys Ile Glu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:148:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.150"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:148:
Lys Trp Ala Phe Ala Lys Lys Gln Lys Lys Arg Leu Lys Arg Gln Trp Leu Lys Lys Phe (2) INFORMATION FOR SEQ ID N0:149:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.153"

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:149:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys "' (2) INFORMATION FOR SEQ ID N0:150:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.154"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 5 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified°site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:150:
Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:151:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.155"
(ix) FEATURE:
- (A) NAME/KEY: Modified-site (B) LOCATION: 15 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 15 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 2~~22~~

(C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 16 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:151:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2} INFORMATION FOR SEQ ID N0:152:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: °'BPI.156"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 5 is beta-1-naphthyl-substituted.°' (ix) FEATURE:
(A) NAME/KEY: Modified-site {B) LOCATION: 6 {C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B} LOCATION: 15 {C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 15 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 16 is beta-1-naphthyl-substituted.°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:152:
Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:153:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids (B) TYPE: amino acid WO 95/08344 PCT/US94i11225 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.157"
(ix) FEATURE:

(A) NAME/KEY:Modified-.site (B) LOCATION:5 (C) OTHER
INFORMATION:
/label=
Substituted-Ala /note= "Position 5 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY:Modified-site (B) LOCATION:6 (C) OTHER
INFORMATION:
/label=
Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY:Modified-site (B) LOCATION:15 (C) OTHER
INFORMATION:
/label=
Substituted-Ala /note= "Position 15 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY:Modified-site (B) LOCATION:16 (C) OTHER
INFORMATION:
/label=
Substituted-Ala /note= "Position 16 is beta-1-naphthyl-substituted.' (ix) FEATURE:

(A) NAME/KEY:Modified-site (B) LOCATION:25 (C) OTHER
INFORMATION:
/label=
Substituted-Ala /note= "Position 25 is beta-1-naphthyl-substituted."

(ix) FEATURE:

(A) NAME/KEY:Modified-site (B) LOCATION:26 (C) OTHER
INFORMATION:
/label=
Substituted-Ala /note= "Position 26 is beta-1-naphthyl-substituted."

(xi) SEQUENCE PTION: SEQ ID N0:153:
DESCRI

Lys Trp Lys Ala Ala Arg Phe Leu Lys Lys Trp Ala Ala Lys Ala Ala Arg Phe Leu Lys Trp Lys Ala Ala Ala Arg Lys Lys Phe Leu (2) INFORMATION ID N0:154:
FOR SEQ

(i) SEQUENCE
CHARACTERISTICS:

(A) LENGTH: amino acids (B) TYPE: o acid amin (D) TOPOLOGY:linear (ii) MOLECULE peptide TYPE:

WO 95108344 ~ PCTlUS94111225 (ix) FEATURE:
(A) NAME/KEY: misc_feature {D) OTHER INFORMATION: "BPI.158"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 11 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:154:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:155:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: misc feature {D) OTHER INFORMATION: "BPI.159"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 2 is beta-1-naphthyl-substituted.'°
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:155:
Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:156:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear WO 95/08344 217 2 2 4 ~ ' pCT/US94/11225 (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.160"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 2 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 12 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 16 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:156:
Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:157:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.161"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:157:
Lys Ser Lys Val Lys Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:158:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid WO 95108344 PCTlUS94111225 2~~2245 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.162"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:158:
Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:159:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.163°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:159:
Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys Lys Trp Lys Ala Gln Trp Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:160:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.164"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-A1a /note= "Position 5 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) hOCATZON: 15 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 15 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: 5EQ ID N0:160:

Lys Trp Lys Ala Ala Lys Arg Phe Leu Lys Lys Trp Lys Ala Ala ° Lys Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:161:
' (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.165"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 2 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:161:
Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:162:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.166"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:162:
Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:163:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.167"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:163:
Lys Trp Lys Ala Gln Lys Arg Phe (2) INFORMATION FOR SEQ ID N0:164:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
{A) NAME/KEY: misc_feature {D) OTHER INFORMATION: "BPI.168"
{xi) SEQUENCE DESCRIPTION: SEQ ID N0:164:
Cys Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Cys (2) INFORMATION FOR SEQ ID N0:165:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: circular (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.169"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:165:
Cys Lys Trp Lys Ala Gln Lys Arg Phe Cys (2) INFORMATION FOR SEQ ID N0:166:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.221°' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 13 is beta-1-naphthyl-substituted."

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:166:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Ala Leu Lys ° 1 5 10 15 (2) INFORMATION FOR SEQ ID N0:167:
(i) SEQUENCE CHARACTERISTICS:
' (A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.222'°
(ix) FEATURE:
{A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 14 is beta-1-naphthyl-substituted.°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:167:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Ala (2) INFORMATION FOR SEQ ID N0:168:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.223"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site {B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:168:

WO 95108344 ~ ~ PCT/US94/11225 Lys Ser Lys Val Gly Ala Leu Ile Gln Ala Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:169:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.224"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 9 is para-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:169:
Lys Ser Lys Val Gly Ala Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:170:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D} TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.225"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 5 is para-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:170:
Lys Ser Lys Val Phe Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:171:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear ~. (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.226"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:171:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:172:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (8) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.227"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 14 is beta-1-naphthyl-substituted.°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:172:
Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe His Lys Ala (2) INFORMATION FOR SEQ ID N0:173:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.228'°
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 9 is para-amino-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 14 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:173:
'i:
Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Ala (2) INFORMATION FOR SEQ ID N0:174:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.229"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 5 is para-amino-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 14 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:174:
Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe His Lys Ala WO 95/08344 2 i 7 2 2 4 5 1'CTIUS94/11225 (2) INFORMATION FOR SEQ ID N0:175:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.230"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 14 is beta-1-naphthyl-substituted.°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:175:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Ala (2) INFORMATION FOR SEQ ID N0:176:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (8) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.231°' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:176:
Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Phe Ala Lys Lys (2) INFORMATION FOR SEQ ID N0:177:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: °'BPI.232"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 9 is para-amino-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:177:
Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe Ala Lys Lys (2) INFORMATION FOR SEQ ID N0:178:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.233"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 5 is para-amino-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:178:
Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Phe Ala Lys Lys (2) INFORMATION FOR SEQ ID N0:179:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.234"

WO 95/08344 PCTlUS94/11225 (ix) FEATURE:
(Ay NAME/KEY: Modified-site (B) LOCATION: 12 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 12 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:179:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp Ala Lys Lys (2) INFORMATION FOR SEQ ID N0:180:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids {B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.235"
(ix) FEATURE:
(A) NAME/FCEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 9 is para-amino-substituted.°' (ix) FEATURE:
(A) NAME/KEY: Modified-site {B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:180:
Lys Ser Lys Val Gly Trp Leu Ile Phe Ala Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:181:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.236"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 5 is para-amino-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:181:
Lys Ser Lys Val Phe Trp Leu Ile Gln Ala Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:182:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.237"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:182:
Lys Ser Lys Val Gly Trp Leu Ile Gln Ala Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:183:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.238"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 5 is para-amino-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 9 is para-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:183:
Lys Ser Lys Val Phe Trp Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:184:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.239"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 9 is para-amino-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:184:
Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:185:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.240"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (C) OTHER INFORMATION: /label= Substituted-Phe /note= "Position 5 is para-amino-substituted.'°
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:185:
Lys Ser Lys Val Phe Trp Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:186:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.247"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 2 ~ 1224 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 2 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:186:
Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:187:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.245"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:187:
Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:188:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.246"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 16 is D-beta-2-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:188:
Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:189:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids _. (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.248°' (ixy FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /label= Substituted-Ala /note= °'Position 2 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is beta-1-naphthyl-substituted."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 16 is D-beta-2-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:189:
Lys Ala Lys Ala Gln Ala Arg Phe Leu Lys Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:190:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.242"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is D-beta-2-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:190:

WO 95/08344 PCTlUS94111225 Lys Ser Lys Val Gly Ala Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:191:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.272"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:191:
Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:192:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.275"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:192:
Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:193:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.270"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:193:
Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:194:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.271"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:194:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:195:
(~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.273"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:195:
Lys Ser Lya Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:196:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.274"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:196:
Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:197:
(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.276"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:197:
Lys Trp Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Phe Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:198:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.241"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:198:
Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:199:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.243"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is D-beta-2-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:199:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:200:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.244"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "Position 6 is D-beta-2-naphthyl-substituted.°' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:200:
Lys Ser Lys Val Gly Ala Leu Ile Leu Leu Trp His Lys Lys (2) INFORMATION FOR SEQ ID N0:201:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 14 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.249"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:201:
Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:202:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.250"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:202:
Lys Ser Lys Val Gly Leu Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:203:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/REY: misc feature (D) OTHER INFORMATION: ~BPI.254"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= beta-Ala /note= "The amino acid at position 6 is beta-alanine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:206:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:207:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.255"
(ix) FEATURE:
(A) NAME/REY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= delta-aba /note= "The amino acid at position 6 is delta-aminobutyric acid"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:207:
Lys Ser Lys Val Gly Xaa Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:208:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.256"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= gaba /note= "The amino acid at position 6 is gamma-aminobutyric acid"
RECTIFIED SHEET (RULE 91) ISA/EP

(xi) SEQUENCE DESCRIPTION: SEQ ID N0:208:
Lys 5er Lys Val Gly Xaa Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:209:
(I) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOt~LOGY: linear (i~) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.257"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= d-methyl-A
/note= "The amino acid at position 6 is delta-Methyl-alanine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:209:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:210:
(I) SEQUENCE CHARACTERISTICS:
(A) LENGTH: Z4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.258"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= t-butyl-G
/note= "The amino acid at position 6 is tent-butyl-glycine"
(xi) SEQUENCE DESCRIPTION: SEg ID N0:210:
Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:211:
(I) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide RECTIFIED SHEET (RULE 91) ISA/EP

WO 95/08344 2 ~ 7 2 2 ~ 5 PCTIUS94111225 (2) INFORMATION FOR SEQ ID N0:209:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.257"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= d-methyl-A
/note= "The amino acid at position 6 is delta-Methyl-alanine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:209:
Lys Ser Lys Val Gly Ala Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:210:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.258"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= t-butyl-G
/note= "The amino acid at position 6 is tert-butyl-glycine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:210:
Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:211:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.259"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= N-methyl-G
/note= "The amino acid at position 6 is N-Methyl-glycine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:211:
Lys Ser Lys Val Gly Gly Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:212:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/FCEY: misc feature (D) OTHER INFORMATION: '°BPI.260"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= N-methyl-V
/note= "The amino acid at position 6 is N-Methyl-valine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:212:
Lys Ser Lys Val Gly Val Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:213:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.261'°
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= N-methyl-L
/note= "The amino acid at position 6 is N-Methyl-leucine"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:213:
Lys Ser Lys Val Gly Leu Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:214:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear WO 95/08344 PCTlUS94/11225 (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.262"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:214:
Lys Ser Lys Val Gly Trp Leu Ile Asn Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:215:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.263"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:215:
Lys Ser Lys Val Gly Trp Leu Ile Glu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:216:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 14 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.264"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:216:
Lys Ser Lys Val Gly Trp Leu Ile Asp Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:217:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.265"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:217:
Lys Ser Lys Val Gly Trp Leu Ile Lys Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:218:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.266"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:218:
Lys Ser Lys Val Lys Val Leu Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:219:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.267'°
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:219:
Lys Ser Lys Val Lys Trp Ala Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:220:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (8) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc feature (D) OTHER INFORMATION: "BPI.268"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:220:
Lys Ser Lys Val Gly Val Ala Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:221:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.269'°
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:221:

Lys Ser Lys Val Lys Val Ala Ile Gln Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:222:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/ICEY: misc feature (D) OTHER INFORMATION: "BPI.277"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 2 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:222:
Lys Ala Lys Ala Gln Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Trp Leu Ile Leu Leu Phe His Lys Lys (2) INFORMATION FOR SEQ ID N0:223:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear {ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.278"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:223:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Trp Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:224:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: misc_feature (D) OTHER INFORMATION: "BPI.279"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala WO 95/08344 ~ ~ ~ ~ ~ 4 5 PCTIUS94111225 /note= "The alanine at position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:224:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:225:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.280"
(xi) SEQUENCE DESCRIPTION: 5EQ ID N0:225:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Phe Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:226:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.281°"
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (C) OTHER INFORMATION: /label= Substituted-Ala /note= "The alanine at position 10 is beta-1-naphthyl-substituted."
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:226:
Ile Lys Ile Ser Gly Lys Trp Lys Ala Ala Ala Arg Phe Leu Lys (2) INFORMATION FOR SEQ ID N0:227:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: mist feature (D) OTHER INFORMATION: "BPI.170"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:227:
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser

Claims (60)

CLAIMS:

1. Use of a bactericidal/permeability-increasing (BPI) protein product for the manufacture of a medicament for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with an aminoglycoside antibiotic, a sulfonamide or trimethoprim antibiotic, a fluoroquinolone or quinolone antibiotic, a polymyxin antibiotic, a tetracycline antibiotic, a macrolide antibiotic, vancomycin, chloramphenicol, clinda-mycin, nitrofurantoin, or a .beta.-lactam antibiotic, wherein the .beta.-lactam antibiotic is aztreonam, imipenen, amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin.

2. A use according to Claim 1, wherein the medicament is for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with an aminoglycoside antibiotic, or for improving the therapeutic effectiveness in a gram-negative bacterial infection in mammals of an aminoglycoside antibiotic, such as for increasing the susceptibility to an aminoglycoside antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to an aminoglycoside antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or aminoglycoside antibiotic alone.

3. A use according to Claim 2, wherein the aminoglycoside antibiotic is amikacin, gentamicin, netilmicin or tobramycin.

4. A use according to Claim 2 or 3, wherein the causative agent of the gram-negative bacterial infection is Citrobacter, Edwardsiella, Enterobacter, Escherichia, Klebsiella, Morganella, Providencia, Proteus, Pseudomonas, Xanthamonas, Salmonella or Serratia species.

5. A use according to Claim 1, wherein the medicament is for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with a sulfonamide or trimethoprim antibiotic, or for improving the therapeutic effectiveness in a gram-negative bacterial infection in mammals of a sulfonamide or trimethoprim antibiotic, such as for increasing the susceptibility to a sulfonamide or trimethoprim antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to a sulfonamide or trimethoprim antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergisric or potentiating effects beyond the individual or additive effects of the BPI
protein product or sulfonamide or trimethopnim antibiotic alone.

6. A use according to Claim 5, wherein the sulfonamide or trimethoprim antibiotic is sulfamethoxazole or the combination antibiotic trimethoprim/sulfamethoxazole.

7. A use according to Claim 5 or 6, wherein the causative agent of the gram-negative bacterial infection is Pseudomonas, Xantharnonas, Klebsiella, Enterobacter or Proteus species.

8. A use according to Claim 1, wherein the medicament is for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with a fluoroquinolone or quinolone antibiotic, or for improving the therapeutic effectiveness in a gram-negative bacterial infection in mammals of a fluoroquinolone or quinolone antibiotic, such as for increasing the susceptibility to a fluoroquinolone or quinolone antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to a fluorocluinolone or quinolone antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or fluoroquinolone or quinolone antibiotic alone.

9. A use according to Claim 8, wherein the fluoroquinolone or quinolone antibiotic is ciprofloxacin, norfloxacin, ofloxacin or cinoxacin.

10. A use according to Claim 8 or 9, wherein the causative agent of the gram-negative bacterial infection is Pseardomonas, Xanthamonas, Klebsiella or Enterobacter species.

11. A use according to Claim 1, wherein the medicament is for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with a .beta.-lactam antibiotic, wherein the .beta.-lactam antibiotic is aztreonam, imipenen, amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin, or for improving the therapeutic effectiveness in a gram-negative bacteaial infection in mammals of a .beta.-lactam antibiotic, wherein the .beta.-lactam antibiotic is aztreonam, imipenen, amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin, such as for increasing the susceptibility to said antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to said antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or said antibiotic alone.

12. A use according to Claim 11, wherein the .beta.-lactam antibiotic is aztreonam or imipenem.

13. A use according to Claim 11, wherein the .beta.-lactam antibiotic is a penicillin antibiotic selected from amoxicillin, anlpicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin or ticarcillin.

14. A use according to Claim 11, wherein the .beta.-lactam antibiotic is a cephalosporin antibiotic selected from cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin.

15. A use according to any one of Claims 11 to 14, wherein the causative agent of the gram-negative bacterial infection is Pseudomonas, Citrobacter, Enterobacter, Proteus or Providencia species.

16. A use according to Claim 1, wherein the medicament is for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with a polymyxin antibiotic, or for improving the therapeutic effectiveness in a gram-negative bacterial infection in manunals of a polymyxin antibiotic, such as for increasing the susceptibility to a polymyxin antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to a polymyxin antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or polymyxin antibiotic alone.

17. A use according to Claim 16, wherein the polymyxin antibiotic is polymyxin B.

18. A use according to Claim 16 or 17, wherein the causative agent of the gram-negative bacterial infection is Pseudonzonas, Escherichia, Enterobacter or Providencia species.

19. A use according to Claim 1, wherein the medicament is for the co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with a tetracycline antibiotic.

20. A use according to Claim 19, wherein the tetracyline antibiotic is doxycycline.

21. A use according to Claim 1, wherein the medicament is for co-treatment or prophylaxis of a gram-negative bacterial infection in mammals with a macrolide antibiotic.

22. A use according to Claim 21, wherein the macrolide antibiotic is erytlu-omycin, clarithromycin or azitlwonrycin.

23. Use of a BPI protein product and an antibiotic for the manufacture of a medicament for the treatment or prophylaxis of a gram-negative bacterial infection in mammals, wherein the antibiotic is an aminoglycoside antibiotic, a sulfonamide or trimethoprim antibiotic, a fluoroquinolone or quinolone antibiotic, a polymyxin antibiotic, a tetracycline antibiotic, a macrolide antibiotic, vancomycin, cliloramphenicol, clindamycin, niti-ofurantoin, or a .beta.-lactam antibiotic, wherein the .beta.-lactam antibiotic is azh-eonam, imipenen, amoxicillin, ampieillin, azlocillin, carbenicillin, mezloeillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin.

24. A use according to Claim 23, wherein the antibiotic is an aminoglycoside antibiotic and wherein the medicament is for the treatment or prophylaxis of a gram-negative bacterial infection in mammals, or for improving the therapeutic effectiveness of the aminoglycoside antibiotic in a gram-negative bacterial infection in mammals, such as for increasing the susceptibility to the aminoglycoside antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to the aminoglycoside antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or aminoglycoside antibiotic alone.

25. A use according to Claim 24, wherein the aminoglycoside antibiotic is amikacin, gentamicin, netilmicin or tobramycin.

26. A use according to Claim 24 or 25, wherein the causative agent of the gram-negative bacterial infection is Citrobacter, Edwardsiella, Enterobacter, Escherichia, Klebsiella, Morganella, Providencia, Proteus, Psuedomonas, Xanthamonas, Salmonella or Serratia species.

27. A use according to Claim 23, wherein the antibiotic is a sulfonamide or trimethoprim antibiotic and wherein the medicament is for the treatment or prophylaxis of a gram-negative bacterial infection in mammals, or for improving the therapeutic effectiveness of the sulfonamide or trimethoprim antibiotic in a gram-negative bacterial infection in mammals, such as for increasing the susceptibility to the sulfonamide or trimethoprim antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to the sulfonamide or trimethoprim antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or sulfonamide or h-imethoprim antibiotic alone.

28. A use according to Claim 27, wherein the sulfonamide or trimethoprim antibiotic is sulfamethoxazole or the combination antibiotic trimethoprim/sulfamethoxazole.

29. A use according to Claim 27 or 28, wherein the causative agent of the gram-negative bacterial infection is Psezrdomonas, Xanthamonas, Klebsiella, Enterobacter or Proteus species.

30. A use according to Claim 23, wherein the antibiotic is a fluoroquinolone or quinolone antibiotic and wherein the medicament is for the treatment or prophylaxis of a gram-negative bacterial infection in mammals, or for improving the therapeutic effectiveness of the fluoroquinolone or quinolone antibiotic in a gram-negative bacterial infection in mammals, such as for increasing the susceptibility to the fluoroquinolone or quinolone antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to the fluoroquinolone or quinolone antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or fluoroquinolone or quinolone antibiotic alone.

31. A use according to Claim 30, wherein the fluoroquinolone or quinolone antibiotic is ciprofloxacin, nonfloxacin, ofloxacin or cinoxacin.

32. A use according to Claim 30 or 31, wherein the causative agent of the gram-negative bacterial infection is Pseudomonas, Xanthamonas, Klebsiella or Enterobacter species.

33. A use according to Claim 23, wherein the antibiotic is a (3-lactam antibiotic, wherein the .beta.-lactam antibiotic is aztreonam, imipenen, amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, cefri-iaxone, cefuroxime, cephalexin or cephalothin, and wherein the medicament is for the treatment or prophylaxis of a gram-negative bacterial infection in mammals, or for improving the therapeutic effectiveness of said antibiotic in a gram-negative bacterial infection in mammals, such as for increasing the susceptibility to said antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to said antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI
protein product or said antibiotic alone.

34. A use according to Claim 33, wherein the .beta.-lactam antibiotic is aztreonam or imipenem.

35. A use according to Claim 33, wherein the .beta.-lactam antibiotic is a penicillin antibiotic selected from amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin or ticarcillin.

36. A use according to Claim 33, wherein the .beta.-lactam antibiotic is a cephalosporin antibiotic selected from cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin.

37 A use according to any one of Claims 33 to 36, wherein the causative agent of the gram-negative bacterial infection is Pseudomonas, Citrobacter, Enterobacter, Proteus or Providencia species.

38. A use according to Claim 23, wherein the antibiotic is a polymyxin antibiotic and wherein the medicament is for the treatment or prophylaxis of a gram-negative bacterial infection in mammals, or for improving the therapeutic effectiveness of the polymyxin antibiotic in a gram-negative bacterial infection in marrunals, such as for increasing the susceptibility to the polymyxin antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for reversing resistance to the polymyxin antibiotic of gram-negative bacteria involved in the gram-negative bacterial infection, or for providing synergistic or potentiating effects beyond the individual or additive effects of the BPI protein product or polymyxin antibiotic alone.

39. A use according to Claim 38, wherein the polymyxin antibiotic is polymyxin B.

40. A use according to Claim 38 or 39, wherein the causative agent of the gram-negative bacterial infection is Pseudomonas, Escherichia, Enterobacter or Providencia species.

41. A use according to Claim 23, wherein the antibiotic is a tetracyline antibiotic.

42. A use according to Claim 41, wherein the tetracycline antibiotic is doxycycline.

43. A use according to Claim 23, wherein the antibiotic is a macrolide antibiotic.

44. A use according to Claim 43, wherein the macrolide antibiotic is erythromycin, clarithromycin or azithromycin.

45. A use according to any one of Claims 1 to 44, wherein the BPI protein product is an N-terminal fragment with a molecular weight of approximately 21 to 25kD, or a dimeric form thereof.

46. A use according to any one of Claims 1 to 44, wherein the BPI protein product is rBPI23, rBPI21, or rBPl50.

47. A use according to any one of the preceding claims, wherein the BPI
protein product is for administration at a dose of from 1µg/kg/day to 100mg/kg/day.

48. A use according to Claim 47, wherein the BPI protein product is for administration at a dose of from 1mg/kg/day to 20mg/kg/day.

49. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising an aminoglycoside antibiotic and a BPI
protein product in an amount effective to improve the therapeutic effectiveness of the aminoglycoside antibiotic.

50. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising a sulfonamide or trimethoprim antibiotic and a BPI protein product in an amount effective to improve the therapeutic effectiveness of the sulfonamide or trimethoprim antibiotic.

51. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising a fluoroquinolone or quinolone antibiotic and a BPI protein product in an amount effective to improve the therapeutic effectiveness of the fluoroquinolone or quinolone antibiotic.

52. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising a .beta.-lactam antibiotic, wherein the .beta.-lactam antibiotic is aztreonam, imipenem, amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephalexin or cephalothin, and a BPI protein product in an amount effective to improve the therapeutic effectiveness of said antibiotic.

53. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising a polymyxin antibiotic and a BPI
protein product in an amount effective to improve the therapeutic effectiveness of the polymyxin antibiotic.

54. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising a tetracycline antibiotic and a BPI
protein product in an amount effective to improve the therapeutic effectiveness of the tetracycline antibiotic.

55. A pharmaceutical composition for treatment or prophylaxis of gram-negative bacterial infection comprising a macrolide antibiotic, vancomycin, chloramphenicol, clindamycin or nitrofuratoin, and a BPI protein product in an amount effective to improve the therapeutic effectiveness of said antibiotic.

56. A pharmaceutical composition according to any one of Claims 49 to 55, wherein the BPI protein product is an N-terminal fragment with a molecular weight of approximately 21 to 25 kD, or a dimeric foam thereof.

57. A pharmaceutical composition according to any one of Claims 49 to 55, wherein the BPI protein product is rBPI23, rBPh21 or rBPI50.

58. An in vitro method of decontaminating a fluid or surface, which method comprises administering a BPI protein product in combination with an aminoglycoside antibiotic, a sulfonamide or trimethoprim antibiotic, a fluoroquinolone or quinolone antibiotic, a polymyxin antibiotic, a tetracycline antibiotic, a macrolide antibiotic, vancomycin, chloramphenicol, clindamycin, nitrofurantoin, or a (3-lactam antibiotic, wherein the .beta.-lactam antibiotic is aztreonam, imipenen, amoxicillin, ampicillin, azlocillin, carbenicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cefamandole, cefazolin, cefonicid, cefoperazone, cefotetan, cefotaxime, cefoxitin, ceftazidime, ceftizoxime, cefti-iaxone, cefuroxime, cephalexin or cephalothin.

59. A method according to Claim 58, wherein the BPI protein product is an N-terniinal fragment with a molecular weight of approximately 21 to 25 kD, or a dimeric foam thereof.

60. A method according to Claim 58, wherein the BPI protein product is rBPI23, rBPI21 or rBPI50.